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Cure from hematological malignancies depends on successful elimination of the 
malignant cells. Treatment regimens can consist of primary remission induction 
followed by myeoloablative consolidation therapy with high dose irradiation and 
or chemotherapy, which severely damages normal hematopoietic cells. To 
restore hematopoiesis, autologous stem cell transplantation (autoSCT) with 
hematopoietic stem cells (HSC) that were harvested and stored prior to 
consolidation therapy can be performed1,2.
As alternative source, HSC can be harvested from a healthy donor. Allogeneic 
stem cell transplantation (alloSCT) requires matching of patient and donor 
major histocompatibility complex (MHC), also called human leukocyte antigens 
(HLA), to prevent host-versus-graft reactivity resulting in graft rejection, and
graft-versus-host disease (GvHD), a life threatening complication caused by 
donor-derived alloreactive cells. Myeloablative consolidation therapy causes 
both tissue damage and lymphopenia thereby creating an inflammatory 
environment that supports activation and homeostatic proliferation of 
transplanted alloreactive cells, respectively. The cascade or ʻcytokine stormʼ 
that follows is a major contributor to the development GvHD3,4,5.
As compared to autoSCT, lower relapse rates are observed after alloSCT, 
which can be attributed to curative graft-versus-leukemia (GvL) reactions6,7.
Patients who received alloSCT from an HLA-identical sibling also had lower 
relapse rates as compared to patients who were transplanted with a syngeneic 
donor (identical twin sibling)8. These observations indicate that GvL reactivity
after alloSCT is the result of donor-to-patient alloreactivity that requires a certain
degree of tissue incompatibility. In addition, many soluble and cell-bound 
ligands and receptors have been identified that play a role in activation or 
regulation of immune responses after alloSCT. The specific role for these 
factors in development of GvHD and how to manipulate these factors in order to 
selectively induce curative GvL reactions, however, is largely unknown9.
Enhancing applicability and specificity of alloSCT
To treat patients with alloSCT who cannot tolerate the toxicity of myeloablative 
consolidation therapy, non-myeloablative (NMA) conditioning was developed. 
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NMA conditioning may however also lead to less efficient tumor reduction,
thereby increasing the risk of relapse. Curative alloSCT following NMA 
conditioning is therefore likely to depend more on induction of GvL 
reactivity10,11,12,13,14.
GvHD after alloSCT can be treated with immune suppression. Alternatively, 
alloSCT with a graft from which T cells are depleted results in reduced 
frequencies and severity of GvHD15. However, since GvL reactions are strongly 
correlated with occurrence of GvHD, these strategies also inhibit GvL 
reactions16. It was shown that postponed donor lymphocyte infusion (DLI) after 
T-cell depleted alloSCT could induce GvL reactivity with reduced incidence and 
severity of GvHD17,18. It is likely that at the moment of postponed DLI, 
consolidation therapy-induced tissue damage is resolved and donor HSC have 
restored normal hematopoiesis. Infused alloreactive donor T cells encounter 
fewer patient antigen presenting cells (APC) under less activating 
circumstances, thereby limiting development of GvHD19,20,21. Moreover, viral 
reactivations that occur frequently after alloSCT may be better controlled 
leading to a lower inflammatory environment22,23,24. Inflammatory conditions may 
also increase susceptibility of healthy non-hematopoietic tissues to T-cell 
damage because of increased expression of adhesion and costimulation 
molecules25.
Although T-cell depleted alloSCT followed by delayed DLI illustrates that GvHD
can be separated from GvL reactivity, GvHD remains a significant cause of 
morbidity and mortality in these patients.
AlloSCT and DLI for treatment of solid tumors
To exploit the T-cell mediated curative effect of alloreactivity, patients suffering 
from advanced stages of solid tumors have been treated with alloSCT26,27,28,29.
Graft-versus-tumor (GvT) reactivity was induced by withdrawal of immune 
suppression shortly after alloSCT resulting in tumor regression in several 
patients albeit in most cases at the cost of severe GvHD. Similarly, in the setting 
of T-cell depleted alloSCT and DLI, tumor regressions in the presence of GvHD
have been observed18,30,31. This demonstrates that in addition to undesired 
targeting of healthy tissues in GvHD, malignant non-hematopoietic cells can be




Targeting of alloantigens by donor-derived T cells on solid tumors requires
primary T-cell activation by patient-derived professional antigen presenting cells 
(APC)19. GvT reactivity without GvHD can only be obtained if the targeted 
alloantigens are selectively expressed on tumor cells but not on healthy tissue 
cells. Many solid tumors originate from epithelial cells and it can therefore be
expected that they share many antigens, which may explain the strong 
association between GvT and GvHD. Selective induction of alloreactivity to treat
transplanted patients with solid tumors requires identification of alloantigens that 
are expressed by both professional APC and solid tumor cells, but not by 
normal tissue cells. Thus far, such alloantigens have not been identified.
Responding cells: The T-cell repertoire
The T-cell repertoire develops in the thymus, where committed lymphoid 
progenitor cells mature into T cells that express a functional T-cell receptor 
-chain (TRA -chain 
(TRB -chain -chain. Whereas T cells that -TCR are 
primarily involved in first- -T cells can specifically recognize 
peptides presented by HLA32.
Genomic TCR gene segments require somatic recombination in order to 
become a functional TCR gene. The diversity of TCR is generated by 
recombination of variable, diversity, joining and constant gene segments, 
random insertion and deletion of nucleotides at the newly formed junctions 
chains33. TRB gene segments are rearranged until a productive -chain is 
obtained which -chain to form a pre T-cell receptor. 
Since each single TRB allele can rearrange twice at the two TRB loci, four 
attempts per cell can be made to produce a functional TCR. Theoretically, 80% 
of thymocytes succeed -chain. In a next step, CD4 
and CD8 co-receptors are expressed and T cells acquire the capacity to 
produce progeny, leading to expansion of a T-cell clone in which all cells 
-chains. At that time, simultaneous rearrangement of the 2
TRA loci commences. If TRA -
chain, developing T cells die by apoptosis.
Rearrangement is a random process resulting in a repertoire of TCR that may 
recognize ʻselfʼ and ʻnon-selfʼ antigens. The ʻnegative selection modelʼ proposes 
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that only T cells expressing TCR that lack binding to self-peptides will pass 
thymic selection thereby preventing autoimmunity34. Mature naive CD4 and 
CD8 T cells are then released from the thymus. Due to this negative selection in 
the thymus, DLI is devoid of T cells recognizing antigens that are shared 
between patient and donor. In contrast, T cells expressing high-affinity TCR 
recognizing patient-specific antigens that are non-self to the donor can be 
present within the donor T-cell repertoire.
In addition to thymic selection, peripheral tolerance provides mechanisms to 
prevent T-cell responses against self-antigens35. These mechanisms include 
suppression by regulatory T cells and induction of anergy or apoptosis following 
inappropriate TCR stimulation. It can be speculated, however, that peripheral 
tolerance to self-antigens may be broken if strong T-cell responses against non-
self antigens occur. If true, strong alloreactive T-cell responses may stimulate T-
cell responses against self-antigens, which may explain the frequent 
development of autoimmune diseases following alloSCT36,37.
Minor histocompatibility antigens (MiHA)
In HLA-matched alloSCT, alloreactive T cells that mediate GvL reactivity and 
GvHD recognize minor histocompatibility antigens (MiHA), which are 
polymorphic peptides presented by self human leukocyte antigens (HLA)38,39.
Peptides are generated in the cytosol by proteasomes, which are large 
enzymatic complexes. Proteasomes can hydrolyze the peptide bond between 
amino acid residues of proteins resulting in peptides of variable length that are 
further degraded by amino peptidases. ʻTransporters associated with antigen 
processingʼ (TAP1 and TAP2) can translocate peptides of 8-12 amino acids 
from the cytosol to the endoplasmic reticulum (ER). In the ER, these peptides 
may bind in the groove of HLA-class I molecules and peptide-HLA complexes 
are subsequently transported via the Golgi complex to the cell membrane where 
they are presented to the TCR of CD8 T cells. Peptides from extracellular 
proteins are taken up, degraded via endosomes, and assembled in HLA-class II 
molecules for presentation to CD4 T cells40.
The groove of HLA class I molecules can bind peptides non-covalently by the 
presence of specific anchor amino acid residues at both the N- and C-terminus 
of the peptide. HLA-A, HLA-B and HLA-C encode three human class I HLA




structural changes that reside predominantly in the peptide-binding groove and 
thereby influence binding and presentation of peptide subsets41,42. In self-HLA, 
peptides degraded from endogenous proteins are considered as ʻselfʼ.
Following viral infection, peptides derived from viral proteins can be recognized 
as ʻnon-selfʼ resulting in a T-cell mediated anti-viral response. Similarly, in the 
setting of HLA-matched alloSCT, donor T cells can recognize polymorphic,
patient-specific peptides as ʻnon-selfʼ antigens and elicit an alloreactive 
response. Non-self peptides can be encoded by genomic patient-to-donor 
variations that lead to patient-specific amino acid polymorphisms. The absence 
of these patient-specific polymorphisms in the donor allows the presence of 
alloreactive donor-to-patient high-affinity TCR within the donor T-cell repertoire.
Non-self peptides can be encoded by patient-specific single nucleotide 
polymorphisms (SNPs). SNPs may encode patient-specific amino acid 
substitutions that result in structurally different peptides for which high-affinity 
TCR exist in the donor T-cell repertoire. Missense SNPs can encode an amino 
acid substitution in the normal protein sequence that is present in the antigenic 
peptide43,44,45,46,47,48,49. SNPs that do not cause an amino acid substitution in the 
normal protein sequence (synonymous SNPs) can, as a result of an upstream 
alternative start codon which is out-of-frame, encode an amino acid substitution 
in an alternatively translated polypeptide50. It has been hypothesized that MiHA 
derived from such ʻdefective ribosome productsʼ make up a considerable part of 
the MiHA repertoire 51,52.
Furthermore, SNPs that substitute a non-anchor amino acid by an anchor 
amino acid can lead to binding of the peptide to HLA and presentation to donor 
T cells43,44. Differential peptide expression can also be the result of SNPs that 
are not located in exons but in introns. During mRNA maturation, introns are 
removed from the pre-mRNA by spliceosomes requiring donor-, branch- and 
acceptor-splice motifs contained within the intron. Intron SNPs may introduce or 
disturb such motifs resulting in transcripts with differences in exon composition 
or length, leading to disparate protein sequences between patient and 
donor53,31. One observation was made in which a SNP-encoded amino acid 
polymorphism introduced proteasomal splicing and annealing of two 
noncontiguous peptide segments to form a MiHA54.
Not only single nucleotide polymorphisms, but also single nucleotide insertions 
or deletions can encode patient-to-donor protein disparities by shifting the 
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translation reading frame55. In addition, complete proteins can be absent in the 
donor if the encoding genes are absent due to homozygous gene deletions56,57.
Although it appears that MiHA encoded by missense SNPs are the most 
common, this observation may be biased by the fact that these MiHA are 
identified easier as compared to MiHA that are encoded by other SNPs and 
insertions/deletions.
MiHA identification strategies
The first MiHA were identified by mass spectrometric analysis of the antigenic 
peptide46,58,44,43,59,45. This requires laborious isolation of peptide-HLA complexes 
from billions of MiHApos cells followed by HPLC purification and fractionation. A
different approach aims at identification of the MiHA-encoding transcript in 
plasmid libraries that contain cDNA generated from mRNA of MiHApos cells. 
Subcloning of a positive cDNA pool may identify MiHApos single plasmids that 
can be sequenced to detect the MiHA-encoding SNP. As compared to 
biochemical purifications, cDNA library methods do not require laborious 
handling of large cell numbers, but still, large numbers of plasmids need to be 
produced and tested. Nevertheless, several HLA class I restricted MiHA were 
discovered by this method60,50,61,62,54. In addition, by adapting the cDNA library 
method, HLA class II restricted MiHA targeted by CD4 T-cell clones were 
identified48,63.
Whole genome association scanning (WGAs) for MiHA identification utilizes a 
panel of cells of which SNP genotype data are available. All panel cells are 
tested for recognition by the T-cell clone, MiHApos and MiHAneg cells are 
separated, and the SNP-genotype data are searched for SNPs with similar 
distribution between MiHApos and MiHAneg cells. If low-resolution SNP-genotype 
data are used, WGAs can identify the region or gene containing the MiHA-
encoding SNP47,64,65,55,49,66,67. By using high-resolution SNP-genotype data,
WGAs can directly identify the MiHA-encoding SNP, provided that the MiHA 
encoding SNP is present in the data68,69,49,70. If the MiHA-encoding SNP is not 
included in the SNP genotype data, SNPs that are in linkage disequilibrium with 
the MiHA-encoding SNP may be identified. Subsequent Sanger sequencing of 
gene transcripts derived from both patient and donor can reveal the patient-to-





All methods for MiHA discovery as described above are based on read-out 
systems that use MiHA specific T-cell clones as tools to identify MiHApos peptide 
fractions or cDNA pools, or to separate MiHApos from MiHAneg test cells. 
Consequently, each of these approaches for MiHA discovery depends on the 
generation of stable T-cell clones from samples of patients who responded to 
alloSCT (and DLI).
Detection of MiHA-specific T cells
T cells that are involved in alloreactive immune responses can be detected and 
isolated by secretion of cytokines71,72,73 and expression of cell surface 
markers74,75,76. Isolation and in vitro clonal expansion allows subsequent MiHA 
identification and detailed analysis of the tissue specificity of isolated T-cell 
clones. After identification of the MiHA peptide, HLA-peptide monomers can be 
produced and used to generate multimers coupled to a fluorescent label to 
validate T-cell binding to newly discovered MiHA77. Flowcytometric analyses 
can be performed to analyze sequentially taken blood samples from patients 
with GvL reactivity, which demonstrated vigorous expansion followed by 
retraction of MiHA-specific cells.78,50. Detection levels of approximately 0.01% 
can be reached, and lower frequencies may be visualized after peptide 
stimulation to obtain expansion of MiHA-specific T cells79.
Since some HLA class I monomers seem to be difficult to produce stably, 
applicability of multimers to detect alloreactive T cells is limited by the ability to 
produce monomers in vitro. As a consequence, research has been focused on 
common HLA class I alleles such as HLA-A*02 and B*07, while neglecting less 
frequent HLA alleles. Therefore, our knowledge on frequencies and composition 
of MiHA specific T-cell responses in peripheral blood may be biased and not 
completely cover in vivo immune responses after alloSCT and DLI.
Tissue distribution of MiHA
After activation and expansion of infused MiHA specific donor T cells, it is likely 
that induction of GvL reactivity without or with GvHD depends on the tissue 
distribution of the MiHA that are targeted by the alloimmune response. Several 
MiHA specific T-cell clones that specifically recognized hematopoietic cells have 
been isolated indicating that MiHA can be differentially expressed
44,43,60,55,50,49,44,43,60,69,55,50,49. Whether a MiHA is selectively expressed by 
malignant hematopoietic cells or by all hematopoietic cells of the patient is not 
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relevant. After alloSCT, patient hematopoiesis is replaced by donor HSC
thereby allowing eradication of both the malignant and normal hematopoietic 
cells of the patient. Targeting of patient hematopoiesis restricted MiHA that are
also expressed by the malignant cells can therefore induce GvL reactivity 
without GvHD. In contrast, targeting of MiHA that are presented by non-
hematopoietic tissue cells is likely to result in GvHD46,80,45,62,81.
To test whether MiHA are broadly expressed or have a hematopoiesis-restricted 
expression pattern, in vitro T-cell recognition of non-hematopoietic cells can be 
performed. Skin-derived fibroblasts of the patient are relatively easy to obtain 
and are suitable targets for first screening of MiHA distribution. They however 
represent only a fraction of tissues that can be targeted during GvHD. To 
generate a comprehensive test cell panel, non-hematopoietic tissue cells and 
cell lines from third party individuals can be used. This however requires that 
test cells are positive for both the HLA-restriction molecule and the MiHA-
encoding SNPs, which may be difficult to achieve for MiHA with low frequencies 
and MiHA presented by rare HLA-alleles.
Testing of MiHA recognition requires that several different T-cell clones with
different TCR that recognize the same MiHA are used. Different T-cell clones
with similar recognition of hematopoietic test cells may display different strength 
of recognition of non-hematopoietic cells due to sub-optimal adhesion and 
costimulation of non-hematopoietic cells25. Under these conditions, lower TCR 
affinity and decreased effector function of the T-cell clone may lead to under-
estimation of MiHA expression by non-hematopoietic cells.
In addition to measurement of recognition by MiHA-specific T-cell clones, 
expression levels of MiHA-encoding genes can be quantified to predict absence 
or presence of MiHA on cells from various tissue types. Gene-specific primers 
and probes are used in both real-time PCR and array-based platforms to detect 
and quantify mRNA of MiHA-encoding genes. Whereas absence of gene 
expression is expected to correlate with lack of T-cell recognition, it remains 
difficult to predict how gene expression is related to the amount of protein that is 
produced and the actual epitope density that is displayed on the cell surface. 
Estimation of MiHA tissue distribution should therefore be based on both
functional analyses using MiHA-specific T-cell clones and investigation of MiHA-




In summary, alloSCT and DLI can be performed to treat patients who suffer 
from malignant diseases. It has been shown that recognition of MiHA by donor-
derived alloreactive T cells is important for both curative GvL reactivity and 
detrimental GvHD. MiHA discovery implies both elucidation of the antigenic 
structure of MiHA, which can be achieved by different technical approaches, 
and investigation of expression patterns of MiHA-encoding genes by malignant 
and normal cell types. Identification of MiHA that are specifically expressed by 
malignant cells allows development of future adoptive immunotherapies that 
can induce GvL reactivity without GvHD.
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Aim of the study
In alloSCT, depletion of donor T cells from the stem cell graft leads to lower 
prevalence and severity of GvHD, illustrating that T cells play a major role in 
GvHD. However, this coincides with an increase in relapse rates, which requires 
additional treatment with DLI. The aim of the study as described in this thesis is 
to analyze the role of MiHA-specific CD8 T cells in patients with GvL reactivity 
without or with GvHD after alloSCT and DLI. Immune responses were studied at 
the clonal T-cell level and various tools for MiHA discovery have been 
developed and validated. Recognition strength and specificity of T-cell clones 
for different types of MiHA were investigated for their potential role in GvL
reactivity and GvHD.
In chapter 2, we explored biochemical purification and mass spectrometry for
characterization of MiHA peptides. From a patient who was cured from multiple 
myeloma after T-cell depleted alloSCT and DLI, multiple T-cell clones were 
isolated, including T-cells targeting HA-1 and LB-ECGF-1H. A T-cell clone that 
was isolated at a high frequency recognized an unknown MiHA presented by 
HLA-A*02. It was therefore likely that this T-cell clone played a dominant role in 
the graft-versus-myeloma effect and we investigated the capacity of this T-cell 
clone to recognize myeloma cells and both hematopoietic and non-
hematopoietic normal cells. Characterization of the MiHA recognized by this T-
cell clone involved culturing of large numbers of patient EBV-LCL followed by
biochemical purification, fractionation and mass spectrometric analysis.
To increase the throughput of MiHA identification, in chapter 3 we applied 
whole genome association scanning (WGAs) as method for MiHA discovery.
This method requires a panel of EBV-LCL test cells from which detailed SNP
genotype data have to be generated by micro-array techniques. By testing of 
recognition of individual EBV-LCL in the panel and combining this with the SNP 
genotype data, MiHA-encoding SNP can be identified. We aimed at analyzing 
multiple T-cell clones restricted to HLA-A*02 or B*07 that were isolated from 2 
patients who obtained long-term remissions following alloSCT and DLI. 
Therefore, we composed a panel of 80 EBV-LCL that endogenously expressed 
both HLA-A*02 and HLA-B*07. Characterization of the potential antigenic 
peptides was performed by prediction of HLA-binding, and by testing of 
recognition at low concentrations. Generation of tetramers of identified MiHA 




In chapter 4, we wanted to improve applicability of WGAs by batch-wise 
retroviral transduction of non-endogenously expressed HLA-molecules into 
EBV-LCL of the WGAs panel. We analyzed three HLA B*40:01 restricted T-cell 
clones that were isolated from a patient with CML who achieved long term 
clinical remission following alloSCT and DLI. In addition, one HLA B*40:01 
restricted MiHA was analyzed using cDNA cloning techniques. To estimate the 
role of the individual T-cell clones in GvL reactivity and GvHD, we selected a
comprehensive panel of both normal and malignant hematopoietic cells and 
tested recognition by the T-cell clones.
In addition to patients suffering from hematological malignancies, T-cell 
depleted alloSCT and postponed DLI was applied to treat patients with solid
tumors. Remissions were observed, but often coincided with severe GvHD. In 
chapter 5 we report application of alloSCT and DLI to treat a patient who 
suffered from metastatic renal cell carcinoma (RCC). Treatment resulted in 
stable disease at the cost of severe long term GvHD. T-cell clones were 
isolated at the onset of GvHD after DLI and analyzed for their potential role in 
the observed graft-versus-tumor reactivity and GvHD. We further investigated 
the likelihood that effective GvT reactivity in the absence of GvHD can occur by 
using micro-array gene expression data.
In chapter 6 we analyzed GvL reactivity that was observed after alloSCT and 
DLI in 6 patients without and 5 patients with GvHD. We focused on MiHA-
specific CD8 T cells and determined the magnitude of the alloreactive CD8 T-
cell response. Tissue specificity of the isolated T-cell clones was analyzed by 
testing the capacity of individual T-cell clones to respond to hematopoietic and 
non-hematopoietic stimulator cells. As non-hematopoietic stimulator cells, 
fibroblasts were cultured from patient derived skin biopsies in the absence or 
presence of IFN- to mimic inflammation. Finally, WGAs was performed to 
identify the repertoire of targeted MiHA thereby enabling investigation of the
tissue distribution of the MiHA-encoding genes by microarray gene expression 
analysis.
In chapter 7, we summarize the analyses presented in chapters 2 to 6 of T-cell 
mediated immune responses in various patients who responded to the infusion 
of donor lymphocytes to treat recurring disease or incomplete donor chimerism. 
We discuss strategies for selection of alloreactive T cells and subsequent MiHA 
discovery, including ʻreversalʼ of MiHA discovery. The influence of MiHA tissue 
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distribution and environmental factors is discussed as well as possibilities and 
limitations to elicit GvL reactivity without GvHD in the setting of alloSCT to treat 
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Minor histocompatibility antigens (MiHA) play an important role in both graft-
versus-tumor effects and graft-versus-host disease (GvHD) after allogeneic 
stem cell transplantation. We applied biochemical techniques and mass 
spectrometry to identify the peptide recognized by a dominant tumor-reactive 
donor T-cell reactivity isolated from a patient with relapsed multiple myeloma 
who underwent transplantation and entered complete remission after donor 
lymphocyte infusion. A frequently occurring single nucleotide polymorphism in 
the human ATP-dependent interferon-responsive (ADIR) gene was found to 
encode the epitope we designated LB-ADIR-1F. Although gene expression 
could be found in cells from hematopoietic as well as non-hematopoietic 
tissues, the patient suffered from only mild acute GvHD despite high 
percentages of circulating LB-ADIR-1F–specific T cells. Differential recognition 
of non-hematopoietic cell types and resting hematopoietic cells as compared 
with activated B cells, T cells, and tumor cells was demonstrated, illustrating 
variable LB-ADIR-1F expression depending on the cellular activation state. In 
conclusion, the novel MiHA LB-ADIR-1F may be a suitable target for cellular 
immunotherapy when applied under controlled circumstances. 
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Allogeneic stem cell transplantation (SCT) is a curative treatment in patients 
with hematologic cancers. In addition to the antitumor effects of chemotherapy, 
antibody treatment and/or irradiation administered as the conditioning regimen 
prior to transplantation, an allogeneic graft-versus-tumor (GvT) immune-
reactivity significantly contributes to the curative potential of this therapy.1–5 This 
GvT reactivity following HLA-matched SCT has been demonstrated to be 
mediated primarily by T cells from the donor. Allo-reactive T cells from donor 
origin may not only mediate the beneficial GvT effect but are also responsible 
for the development of graft-versus-host disease (GvHD), which is the major 
detrimental complication after allogeneic SCT.6,7 T-cell depletion of the stem cell 
graft removes both GvHD and GvT effect.8–10 The antitumor reactivity can be 
reintroduced in case of persistent or relapsed hematologic malignancies after 
transplantation by donor lymphocyte infusion (DLI).11–15 Whereas profound 
antitumor effects are frequently associated with GvHD in patients responding to 
DLI, postponed administration of DLI has been associated with a decreased risk 
of severe GvHD, and clinical observations indicate that more subtle antitumor 
reactivities can also be observed in the absence of GvHD.16–18 
 
The main targets of both GvHD and GvT reactivity after HLA-matched 
allogeneic SCT are minor histocompatibility antigens (MiHA).19–21 MiHA are 
peptides differentially expressed by donor and recipient that can be recognized 
in the context of self-HLA molecules. MiHA may arise from differential 
processing of peptides due to polymorphisms in the gene encoding the protein 
or by direct polymorphisms in the peptide sequence that is presented in the 
HLA molecules.22,23 
 
The clinical manifestation of immune responses against MiHA is likely to be 
determined by the specific tissue expression of the proteins encoding these 
antigens. Whereas MiHA constitutively expressed in many tissues are likely to 
be targets for combined alloreactive GvHD and GvT responses, T-cell 
responses directed against antigens that are restricted to the hematopoietic cell 
lineages including the malignant cells of hematopoietic origin are likely to 
mediate a GvT reactivity without severe GvHD.21,24–31 However, antigens with 
variable expression in tissues may also be targets for relatively specific GvT 
responses because these proteins may not be expressed or recognized on 
normal tissues under steady state conditions.19,32,33 By specific stimuli like 
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inflammatory reactions they may be induced in target tissues of GvHD, leading 
to a detrimental local immune response.7,34,35 Characterization of MiHA from 
patients responding to cellular immunotherapeutic interventions following 
allogeneic SCT in the presence or absence of GvHD will lead to a better 
understanding of the pathogenesis of GvHD and GvT and may lead to the 
development of specific antitumor T-cell therapy. 
 
Recently, we studied in detail several patients treated for relapsed hematologic 
malignancies after allogeneic SCT with DLI. During the clinical GvT response, 
we isolated tumor-reactive T cells based on their ability to produce IFN-γ in 
response to specific activation by bone marrow containing the malignant 
cells.28,36 From one of the patients who were treated with DLI for relapsed 
multiple myeloma (MM) after transplantation with DLI and IFN-α we isolated a 
dominant cytotoxic T lymphocyte (CTL) clone capable of recognizing the 
malignant MM cells from the patient. At the time of the clinical response the 
patient suffered from mild acute GvHD of skin and liver (grade II), which 
resolved after discontinuation of IFN-α and short-term treatment with 
prednisone and cyclosporine. The patient entered a complete remission and is 
now, 6 years later in persistent complete remission without GvHD. 
 
In the present study we identified the MiHA recognized by this CTL clone to be 
encoded by the ATP-dependent interferon-responsive (ADIR) gene.37 This gene 
was found to be highly expressed in the MM cells, in other hematopoietic 
tumors, as well as non-hematopoietic tumor cell lines. Recognition of normal 
nonmalignant cells appears to be minor under steady state conditions, but 
activation of the target cell populations resulted in enhanced recognition by the 
CTL clone. We hypothesize that T-cell responses against MiHA encoded by the 
ADIR gene may lead to a strong GvT reactivity, potentially coincident with 
GvHD depending on the activation state of the target tissues. 
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Materials and methods 
 
CTL generation and culture 
The HLA-A2–restricted MiHA-specific CTL clone RDR2 was previously isolated 
using the IFN-γ secretion assay from a peripheral blood (PB) sample of a 
patient at the time of clinical response to DLI as treatment for relapsed MM after 
SCT.36 CTL clone RDR2 and the allo–HLA-A2 control clone MBM13 were 
expanded by stimulation with irradiated (50 Gy) allogeneic mononuclear cells 
(MNCs) and patient-derived Epstein-Barr virus lymphoblastoid cell line (EBV-
LCL) in IMDM (Cambrex, Verviers, Belgium) supplemented with penicillin-
streptomycin (Cambrex), 3 mM L-glutamine (Cambrex), 5% fetal bovine serum 
(FBS) (Cambrex), 5% pooled human serum, 100 U/mL IL-2 (Chiron, 
Amsterdam, The Netherlands), and 0.8 μg/mL PHA (Remel, Dartford, United 
Kingdom). 
 
Target cell populations 
After informed consent was obtained in accordance with the Declaration of 
Helsinki, with approval from Leiden University Medical Center's Institutional 
Review Board, BM and PB samples were collected from patients and donors, 
and MNCs were isolated by Ficoll-Isopaque separation. Recognition of target 
cells was measured in cytotoxicity assays, and stimulation of responder cells 
was measured using INF-γ secretion. Lineage-specific hematopoietic cell 
populations were isolated from PBMCs by magnetic-activated cell sorting using 
magnetic microbeads coupled to CD4, CD8, CD14, and CD19 monoclonal 
antibody (mAb) (Mylteni Biotec, Bergisch Gladbach, Germany) according to 
manufacturer's instructions. PHA blasts were generated from PBMCs by 
stimulation with 0.8 μg/mL PHA and subsequent culturing in IMDM 
supplemented with 100 IU/mL IL-2 and 10% FBS. EBV-LCLs were cultured in 
IMDM supplemented with 10% FBS. The HLA-A2–positive lymphoblastoid-
processing defective cell line T238 was cultured in IMDM supplemented with 
10% FBS. Hela/A2 was generated by retroviral transduction of HLA-A*02:01 in 
Hela Tk− cells and cultured in IMDM supplemented with 10% FBS. 
Mesenchymal stem cells (MSCs) were generated from bone marrow cells by 
culturing adherent cells in low-glucose DMEM (Invitrogen, Paisley, Scotland) 
supplemented with 10% FBS.39 Commercially obtained biliary epithelial cells 
(BECs) (Sciencell, San Diego, CA) were grown in DMEM F12 (Cambrex) 
supplemented with 5% FBS, 2 × 10−9 M T3 hormone, 8.2 × 10−7 M 
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hydrocortisone, 2 ng/mL epidermal growth factor, and 5 μg/mL insulin and were 
retrovirally transduced with HLA-A*02:01. IFN-α modulation of stimulator cells 
was performed by addition of 1000 IU/mL IFN-α-2a (Roche, Woerden, The 
Netherlands). Adherent solid tumor cell lines from thyroid carcinoma (TT), 
breast adenocarcinoma (MCF7), and cervical carcinoma (CaSki) from the 
American Type Culture Collection (ATCC, Manassas, VA) and a melanoma cell 
line (Brown) were cultured in RPMI supplemented with 10% FBS. 
 
Cytotoxicity assays 
CTL-induced specific cytotoxicity of defined cell types in a heterogeneous target 
cell population was determined in CFSE-based cellular cytotoxicity assays as 
described before.40 Briefly, target cells were labeled with 2.5 μM CFSE 
(Molecular Probes, Leiden, The Netherlands) and incubated with target cells at 
a 1:1 ratio. After 4 and 24 hours, specific cell populations were counterstained 
with PE- or APC-labeled CD138, CD3, CD4, CD8, CD14, or CD19 mAb (Becton 
Dickinson, Erembodegem-Aalst, Belgium), and propidium iodide was added to 
exclude dead cells. To allow quantification of the surviving cell numbers in each 
sample, 104 Flow-count Fluorospheres (Coulter, Miami, FL) were added 
immediately before flow cytometric analysis. Cytotoxicity of CTL clones in 
standard 51Cr release assays was performed as described previously.41 HPLC-
purified natural peptides or diluted synthetic peptides were tested for reactivity 
by loading 51Cr-labeled T2 cells for 1 hour at 37°C and 5% CO2 prior to addition 
of CTLs. 
 
IFN-γ secretion assays 
Quantification of CTL stimulation was performed by IFN-γ secretion assays. 
CTLs were cocultivated with various freshly isolated PBMC cell populations, 
EBV-LCLs, PHA blasts, transfected Hela/A2 cells, MSCs, or BECs. Stimulator 
cells and CTLs were diluted in IMDM supplemented with 10% FBS and cultured 
in 96-well microtiterplates for 24 hours at various responder-stimulator ratios. In 
each well 5 × 103 CTLs were stimulated with 2 × 104 PBMCs or Hela/A2, 5 × 
103 BECs, or 1 × 103 MSCs. Supernatant was harvested, and IFN-γ was 
measured by standard enzyme-linked immunosorbent assay (ELISA) (Sanquin, 
Amsterdam, The Netherlands). 
 
Peptide isolation, purification, and characterization 
Purification of peptides from 8 × 1010 EBV-LCLs was performed as described 
before.24,42 Briefly, frozen cell pellets were lysed and affinity purified. Peptides 
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were separated from proteins by size-exclusion centrifugation, and peptide 
concentrates were injected on a Smart System (Amersham Biosciences, 
Freiburg, Germany) and subjected to reverse-phase high-performance liquid 
chromatography (RP-HPLC) on a 10 cm × 2.1 mm C2/C18 3 μm particle 
column at 0.2 mL/min. A gradient from 20% to 50% organic phase containing 
0.1% TFA was run while 0.1 mL fractions were collected in siliconized vials and 
stored at −80°C. Isopropanol or acetonitrile was used as organic phase. 
Reactive fractions were injected on a 15 cm × 75 um C18-Pepmap nano 
column (LC Packings/Dionex, Breda, The Netherlands), which was directly 
coupled to a QTOF1 mass spectrometer (Micromass Waters, Manchester, 
United Kingdom). The flow was delivered by a conventional JASCO binary 
gradient system (JASCO, Maarssen, The Netherlands), which was reduced to 
approximately 300 nL/min by an in-house–constructed flow splitter. Injections 
were performed with a FAMOS (LC Packings/Dionex). On-line HPLC tandem 
mass spectrometry analysis on the HCTplus (Bruker Daltonics, Bremen, 
Germany) was performed in a similar fashion. In this case the flow was 
delivered by an Ultimate (LC Packings/Dionex). 
 
Sequence analysis of the ADIR gene 
Trizol reagent (Invitrogen) was added to patient and donor cell pellets, RNA was 
isolated and purified, and 4 μg was reverse transcribed into cDNA for 1 hour at 
37°C using Moloney murine leukemia virus (M-MLV) reverse transcriptase 
(Invitrogen) in accordance with the manufacturer's instructions. Polymerase 
chain reactions (PCRs) of nucleotides 1 to 327 of the ADIR gene were 
performed in 50 μL GeneAmpII PCR buffer containing 1.5 mM MgCl2, 250 μM 
dNTPs, 800 nM forward primer (nucleotides 1 to 18), 800 nM reverse primer 
(nucleotides 309 to 327), 2% DMSO, and 1.5 units of AmpliTaq DNA 
polymerase. Amplification on an Applied Biosystems GeneAmp PCR system 
2400 was achieved in 35 cycles of 15 seconds at 95°C and 30 seconds at 58°C. 
Sequence reactions were performed on 1 μL of purified PCR product using the 
Big Dye Terminator v3.1 sequencing kit (Applied Biosystems, Foster City, CA) 
and 1 μM reverse primer in 25 cycles of 10 seconds at 96°C, 5 seconds at 
58°C, and 4 minutes at 60°C. After DNA purification, sequencing was performed 
using an ABI310 sequencer. 
 
Transfection of constructs containing the LB-ADIR-1F epitope 
Constructs from donor and patient cDNA containing the ADIR gene were 
generated using 3 different forward primers and 1 reverse primer and ligated in 
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pCR3.1 expression vector (Invitrogen) as described previously.31 A mixture of 
100 ng plasmid and 0.8 μL Lipofectamine (Invitrogen) was incubated for 30 
minutes at room temperature and used to transiently transfect 2 × 104 Hela/A2 
cells. After 5 hours of incubation at 37°C, 50 μL IMDM/10% FBS was added. 
After 24 hours, 104 RDR2 cells were added and again after 24 hours 50 μL of 
supernatant was harvested and tested for IFN-γ secretion in ELISA. 
 
Ex vivo detection of LB-ADIR-1F specific T cells and T-cell receptor-β 
variable chain analysis 
Recombinant biotinylated HLA-A*02:01 monomers were folded with both ADIR 
peptide variants. Streptavidin-APC tetramers were produced as described 
previously.43 Tetramer-positive events in thawed patient samples were sorted 
by fluorescence-activated cell sorting (FACS) to single cells per well, expanded, 
and tested for cytotoxicity as described previously.21 T-cell receptor-β variable 
chain (TCRBV) expression of cytotoxic clones and tetramer-positive T cells in 
patient material was determined by staining with FITC-conjugated mAb to 
TCRBV7 (Beckman Coulter, Mijdrecht, The Netherlands). Sequences of the 
TCRBV were determined as described previously,36 and TCR chains were 
named in accordance with the nomenclature described by Arden et al.44 
 
Quantitative real-time-PCR to analyze gene expression 
Quantitative real-time PCR analysis was performed as described previously.45 
To normalize for variations in the procedures for RNA isolation and cDNA 
synthesis, 1% mouse spleen cells were added to each cell sample. Quantitative 
real-time PCR was performed on an ABI/PRISM 7700 Sequence Detector 
System (Applied Biosystems) using qPCR-Core Kit (Eurogentec, Seraing, 
Belgium). Human ADIR and PBGD results were normalized using the murine 
Gapdh expression. For each sample, relative gene expression was calculated 
using the results obtained from a serial diluted EBV-LCL. EBV-LCL expression 
was set to 100. Primers for human ADIR were designed spanning exons 1 to 3: 
forward 5′-GACGACTGTGACGAGGACGA-3′ 
reverse 5′-CAAATGCTGGCCATGCAG-3′  
and probe 5′-(TET)-CTGGGCTGGCGCCTTCCTCTGT-(TAMRA)-3′. 
Primers and probe for human PBGD were as follows: 
forward 5′-GCAATGCGGCTGCAA-3′, 
reverse 5′-GGGTACCCACGCGAATG-3′, 
and probe 5′-(TET)-CTCATCTTTGGGCTGTTTTCTTCCGCC-(TAMRA)-3′. 
Primers and probe for murine Gapdh were as follows: 
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and probe 5′-(TET)-TCCTACCCCCAATGTGTCCGTCGT-(TAMRA)-3′. 
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Isolation of the HLA-A2–restricted CD8 CTL clone RDR2 recognizing a 
frequently expressed MiHA 
We previously described the isolation of various CTL clones from a female 
patient who was successfully treated with DLI after relapsed MM.36 CTL clones 
were generated by direct cloning of IFN-γ–producing cells upon stimulation by 
irradiated bone marrow cells harvested from the patient prior to SCT. Panel 
studies using unrelated EBV-LCLs and blocking studies with HLA allele–specific 
mAb showed that recognition by the most dominant CTL clones was restricted 
by HLA-A2. Extensive panel studies using PHA blasts and EBV-LCLs of 
unrelated sibling pairs demonstrated that most HLA-A2–restricted CTL clones 
designated RDR2 displayed an identical recognition pattern and lysed 57% of 
targets from all HLA-A2 individuals tested. All RDR2 clones were found to 
express an identical TCR-BV7S1, N region, and BJ1S4, illustrating that they 
were derived from the same clonal T cell.36 Because RDR2 was isolated from a 
MM patient, we investigated the sensitivity of her MM cells to lysis by the T-cell 
clone. The CFSE-based cytotoxicity assay was performed to allow quantitative 
measurement of lysis of MM cells that were present in relatively low frequencies 
within the heterogeneous bone marrow samples.40 Figure 1A shows dot plots of 
a quantitative CFSE-based cytotoxicity assay performed on thawed bone 
marrow cells from a MiHA-positive patient containing 10% MM cells. Lysis was 
measured after incubation with a control CMV-pp65-A2–specific CTL clone or 
with CTL RDR2. CD138 was used as a marker for the malignant MM cells. A 
strong decrease of the number of CD138+ cells was observed. In a sample 
containing 1% MM cells that was taken from the patient from which CTL RDR2 
was isolated, lysis was measured of bone marrow cells using CD138 as a 
marker for the malignant MM cells and CD3 as a marker for nonmalignant 
patient-derived T cells. Figure 1B illustrates that MM cells from the patient were 
strongly lysed whereas lysis of normal unstimulated T cells was low. Activated T 
cells (PHA blasts) and EBV-LCLs from the patient were strongly recognized. 
Donor-derived PHA blasts and EBV-LCLs were not recognized (data not 
shown). To further study susceptibility of normal hematopoietic cells to lysis by 
RDR2, PBMC subpopulations from HLA-A2–positive MiHA-positive donors were 
tested for recognition by RDR2 and an allo-A2 clone. Whereas similar 
recognition of PHA blasts and EBV-LCLs by the allo-A2 clone and RDR2 was 
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observed, RDR2-mediated lysis of normal B cells and T cells was lower as 



















Figure 1. Recognition pattern of CTL clone RDR2 on MM cells and normal 
hematopoietic cells. (A) Recognition of MM cells by RDR2 in a heterogeneous bone 
marrow sample of an MiHA-positive patient was determined in CFSE-based cytotoxicity 
assays after incubation with a control CMV-pp65-A2–specific CTL clone (left dot plot) or 
with CTL RDR2 (right dot plot) in 1:1 effector-target (E/T) ratios. CFSE-negative cells 
represent the CTL clones. Strong specific recognition of CFSE-positive CD138 APC-
counterstained MM cells was observed. (B) Recognition by RDR2 (closed bars) and 
control allo-A2 CTL (open bars) was tested in CFSE-based cytotoxicity assays and by 
IFN-γ secretion. Heterogeneous cell samples were incubated with CTLs at a 1:1 E/T 
ratio for 4 hours. Patient bone marrow cells were counterstained with CD138 mAb for 
detection of MM cells or with CD3 mAb for detection of T cells. Patient-derived MM cells 
were strongly lysed by RDR2 whereas T cells were weakly recognized. Both EBV-LCLs 
and PHA blasts were strongly lysed. (C) PBMCs from 3 healthy MiHA-positive donors 
were counterstained with different lineage-specific markers. Lysis by RDR2 was 
significantly diminished in both B cells (P = .02) and T cells (P < .001) as compared with 
lysis by allo-A2 CTL (shown as mean value ± SD). (D) Stimulation of CTLs was 
measured by INF-γ release after 24 hours of coculture. RDR2 stimulation by resting 
PBMC subpopulations was low as compared with allo-A2 CTL stimulation whereas 
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separated by magnetic bead cell sorting into CD4 T cells, CD8 T cells, 
monocytes, and B cells and were used to stimulate RDR2 and allo-A2 CTL in 
IFN-γ release assays. Whereas all stimulator cell subpopulations were equally 
able to induce IFN-γ secretion by allo-A2 CTL, stimulation of RDR2 by normal 
hematopoietic cells was more than 10-fold lower as compared with stimulation 
by EBV-LCLs (Figure 1D). In conclusion, RDR2 recognized an HLA-A2 
restricted epitope causing strong lysis of MM cells and activated T cells and B 
cells. In contrast, reactivity with normal non-activated hematopoietic cells was 
relatively low as measured both by direct cytotoxicity and by IFN-γ secretion. 
 
Purification and mass spectrometric identification of the peptide 
To identify the epitope that was recognized by CTL clone RDR2, EBV-LCL cells 
expressing the antigen were lysed, and peptide-HLA complexes were affinity 
purified using HLA-A2 specific BB7.2 mAb. After elution of peptides, size 
centrifugation was performed to separate peptides from HLA monomers and β2-
microglobulin. After freeze drying, the peptide mixture was subjected to RP 
HPLC using isopropanol as organic solvent and fractions were collected. 51Cr-
labeled T2 cells were loaded with a small sample of each fraction. RDR2 was 
added, and a single positive fraction could be detected. This fraction was 
subsequently subjected to RP HPLC with acetonitrile as organic solvent and 
fractionated. Fractions were tested for reactivity, and again a positive fraction 
was found. To determine the most abundant masses present in this fraction, 
part of the fraction was injected on a nano–liquid chromatography system 
directly coupled to a Q-TOF1 mass spectrometer. Abundantly present masses 
were fragmented by collision-activated dissociation on an HCTplus mass 
spectrometer. Analysis of obtained fragmentation patterns led to the sequence 
of several candidate peptides that were subsequently synthesized. RDR2 
recognized an [M+2H]++ candidate peptide with mass/charge of 528.8 and 
sequence SVAPALALFPA at levels as low as 10 pM (data not shown). 
Furthermore, the fragmentation patterns of the synthetic peptide and the natural 
eluted peptide were identical (data not shown). 
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Identification of a polymorphic gene responsible for RDR2 recognition 
A basic local alignment sequence tool (BLAST) search of sequence 
SVAPALALFPA against a 6-frame translation of the European Molecular 
Biology Laboratory (EMBL) nucleotide database revealed 100% identity to 
amino acids 13 to 23 from an alternative open reading frame (ORF) of the ADIR 
gene, also known as TOR3A37 (National Center for Biotechnology Information 
[NCBI] mRNA Reference Sequence [RefSeq] NM_022371). A known single 
nucleotide polymorphism (SNP) in ADIR at nucleotide 78 from C>T (NCBI 
dbSNP cluster ID rs2296377) results in an amino acid change in an alternative 
transcript from serine (S) to phenylalanine (F) at position 21, corresponding to 
position 9 of the eluted peptide (Figure 2A). Both peptides were synthesized 
and loaded on T2 cells. Patient-type peptide SVAPALAL-F-PA but not donor-
type peptide SVAPALAL-S-PA was recognized by RDR2 (Figure 2B). Sequence 
analysis of the ADIR PCR product flanking the SNP revealed that the donor was 
CC homozygous and the patient CT heterozygous. To demonstrate that patient-
type T but not donor-type C of this gene was responsible for recognition by 
RDR2, constructs were generated from both patient and donor cDNA. Because 
RDR2 recognized a peptide arising from an alterative ORF controlled by a start 
codon 5′ upstream from the normal start codon, 3 different forward primers were 
composed. The first primer was chosen at the normal start codon, thus lacking 
the alternative start codon. The second primer was chosen at the start of the 
transcript, thus providing both start codons. The third primer was chosen at the 
alternative start codon and also contained the normal start codon. The 
constructs were transiently transfected into Hela/A2 cells. Only patient-derived 
constructs induced IFN-γ release by RDR2 CTL. Transfection of constructs 
containing only the normal ORF start codon and lacking the alternative ORF 
start codon showed a strong decrease of CTL recognition (Figure 2C). All 
donor-derived constructs failed to induce IFN-γ by RDR2 (data not shown). 
Next, a panel of 74 unrelated HLA-A2–positive individuals was analyzed by 
sequencing for determination of the polymorphism and susceptibility to lysis of 
PHA blasts by RDR2. A 100% correlation between presence of this specific 
SNP and CTL reactivity proved that this SNP from C>T in the ADIR gene 
generates the MiHA epitope SVAPALALFPA that is recognized by RDR2 (Table 
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Figure 2. Identification of ADIR as the polymorphic gene responsible for RDR2 
recognition. (A) BLAST searching of SVAPALALFPA against a translated EMBL 
database revealed 100% identity to amino acids 13 to 23 from an alternative ORF of the 
ADIR gene. A known SNP at nucleotide 78 results in an amino acid change from S>F. 
(B) Both patient-type peptide SVAPALAL-F-PA (closed symbols) and donor-type peptide 
SVAPALAL-S-PA (open symbols) were synthesized and tested for RDR2 reactivity on T2 
cells in a 51Cr release assay. Only cells loaded with the patient-type peptide but not cells 
loaded with the donor-type peptide were lysed. (C) Constructs containing patient-derived 
DNA were generated. The start of each construct was varied to obtain translation at the 
start of the transcript, resulting in both the normal and the alternative ORF or specific 
translation of only the normal or alternative ORF. Constructs were transiently transfected 
into Hela/A2 cells. RDR2 was cocultured for 24 hours, and IFN-γ release in supernatants 
was measured by ELISA. RDR2 stimulation was observed in all cases. Stimulation by 
constructs containing only the normal ORF start codon and lacking the alternative ORF 
start codon showed strongly diminished CTL recognition. Similar constructs containing 
the donor-derived DNA were not recognized by RDR2 (data not shown). 
 
Table 1. Correlation of SNP and CTL reactivity in 76 individuals 
ADIR nt 78* No. of individuals No. of lysed PHA blasts Frequency, % 
CC 33 0 43 
CT 36 36 47 
TT 7 7 9 
* Sequence analysis of nucleotides 1 to 327 of the ADIR gene in PBMCs. Nucleotide 78 
represents the SNP. 
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Tetramer staining and FACS of LB-ADIR-1F–specific CTLs 
Both peptide LB-ADIR-1F and peptide SVAPALAL-S-PA were able to bind to 
recombinant HLA-A*02:01 molecules, and tetrameric complexes were 
produced. RDR2 specifically bound the LB-ADIR-1F tetramer whereas 
SVAPALAL-S-PA tetramers and irrelevant HA-1 tetramers were negative (data 
not shown). LB-ADIR-1F tetramers were used to analyze a series of peripheral 
blood samples that were taken from the patient before and after DLI. Serum 
paraprotein levels were analyzed as a marker for disease activity. Whereas LB-
ADIR-1F–specific T cells were not detectable prior to DLI, at 7 weeks after DLI 
high numbers of LB-ADIR-1F–specific CD8 T cells could be detected (Figure 
3A). The appearance of LB-ADIR-1F–specific T cells coincided with 
development of acute GvHD grade II and resulted in complete remission. GvHD 
was treated successfully with a short course of 1 mg prednisone per kilogram of 
body weight and cyclosporin. Tetramer-positive T cells were clonally isolated by 
FACS and expanded. All tetramer-positive CTL clones were able to lyse both 
patient EBV-LCLs and LB-ADIR-1F–pulsed donor EBV-LCLs (data not shown). 
TCR characterization of RDR2 showed usage of V-beta BV7S1, J-region 
BJ1S4, and identical CDR3 regions in 43 of 44 growing clones analyzed. One 
clone, however, expressed TCRBV6S4 (Figure 3B). Analysis of the patient 
sample at 7 weeks after DLI revealed that a low percentage of LB-ADIR-1F–
positive T cells did not stain with mAb directed against TCR-BV7 (Figure 3C). 
Functional comparison of the original RDR2, newly isolated identical TCR-
BV7S1 clones, and TCR-BV6S4–expressing clones was performed. Whereas 
cytotoxicity of the original RDR2 and newly isolated BV7S1 clones was similar 
(data not shown), the BV6S4 clone showed diminished recognition of peptide-
loaded T2 cells (Figure 3D). When HLA-A2–positive and LB-ADIR-1F–
expressing EBV-LCL cells were used as target cells, again the BV6S4 clone 
displayed lower cytotoxicity (Figures 3E). Similar results were obtained using 
HLA-A2–positive and LB-ADIR-1F–expressing PHA blasts (data not shown). To 
further investigate differential recognition, reactivity of both TCR BV7S1 and 
TCR BV6S4 was tested on EBV-LCL–expressing HLA-A*0205 and HLA-A*0220 
subtypes. Lysis of LB-ADIR-1F–positive HLA-A*0205 EBV-LCLs was absent 
whereas identical strong lysis between both TCR types was observed of HLA-
A*0220 EBV-LCLs. Pulsing of HLA-A*0205 EBV-LCLs with synthetic peptide 
could only partially restore the recognition to identical levels by both TCR types 
(data not shown). 
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Figure 3. Tetramer staining and clonal analysis of LB-ADIR-1F–specific CTLs in 
the patient. (A) PBMCs from the patient taken at several time points after SCT and DLI 
were stained with LB-ADIR-1F tetramers (squares), and serum paraprotein levels were 
measured (triangles). (B) LB-ADIR-1F tetramer-positive cells present at week 7 after DLI 
were single-well sorted and expanded. TCRBV sequence analysis was performed on 44 
reactive clones revealing TCRBV7S1 in 43 clones and TCRBV6S4 in 1 clone.(C) 
Reanalysis of the patient sample was performed using counterstaining with TCRBV7 
confirming a low percentage of TCRBV7-negative cells in the LB-ADIR-1F–positive 
population (C). Reactivity of TCRBV7S1- (squares) and TCRBV6S4- (triangles) 
expressing clones was determined using 51Cr release assays on peptide-pulsed T2 cells 
(D) and EBV-LCL cells (E), demonstrating that TCRBV6S4-expressing T cells displayed 
lower cytotoxicity. 
Modulation of recognition by IFN-α and ADIR gene expression 
Because previous studies on the ADIR gene indicated that IFN-α could enhance 
gene expression37 and because the patient was also treated with IFN-α, we 
studied the effect of IFN-α on LB-ADIR-1F recognition by RDR2 using MNCs of 
LB-ADIR-1F–expressing donors. MNCs were precultured for 48 hours in the 
absence or presence of 1000 IU/mL IFN-α prior to addition of CTL RDR2 at a 
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saturating concentrations of synthetic peptide. Cytotoxicity was measured in a 
4-hour CFSE assay (Figure 4A), and IFN-γ release was measured after 24 
hours (Figure 4B). A nonsignificant increase of recognition was observed in all 
cases, whereas peptide-pulsed MNCs were recognized at levels comparable to 
EBV-LCL recognition (data not shown). Because recognition of LB-ADIR-1F–
positive cells significantly differed between freshly isolated MNCs and activated 
cells such as EBV-LCLs and PHA blasts, we measured gene expression by 
performing quantitative real-time PCR on freshly isolated MNCs and MNCs 
cultured for 24 and 48 hours in medium containing 10% FBS alone or 
supplemented with either 1000 IU/mL IFN-α or 0.8 μg/mL PHA. To each cell 
sample a fixed percentage of 1% murine spleen cells was added prior to RNA 
isolation and cDNA synthesis. Each sample was assayed for expression of 
ADIR, PBGD, and murine Gapdh. To exclude variation in mRNA isolation and 
cDNA synthesis, both ADIR and PBGD expression levels were normalized to 
the murine Gapdh expression level, which maximally resulted in 2-fold higher or 
lower outcome. Whereas expression of the household gene PBGD was only 
influenced by PHA, ADIR expression already increased upon culturing of the 
cells, irrespective of the presence of IFN-α. High ADIR expression levels in 




Figure 4. Modulation of LB-ADIR-1F–specific recognition by IFN-α. Recognition of 
MNCs from 3 different LB-ADIR-1F–positive donors was measured by (A) direct 
cytotoxicity in 4-hour CFSE assays and by (B) 24-hour IFN-γ release following 
preincubation in medium alone or in medium containing 1000 IU/mL IFN-α for 48 hours 
(shown as mean value ± SD). Recognition of MNCs (closed bars) and MNCs 
exogeneously pulsed with saturating concentrations of synthetic peptide (open bars) was 
measured at an E/T ratio of 1:1. Only minimal up-regulation of recognition in IFN-α 
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control IFN PHA control IFN PHA 
0 9 ± 3 9 ± 3 9 ± 3 5 ± 1 5 ± 1 5 ± 1 
24 24 ± 4 19 ± 6 48 ± 22 5 ± 2 3 ± 1 60 ± 53 
48 36 ± 17 23 ± 10 238 ± 91 8 ± 2 5 ± 2 178 ± 153 
       
PBMCs were incubated for the indicated times in the absence or presence of 1000 
IU/mL INF-α or 0.8 μg/mL PHA. Prior to mRNA isolation and cDNA synthesis, 1% mouse 
spleen cells were added to each sample. Data were normalized to murine Gapdh 
expression. Expression of EBV-LCLs was set to 100. 
 
Recognition of normal non-hematopoietic cells by LB-ADIR-1F specific 
CTLs 
Recognition of non-hematopoietic normal tissues was studied using BECs and 
MSCs expressing the LB-ADIR-1F SNP variant in both direct cytotoxicity assays 
and stimulation assays. Whereas direct cytotoxicity against patient EBV-LCLs 
was strong, lysis of MSCs (Figure 5A) and BECs (Figure 5B) was low. LB-
ADIR-1F peptide pulsing of MSCs and BECs did not significantly increase lysis, 
suggesting overall low susceptibility of these target cells to direct cytotoxicity. 
When MSCs (Figure 5C) and BECs (Figure 5D) were used as stimulator cells in 
IFN-γ release assays again, low stimulation by both non-hematopoietic cell 
types was observed. LB-ADIR-1F peptide pulsing of the stimulator cells 
increased stimulatory capacity of both MSCs and BECs to levels comparable to 
stimulation by patient EBV-LCLs. 
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Figure 5. Recognition of normal non-hematopoietic cells by LB-ADIR-1F specific 
CTLs. Recognition of LB-ADIR-1F–expressing HLA-A2–positive MSCs and BECs by 
CTL RDR2 was studied in 3 separate 4-hour 51Cr release assays and in 3 separate IFN-
γ secretion assays. (A,B) Lysis of untreated target cells (open squares) and target cells 
exogenously pulsed with saturating concentrations of synthetic peptide (closed squares) 
was compared with lysis of patient EBV-LCLs (open triangles). (C,D) IFN-γ secretion by 
CTL RDR2 was measured after 24 hours of co-cultivating CTL RDR2 at a 3:1 responder-
stimulator ratio with untreated cells, peptide-pulsed cells, and patient EBV-LCLs. Data 
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Recognition of malignant hematopoietic cells and solid tumor cell lines 
To investigate susceptibility to lysis by LB-ADIR-1F specific CTLs, a panel of 
HLA-A2 positive malignant hematopoietic cells was subjected to sequence 
analysis on the LB-ADIR-1F polymorphism and lysis by CTL RDR2 and allo-A2 
CTL. Prominent recognition was found of MM cells. Additionally, leukemic cells 
expressing the LB-ADIR-1F polymorphism were susceptible to lysis by RDR2 
(Figure 6A). Furthermore, when a panel of LB-ADIR-1F positive HLA-A2 
expressing solid tumor lines was tested for recognition by RDR2, lysis at levels 







Figure 6. Recognition of malignant hematopoietic cells and solid tumor cell lines. 
(A) Lysis of LB-ADIR-1F expressing MM cells in heterogeneous bone marrow samples 
was measured using the CFSE assay at a 1:1 E/T ratio and leukemic blast cell 
populations using 4-hour 51Cr release assays at an E/T ratio of 20:1. Recognition by 
RDR2 is shown by closed bars and allo-A2 control CTLs by open bars. On the x-axis the 
malignant cell type and the SNP at nucleotide 78 of the ADIR gene are depicted. MM 
and leukemic cells expressing the LB-ADIR-1F epitope (CT or TT) were recognized by 
both CTLs whereas LB-ADIR-1F negative (CC) targets were only lysed by control allo-A2 
CTLs. (B) A panel of HLA-A2 positive LB-ADIR-1F expressing solid tumor cell lines was 
tested for lysis by RDR2 (closed bars) and control allo-A2 CTL (open bars) using 4-hour 
51Cr release assays at an E/T ratio of 20:1. All tumor cell lines were lysed by LB-ADIR-1F 
specific CTLs. 
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In this study, we identified the ATP-dependent interferon-responsive gene to 
encode an activation-induced minor histocompatibility antigen that was 
recognized by MM-reactive T cells. A dominant HLA-A2–restricted CD8 CTL 
clone designated RDR2 was isolated from a patient with relapsed MM after 
allogeneic SCT responding to DLI, resulting in a long-lasting complete 
remission. Biochemical analysis of peptides eluted from HLA molecules 
revealed that this CTL clone recognized the peptide SVAPALALFPA, which was 
encoded by an alternative ORF of the human ADIR gene. This MiHA, 
designated LB-ADIR-1F, differed only by an S>F substitution from the donor-
type allelic counterpart. A population study with 76 HLA-A2 individuals revealed 
a 100% correlation between SNP occurrence and recognition of target cells, 
confirming that the CTL clone was directed against this ADIR-derived epitope, 
which had a population frequency of 57%. 
 
The function of the ADIR gene is unknown. When T-cell recognition of target 
cells and expression levels of ADIR mRNA were analyzed in various cell types, 
we demonstrated a relatively low expression of the gene in resting cells 
corresponding with low recognition. When proliferation was induced in PB T 
cells and B cells, strong gene up-regulation was observed, resulting in high 
recognition by the LB-ADIR-1F specific T cells. Although concurrent expression 
of normally and alternatively transcribed ADIR proteins cannot be directly 
determined in the cell, the strong correlation between the ADIR SNP and 
susceptibility to lysis illustrates the absence of specific expression regulation of 
the alternatively translated protein. 
 
Because the patient was treated with IFN-α and it has previously been 
described that ADIR gene expression could be up-regulated by interferons,37 we 
examined gene expression and LB-ADIR-1F specific recognition of PBMCs that 
were preincubated with IFN-α. A minor increase in ADIR gene expression was 
found after in vitro culture in serum irrespective of IFN-α preincubation. In 
addition, in the presence of IFN-α only a minimal increase in susceptibility to 
lysis and stimulatory capacity was observed. 
 
Not only MM cells but also other hematologic malignancies and non-
hematopoietic solid tumor cell lines were recognized by LB-ADIR-1F specific T 
cells. MSCs and BECs, which may represent possible target tissues of GvHD, 
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displayed low recognition by the ADIR-specific T cells. Our results illustrate 
broad antitumor reactivity of LB-ADIR-1F specific T cells as shown by the lysis 
of malignant hematopoietic cells as well as solid tumor cell lines combined with 
limited recognition of non-activated tissues. 
 
Kinetic studies of PB samples isolated from the patient before and after DLI 
using tetramers recognizing various MiHA differentially expressed in donor and 
recipient illustrated a strong correlation between the clinical response and the 
occurrence of not only a high frequency of LB-ADIR-1Fspecific T cells but also 
of HA-1 and LB-ECGF-1H specific T cells as studied previously.21,28,31,36 The 
LB-ADIR-1F specific T cells were the most dominant, comprising almost 3% of 
the CD8 T cells. Approximately 1% LB-ECGF-1H specific T cells and 0.9% 
HA1-specific T cells were found with similar kinetics. These in vivo circulating 
MiHA-specific T cells represent 80% of activated PB CD8 T cells as identified 
by co-expression of HLA-DR. Furthermore, because HA-1, ECGF, and ADIR 
proteins are highly expressed in MM cells and their relevant polymorphism can 
be recognized by T cells, we hypothesize that the 3 combined strong reactivities 
are likely to have caused the clinical course of the major response to DLI 
resulting in a complete remission lasting now for more than 6 years. 
 
In conclusion, we characterized a novel MiHA encoded by a frequently 
occurring SNP in the ADIR gene that is recognized by tumor-reactive CTLs. We 
hypothesize that the balance between GvT responses and GvHD is not only 
determined by the specificity of T cells but also by the activation state of GvHD 
target tissues.33–35,46 Up-regulated tissue susceptibility to MiHA-specific T cells 
may be caused by the cytokine storm shortly after stem cell transplantation due 
to conditioning regimens resulting in tissue damage and the presence of high 
numbers of recipient-originated antigen-presenting cells. Homeostatic 
proliferation of these T cells during the lymphopenic phase may further amplify 
the magnitude of such responses. This state may result in severe GvHD if these 
T cells are administered as part of the stem cell graft. Immunotherapy of tumor 
cells by postponed adoptive transfer of LB-ADIR-1F specific T cells following 
initially T-cell depleted transplantation may result in a strong GvT response with 
limited risk of GvHD. 
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Patients with malignant diseases can be effectively treated with allogeneic 
hematopoietic stem cell transplantation (allo-SCT). Polymorphic peptides 
presented in HLA molecules, the so-called minor histocompatibility antigens 
(MiHA), play a crucial role in antitumor immunity as targets for alloreactive 
donor T cells. Identification of multiple MiHA is essential to understand and 
manipulate the development of clinical responses after allo-SCT. In this study, 
CD8 T-cell clones were isolated from leukemia patients who entered complete 
remission after allo-SCT, and MiHA-specific T-cell clones were efficiently 
selected for analysis of recognition of a panel of EBV-transformed B cells 
positive for the HLA restriction elements of the selected T-cell clones. One 
million single nucleotide polymorphisms (SNPs) were determined in the panel 
cell lines and investigated for matching with the T-cell recognition data by whole 
genome association scanning (WGAs). Significant association with 12 genomic 
regions was found, and detailed analysis of genes located within these genomic 
regions revealed SNP disparities encoding polymorphic peptides in 10 cases. 
Differential recognition of patient-type, but not donor-type, peptides validated 
the identification of these MiHA. Using tetramers, distinct populations of MiHA-
specific CD8 T cells were detected, demonstrating that our WGAs strategy 








Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a curative 
treatment for malignant diseases1. In case of relapse, persistent disease, or 
incomplete donor chimerism after transplantation, donor lymphocytes can be 
administered to initiate or enhance graft-versus-tumor (GvT) reactivity2. 
Following HLA-matched allo-SCT, minor histocompatibility antigens (MiHA) are 
the target structures for donor-derived T cells. Presented in the context of HLA 
molecules, MiHA are peptides derived from polymorphic proteins that differ 
between individuals due to genomic single nucleotide polymorphisms (SNPs)3–
6. T-cell responses directed against MiHA have been monitored in detail in 
patients responding to donor lymphocyte infusion (DLI)7, 8. In these patients, 
detection of circulating MiHA-specific T cells coincided with rapid 
disappearance of malignant cells, indicating the in vivo efficacy of MiHA-specific 
T cells. Whether donor T cells mediate beneficial GvT effects or harmful graft-
versus-host disease (GvHD) is likely to depend on the tissue distribution of the 
target antigen. Exclusive MiHA expression on malignant cells may result in a 
selective GvT effect, whereas T cells recognizing broadly expressed MiHA may 
lead to detrimental GvHD9. 
 
Initially, biochemical identification of peptides eluted from HLA class I molecules 
recognized by MiHA-specific T cells was used for MiHA discovery10–15. In 
addition, cDNA libraries were generated and screened for T-cell recognition to 
identify the MiHA-encoding gene transcript8, 16–21. Finally, genetic linkage 
analysis has been applied to define the genomic region encoding the MiHA22, 23. 
Irrespective of the MiHA identification method, ultimate validation of each MiHA 
was provided by the strict correlation between a specific SNP genotype and 
recognition by the T-cell clone. 
 
SNPs between patient and donor may lead to MiHA expression by different 
mechanisms. The majority of MiHA are encoded by “missense” SNPs that 
directly encode an amino acid polymorphism in the protein. In addition, SNPs 
“synonymous” in the normal open reading frame (ORF) have been shown to 
encode polymorphic amino acids in MiHA epitopes upon translation of 
alternative reading frames (ARF), as previously described for LB-ECGF-1H8 
and LB-ADIR-1F15. MiHA can also be generated by protein splicing, as 
illustrated for HwA-9, which is spliced together in a noncontiguous order by the 
proteasome18. Furthermore, MiHA can be encoded by gene transcripts that 
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differ between patient and donor due to insertion or deletion of a single 
nucleotide, thereby inducing a shift in the translational reading frame, as shown 
by the LRH-1 MiHA23. Finally, MiHA may be encoded by gene transcripts that 
are homozygously deleted in the donor, as shown for MiHA encoded by the 
UGT2B17 gene17, or by intronic SNPs altering gene expression by RNA 
splicing, as shown for ACC-619.  
Although various MiHA identification approaches have led to the successful 
discovery of 20 HLA class I restricted MiHA, their laboriousness and low 
efficiency hampered identification of the majority of MiHA recognized by T-cell 
clones. Development of advanced array-based SNP genotyping, and the fact 
that MiHA are encoded by polymorphic genomic regions containing specific 
SNPs, enabled application of whole genome association scanning (WGAs) as 
an alternative approach for MiHA discovery24. Association analysis may identify 
associating SNPs that directly encode the amino acid polymorphism or may 
serve as markers for MiHA-encoding SNPs that are not measured by the array. 
These markers are in linkage disequilibrium with MiHA-encoding SNPs and 
therefore associate with T-cell recognition. The feasibility of WGAs as an 
approach to identify new MiHA has been shown by the discovery of individual 
MiHA in BCL2A124, CD1925, SLC1A526, UGT2B1726, SLC19A127, P2RX728, and 
DPH128.  
 
To understand the development of GvT reactivity and GvHD, characterization of 
large numbers of MiHA is essential. High-throughput identification and 
expression analysis of MiHA in patients with various clinical responses after 
allo-SCT may provide insight into the fundamental difference and may allow 
manipulation of the balance between GvT reactivity and GvHD. Here, we report 
the successful application of WGAs for high-throughput characterization of 
MiHA in GvT reactivity. T-cell clones were generated from two patients who 
received an HLA-matched allograft and responded to DLI for recurrence of the 
malignant disease. A panel of 80 EBV-transformed B-cell lines (EBV-LCL) was 
tested for recognition by each T-cell clone. More than 1 million SNPs were 
measured in the EBV-LCL and subsequently searched for association with the 
EBV-LCL recognition pattern of each T-cell clone. Strong association with a 
genomic region was found for 12 of the 17 T-cell clones evaluated. For 10 of 
these 12 T-cell clones, novel MiHA with balanced population frequencies 
presented in the common HLA-A*02:01 or B*07:02 molecules could be 
identified, illustrating the value and efficiency of WGAs for MiHA discovery. 
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Using tetramer analysis, the kinetics of MiHA-specific T-cell responses in the 
patients were shown to coincide with the clinical responses that were observed 
after DLI.  
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Patient H (HLA-A*02:01, B*07:02, B*44:02, C*05:01, C*07:02, DRB1*04, 
DRB1*15, DRB4*01, DRB5*01, DQB1*03, DQB1*06, DPB1*04) had 
myelodysplastic syndrome refractory anemia with excess of blasts type 2. She 
was transplanted with a T-cell depleted peripheral blood stem cell graft from a 
male HLA-matched unrelated donor. Chimerism analysis showed a decrease in 
the percentage of donor cells to 86% during the first 6 months after 
transplantation; therefore, the patient was treated with DLI. After DLI, the 
patient developed GvHD limited to skin and mouth, which coincided with a rapid 
and sustained conversion to 100% donor chimerism. Patient Z (HLA-A*01:01, 
A*02:01, B*07:02, B*44:02, C*05:01, C*07:02, DRB1*11, DRB1*15, DQB1*03, 
DQB1*06, DPB1*04, DPB1*14) is a patient with chronic myelogenous leukemia 
(CML) transplanted with a T-cell depleted peripheral blood stem cell graft from 
his HLA-identical sibling. More than 1 year after transplantation, the patient was 
successfully treated with DLI for cytogenetic relapse of CML. The patient did 
not develop GvHD. 
Materials and methods 
 
Cell collection, preparation, and EBV-LCL culture 
Peripheral blood and bone marrow samples were collected from the patients, 
their donors, and third-party individuals after approval by the Leiden University 
Medical Center Institutional Review Board and informed consent according to 
the Declaration of Helsinki. Mononuclear cells were isolated by Ficoll gradient 
centrifugation and cryopreserved. Stable EBV-LCL were generated by in vitro 
transformation of thawed mononuclear cells of selected HLA-A*02:01–positive 
and B*07:02-positive individuals using EBV supernatant29 followed by culture in 
Iscove's modified Dulbecco's medium (IMDM, Lonza) with 10% fetal bovine 
serum (FBS, Lonza). 
 
Isolation, expansion, and selection of T-cell clones 
Peripheral blood mononuclear cells (PBMC) obtained after DLI were thawed for 
isolation of T-cell clones. Monocytes were depleted using magnetic CD14 
beads (Miltenyi Biotec) according to the manufacturer's instructions. CD14-
negative cells were stained with allophycocyanin (APC)-conjugated anti-CD8 
antibody (Invitrogen) and phycoerythrin (PE)-conjugated anti–HLA-DR antibody 
(Invitrogen). Propidium iodide (Sigma-Aldrich) was added to exclude dead cells, 
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and viable HLA-DR+ CD8 cells were single-cell sorted by flow cytometry. 
Isolated T cells were collected in 96-well U-bottomed plates (Corning) in IMDM 
with 5% pooled human serum, 5% FBS, interleukin 2 (IL-2; 100 IU/mL), 
phytohemagglutinin (0.8 μg/mL, Murex Biotec Limited), and 5 × 104 irradiated 
allogeneic PBMC as feeder cells. Proliferating T-cell clones were restimulated 
every 10 to 14 days under identical stimulatory conditions at 2 × 105 T cells and 
1 × 106 feeder cells per milliliter of culture medium. T-cell (5 × 103 per well) 
recognition of patient- and donor-derived EBV-LCL as well as third-party EBV-
LCL (3 × 104 per well) were tested in 96-well U-bottomed plates in 100 to 150 
μL IMDM with 5% pooled human serum, 5% FBS, and 20 IU/mL of IL-2. After 
overnight coincubation, release of IFN-γ was measured in culture supernatants 
by ELISA according to the manufacturer's instructions (Sanquin). For blocking 
studies, EBV-LCL were preincubated with saturating concentrations of 
antibodies against HLA-A*02 (BB7.2) and HLA-B*07 (VTM3A1) for 30 minutes 
at room temperature before addition of T cells. 
T-cell receptor-β variable chain analysis 
T-cell receptor-β variable chain (TCRBV) usage was investigated by flow 
cytometry using specific monoclonal antibodies as included in the TCRBV 
repertoire kit (Beckman Coulter). T-cell clones with identical TCRBVs were 
analyzed by DNA sequencing of the CDR3 region of the TCRBV after 
amplification by PCR using specific forward and reverse primers. TCRBV 
products were purified with the Qiaquick PCR purification kit (Qiagen) and 
sequenced using the dye terminator cycle sequencing kit (ABI-PRISM, Perkin-
Elmer), according to the manufacturer's instructions. 
 
Whole genome association scanning 
A panel of 80 HLA-A*02:01 and B*07:02-expressing EBV-LCL was selected for 
WGAs. To allow simultaneous analysis of all EBV-LCL for recognition by T-cell 
clones, triplicate samples of EBV-LCL were dispensed at 6 × 104 cells in 50 μL 
per well in 96-well polypropylene U-bottomed plates (Greiner Bio-One). After 
addition of 50 μL medium containing 20% DMSO, the panel plates were sealed, 
frozen, and stored at −140°C. To test the recognition of the EBV-LCL panel by 
each individual T-cell clone, plates were thawed, washed, and incubated for 2 
days, and 5 × 103 MiHA-specific T cells were added to each well. After 24 
hours, supernatants were used for IFN-γ ELISA. Of each EBV-LCL, genomic 
DNA from 5 × 106 cells was isolated using Gentra Puregene Cell Kit (Qiagen). 
According to the manufacturer's instructions, PCR-free whole genome 
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amplification was performed. The DNA samples were subsequently fragmented, 
purified, and hybridized to Illumina Human1M-duo arrays containing probes for 
1.1 million SNPs (Illumina). After hybridization, the bead arrays were stained 
and fluorescence intensities were quantified on an Illumina Bead Array 500GX 
Scanning Station. Raw data were analyzed using Illumina Genome Studio 
software, and SNP genotype reports were generated allowing WGAs analysis 
using the Plink software (http://pngu.mgh.harvard.edu/~purcell/plink, version 
1.0330). For WGAs, categorization of the test results in two separate groups is 
required. Therefore, EBV-LCL were divided into MiHApos and MiHAneg groups 
using five times the level of IFN-γ production in the absence of EBV-LCL as a 
threshold for recognition. WGAs was performed by combining T-cell recognition 
with SNP genotyping data. The level of matching between both patterns was 
calculated according to Fisher's exact test. 
PCR amplification and gene sequencing 
RNA from the patients and their donors was isolated from EBV-LCL using Trizol 
(Invitrogen) and transcribed into cDNA by reverse transcriptase (Invitrogen) 
using oligo-dT primers (Roche Diagnostics). Genes that were located in 
associating genomic regions were amplified by PCR using various forward and 
reverse primers that were selected to comprise entire gene transcript or specific 
SNP-containing regions (see also Table S1). PCR products were purified and 
analyzed by DNA sequencing, and the obtained patient and donor sequences 
were aligned to identify SNP disparities. 
 
Peptide prediction and analysis 
For each SNP that was identified by WGAs and gene sequencing, gene 
fragments comprising the polymorphic patient-type nucleotide flanked by 30 
upstream and downstream nucleotides were translated into different reading 
frames. The online algorithm of NetMHC (31) was used to search for peptides 
with predicted binding to the appropriate HLA molecule. Peptide candidates 
were synthesized and dissolved in DMSO. Dilutions were prepared in IMDM 
and added to MiHAneg donor EBV-LCL (3 × 104 per well) in 96-well U-bottom 
plates for 2 hours at 37°C. T cells (5 × 103 per well) were added, and after 24 
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Tetramer production and staining 
Tetramers were constructed by folding peptides in appropriate biotinylated 
MHC-monomers followed by multimerization using streptavidin conjugated to 
PE or APC as previously described with minor modifications32. Patient samples 
were thawed and stained with FITC-conjugated CD4 and CD14 antibodies to 
exclude nonrelevant cells in flow cytometric analysis. MiHA-specific T cells were 
visualized using PE- or APC-conjugated tetramers and PE-Cy7–labeled anti-
CD8. On average, 5 × 105 viable cells were analyzed per staining using a 
Becton Dickinson FACS CantoII device and DIVA software. 
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Selection of MiHA-specific CD8 T-cell clones eligible for WGAs 
CD8 T cells were isolated from PBMCs obtained 5 or 6 weeks, and 8 weeks 
after DLI from patient H and patient Z, respectively. Single activated CD8 T 
cells were isolated using flow cytometry based on expression of HLA-DR. 
Percentages of CD8 T cells expressing HLA-DR were 11% (week 5) and 19% 
(week 6) for patient H and 3% (week 8) for patient Z (data not shown). Clonal 
expansion was observed for 195 T-cell clones from patient H and 37 T-cell 
clones from patient Z. All 232 clones were tested for recognition of patient- and 
donor-derived EBV-LCL by IFN-γ ELISA. The strategy followed for selection of 
MiHA-specific T-cell clones eligible for WGAs is depicted in Figure 1A. In total, 
62 T-cell clones from patient H and 16 T-cell clones from patient Z differentially 
recognized patient, but not donor, EBV-LCL, indicating recognition of MiHA. All 
78 patient-specific T-cell clones were investigated for HLA restriction using 
specific HLA class I, HLA-A*02, and B*07 blocking antibodies. Restriction to 
HLA-A*02 or B*07 was observed for 43 T-cell clones from patient H and 9 T-cell 
clones from patient Z. To identify whether T-cell clones recognized the same 
MiHA, we tested a panel of 30 HLA-A*02 and B*07 expressing EBV-LCL. In 
addition, TCRBV diversity was determined by flow cytometric analysis using 
specific TCRBV monoclonal antibodies and by DNA sequencing of the TCRBV 
CDR3 regions33. This led to identification of 20 unique MiHA recognition 
patterns, including 13 MiHA recognized by single T-cell clones and 7 MiHA 
recognized by groups of T-cell clones (Table 1). TCRBV diversity was observed 
in five of the seven groups, indicating the presence of polyclonal T-cell 
responses targeting these MiHA. Application of WGAs requires a balanced 
distribution between MiHApos and MiHAneg test samples. Recognition of 30 EBV-
LCL was used to determine this parameter, resulting in exclusion of three 
clones recognizing rare (clones H11 and H15) or common (clone H9) MiHA. 
Cross-reactivity to nonself HLA molecules was excluded by the lack of 
recognition of a panel of 25 HLA-A*02 and B*07 negative EBV-LCL (data not 
shown).  
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Figure 1. T-cell clone selection and WGAs strategy for MiHA identification. 
Strategy outline for selection of CD8 T-cell clones (A) and MiHA identification by WGAs 
(B). The digits in the arrows depict the number of clones that were selected at each step. 
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Abbreviation: nt, not tested. 
*T-cell clones were isolated from patient H and patient Z after DLI at 5 or 6 weeks, and 









H 1 A*02 2 2 50
H 2 A*02 1 1 41
H 3 A*02 1 1 23
H 4 A*02 14 3 50
H 5 A*02 1 1 97
H 6 A*02 1 1 52
H 7 A*02 1 1 0
H 8 B*07 11 1 67
H 9 B*07 4 2 37
H 10 B*07 1 1 60
H 11 B*07 2 2 53
H 12 B*07 1 1 39
H 13 B*07 1 1 13
H 14 B*07 1 1 10
H 15 B*07 1 1 0
Z 1 B*07 1 1 47
Z 2 B*07 1 1 37
Z 3 B*07 4 2 72
Z 4 B*07 1 1 53
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Identification of associating genomic regions by WGAs 
A panel of 80 HLA-A*02:01 and B*07:02 expressing EBV-LCL was generated to 
identify MiHA-encoding genes by WGAs. Genomic DNA was isolated from each 
individual EBV-LCL for SNP genotype analysis using Illumina Human 1M-duo 
bead chips. To estimate the quality of the array data, we extracted SNP 
genotypes for known MiHA. For 16 of the 27 known MiHA, probes were 
included on the Illumina Human 1M-duo bead array, and all SNP genotypes 
were accurately measured with call rates >95% and allele frequencies 
comparable with dbSNP data (see also Table S2). Next, recognition of all EBV-
LCL by each WGAs-eligible T-cell clone was tested using IFN-γ ELISA. Figure 
2 shows the recognition of all EBV-LCL for the selected T-cell clones. Clear 
clustering of MiHApos and MiHAneg EBV-LCL cells was observed for the majority 
of the T-cell clones. For clones H6 and H12, MiHApos EBV-LCL could not be 
clearly discriminated from MiHAneg EBV-LCL due to the large number of EBV-
LCL that were intermediately recognized by the T cells. WGAs was performed 
by comparing each T-cell recognition pattern with all SNP genotypes. The level 
of matching between both patterns was calculated according to Fisher's exact 
test. By selecting SNP genotypes that significantly associated with a T-cell 
recognition pattern with P values <10−9, single genomic regions could be 
identified for 12 T-cell clones. The identified regions varied in length from 1 bp 
up to 100 kb, comprising a maximum number of three genes and containing 1 
to 17 associating SNPs (see also Figure S1 and Table S3). Lack of association 
with a genomic region was observed for five T-cell clones, including clones H6 
and H12, which produced intermediate levels of IFN-γ upon co-incubation with 
a number of EBV-LCL. Clones H13 and H14, which also failed to show 
association with a genomic region, recognized MiHA with low population 
frequencies of 10% and 11%, respectively, suggesting that the power of WGAs 
was not sufficient to identify these MiHA.  
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Figure 2. Recognition of a panel of 80 EBV-LCL by MiHA-specific T-cell clones. 
(A,B) HLA-A*02:01 and B*07:02 restricted T-cell clones recognizing MiHA with 
population frequencies between 10% and 90% were tested for recognition of a panel of 
80 HLA-A*02:01 and B*07:02 EBV-LCL. Each dot represents the mean of triplicate IFN-γ 
production (ng/mL) as measured by ELISA after overnight co-incubation of the T-cell 
clone (indicated on the X axis) with each EBV-LCL. Lines indicate the threshold of five 
times background IFN-γ production to segregate MiHApos from MiHAneg EBV-LCL. 
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Identification of MiHA-encoding SNPs 
The strongest associating SNPs within each region were further examined, and 
associating SNPs were found in coding and noncoding gene regions (Table 2). 
Associating missense SNPs, encoding amino acid polymorphisms in the normal 
ORF, were found in the genes WNK1, SSR1, PRCP, PDCD11, EBI3, and 
APOBEC3B. These SNPs may directly encode the MiHA. Clone H1 and its 
associating SNP rs12828016 located in exon 21 of the WNK1 gene is shown as 
a representative example in Figure 3A. Associating synonymous SNPs were 
found in the genes ARHGDIB and GEMIN4, and associating SNPs in 
noncoding regions were found in the genes TTK, ERAP1, BCAT2, and 
ERGIC1. Associating synonymous SNPs and SNPs in noncoding regions may 
serve as marker SNPs for missense SNPs, which are not measured by the 
bead array. To search for these disparate missense SNPs, all genes 
comprising associating synonymous SNPs and SNPs in noncoding regions as 
identified by WGAs were investigated by analyzing cDNA derived from both 
patient and donor. Sequence analysis of gene transcripts revealed the 
presence of disparate missense SNPs in the genes ERAP1, BCAT2, and 
GEMIN4. Figure 3B shows clone H8 and its associating SNP rs26654 located 
in intron 1 of the ERAP1 gene as a representative example of a marker SNP, 
which is in linkage disequilibrium with SNP rs26654 located in exon 2 identified 
after gene sequencing. Sequence analysis revealed that ARHGDIB gene 
transcripts were completely identical between patient and donor, except for the 
single associating synonymous SNP rs4703 as identified by WGAs. These data 
suggest that this SNP directly encodes the MiHA in an ARF, as previously 
reported for other MiHA8, 15. The TTK and ERGIC1 genes, identified by strong 
association of SNPs in noncoding regions, did not show any SNP disparity 
between patient and donor in coding regions. In conclusion, WGAs in 
combination with gene sequencing led to identification of disparate missense 
SNPs for 10 of the 12 genes (Table 2).  
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Table 2. Identification of MiHA-encoding SNPs 
 
*Additional SNP disparities in coding regions identified after gene sequencing.  
by association P by sequencing* pat don name location
H 1 rs12828016 1.1×10−16 missense AC CC WNK1 exon 21
rs1886568 7.8×10−15 — GG AA SSR1 intron 1
rs10004 7.8×10−15 missense GG AA SSR1 exon 2
rs3778333 7.8×10−15 — GG AA SSR1 intron 2
H 3 rs2298668 1.1×10−12 missense AC AA PRCP exon 4
H 4 rs608962 3.6×10−20 not found — GG AA TTK intron 20
rs26654 1.2×10−19 — AG AA ERAP1 intron 1
rs26653 missense CC GG ERAP1 exon 2
rs736170 1.3×10−16 — AG AA BCAT2 intron 1
rs4801775 1.3×10−16 — AG AA BCAT2 intron 3
rs4802507 1.3×10−16 — AC AA BCAT2 intron 3
rs11548193 missense CG CC BCAT2 exon 6
H 10 rs4703 5.5×10−16 synonymous CG GG ARHGDIB exon 6
rs2986014 4.2×10−15 missense AG GG PDCD11 exon 24
rs2281860 4.2×10−15 — AG GG PDCD11 intron 30
rs6580 4.2×10−15 — AG AA CALHM2 3' UTR
rs1045481 9.1×10−15 synonymous AG GG GEMIN4 exon 2
rs1045491 9.1×10−15 — AG GG GEMIN4 3' UTR
rs4968104 missense AT AA GEMIN4 exon 2
rs1064245 9.1×10−15 — AC AA FAM57A 3' UTR
rs4740 3.4×10−14 missense AG GG EBI3 exon 5
rs4905 3.4×10−14 synonymous AG AA EBI3 exon 5
Z 3 rs2076109 8.8×10−17 missense AG GG APOBEC3B exon 3
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Figure 3 (previous page). Identification of candidate genes and MiHA-encoding 
SNPs by WGAs. Association results and selection of candidate MiHA-encoding SNPs 
are shown for WNK1 (A) and ERAP1 (B) genes as representative examples. 
Significance of association for each individual array SNP as expressed by P-value is 
depicted. Each dot represents the array SNP relative to its physical position on the 
genome. The image below each plot shows the gene aligned to the chromosomal 
position as indicated on the X axis of the plot. Exons and introns are represented by dark 
and light boxes, respectively. A. For clone H1, the strongest associating SNP is located 
in exon 21 of the WNK1 gene and encodes an amino acid polymorphism. B. The 
strongest associating SNP for clone H8 is located in intron 1 of the ERAP1 gene. 
Sequence analysis revealed a disparate missense SNP in exon 2 of the ERAP1 gene. 
 
Prediction and recognition of MiHA epitopes 
Gene sequences containing missense and synonymous SNPs identified by 
WGAs and DNA sequencing were translated in the normal ORF and in all 
ARFs, respectively, and searched for peptides with predicted binding to HLA-
A*02:01 and B*07:02 using the online algorithm of NetMHC (31). All peptide 
variants with predicted binding to HLA-A*02:01 and B*07:02 are shown in Table 
3. Peptides of 9 to 11 amino acids with predicted binding to HLA-A*02:01 or 
B*07:02 were synthesized, exogenously pulsed on MiHAneg donor EBV-LCL, 
and tested for T-cell recognition. For nine polymorphic peptides, strong 
recognition of a single predicted candidate peptide or variable levels of 
recognition for candidate peptides of various lengths was observed (Table 3). 
The SSR1-derived HLA-A*02:01 binding candidate peptide, however, was not 
recognized. Longer 14-mer and 21-mer SSR1-derived peptides spanning the 
identified patient-type amino acid polymorphism were clearly recognized, albeit 
at high peptide concentrations of 50 μmol/L (data not shown), thereby 
confirming that the missense SNP encodes the MiHA epitope, but leaving the 
precise composition of the epitope unknown. For all identified MiHA epitopes as 
shown in Table 3, as well as for the longer SSR1 peptides, no recognition of 
donor-type peptides was observed. This validated the identification of 10 novel 
MiHA encoded by SNPs as identified by our approach of WGAs (Figure 1B).  
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Table 3. Prediction and recognition of MiHA epitopes 
 
 
Abbreviation: nt, not tested. *Patient-type amino acid residues are underlined. 
†Amino acid polymorphism after translation in an ARF. 
Clone 





































H 3 LB-PRCP-1D rs2298668 Asp/Glu A*02:01
H 1 LB-WNK1-1I rs12828016 Ile/Met A*02:01
H 9 LB-BCAT2-1R rs11548193 Arg/Thr B*07:02
H 8 LB-ERAP1-1R rs26653 Arg/Pro B*07:02
H 11 LB-PDCD11-1F rs2986014 Phe/Leu B*07:02
H 10 LB-ARHGDIB-1R rs4703 Arg/Pro† B*07:02
Z 3 LB-APOBEC3B-1K rs2076109 Lys/Glu B*07:02
Z 2 LB-EBI3-1I rs4740 Ile/Val B*07:02
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Detection of MiHA-specific T-cell responses 
To analyze the kinetics of the T-cell responses specific for the novel MiHA as 
identified by WGAs, donor samples as well as sequentially obtained peripheral 
blood samples from the patients were stained with tetramers and analyzed by 
flow cytometry. Except for LB-BCAT2-1R, we could construct stable tetramers 
that successfully stained the respective T-cell clones for all novel MiHA. 
Tetramer analysis revealed the presence of T cells specific for the MiHA in 
patient H, and for one MiHA in patient Z (Figure 4). The frequencies of MiHA-
specific T cells peaked at day 41 and 62 in patients H and Z, respectively, 
coinciding with conversion to full donor chimerism in patient H and 
disappearance of the BCR-ABL fusion product as a marker for disease in 
patient Z. No significant tetramer-positive events were detected using tetramers 

















Figure 4 (facing page). MiHA-specific T-cell responses in patients H and Z. 
Tetramers were constructed to measure MiHA-specific CD8 T cells in peripheral blood 
samples obtained at several time points, as indicated on the X axis. On the primary Y 
axis, the absolute number of tetramer-positive cells per milliliter of blood is depicted. The 
secondary Y axis depicts donor chimerism in patient H (A) and disease status in patient 
Z (B).  
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In this study, we developed an efficient strategy for T-cell selection and MiHA 
identification by WGAs. This WGAs-based strategy allowed detailed 
investigation of the specificity and diversity of antitumor T-cell responses in two 
patients successfully treated with HLA-matched allo-SCT and DLI. The strategy 
is based on efficient selection of MiHA-specific T-cell clones and a panel of 80 
third-party EBV-LCL for simultaneous measurement of T-cell recognition and 
1.1 million SNP genotypes. From the 17 selected T-cell specificities, 10 novel 
MiHA were identified, illustrating the value of this WGAs-based strategy for 
broad characterization of MiHA in clinical immune responses.  
For 5 of the 17 selected T-cell specificities, we failed to show significant 
association with SNP genotypes by WGAs. Two T-cell clones recognized a 
limited number of EBV-LCL, suggesting that the power of the WGAs strategy 
may not be sufficient to identify MiHA with low population frequencies. Two 
other T-cell clones for which we failed to show association with SNP genotypes 
by WGAs released intermediate levels of IFN-γ upon coincubation with a 
number of EBV-LCL, thereby hampering separation of EBV-LCL in MiHApos and 
MiHAneg groups. Finally, for one T-cell clone, a balanced segregation of MiHApos 
and MiHAneg EBV-LCL was observed; however, no significant association with 
any SNP genotype was detected. For this T-cell clone, association may be 
found by measuring more SNP genotypes, for example, by testing EBV-LCL 
from the International HapMap project, which have been genotyped for more 
than 4 million SNPs and recently shown to represent a valuable source for 
MiHA discovery25–27.  
Our WGAs-based strategy revealed a number of SNPs that associated with T-
cell recognition with significant P-values. We separated the missense SNPs 
from the synonymous SNPs and SNPs located in noncoding regions. Missense 
SNPs were directly analyzed for HLA binding prediction and identification of the 
MiHA peptide epitopes. All six missense SNPs were found to encode the MiHA 
epitope. Synonymous SNPs and SNPs in noncoding regions may serve as 
markers for MiHA-encoding SNPs that are not measured by the bead array. 
Therefore, genes comprising marker SNPs were first analyzed by gene 
sequencing to reveal all SNP disparities between patient and donor. For two T-
cell clones, associating synonymous SNPs were found, of which one was 
shown to serve as a marker for a MiHA-encoding missense SNP and the other 
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directly encoded the MiHA epitope translated in an ARF, as previously 
described for LB-ECGF-1H8 and LB-ADIR-1F15. Finally, for four T-cell clones, 
associating SNPs were located in noncoding regions. In two cases, intron SNPs 
were in linkage disequilibrium with MiHA-encoding missense SNPs, whereas no 
SNP disparities in coding gene regions were found for the other two T-cell 
clones.  
For two T-cell clones showing strong association with intron SNPs, without SNP 
disparities in the coding regions of the associating genes of patient and donor, 
we explored the possibility that a monomorphic epitope is recognized, which 
may be under differential control of a SNP located in a regulatory region. The 
entire coding regions of the TTK and ERGIC1 genes were cloned into an 
expression vector and introduced into MiHA-negative cells, but no T-cell 
recognition of the transfected genes was observed (data not shown). Therefore, 
we consider it likely that these MiHA are encoded by SNPs located outside 
known protein coding regions of the candidate genes, for example, by an intron 
SNP of an alternative mRNA splice variant, as previously described for        
ACC-619, and we speculate that these MiHA may be most difficult to identify by 
WGAs.  
As a final step in the discovery of MiHA, specific recognition of patient-type 
peptide was established. All identified MiHA epitopes were accurately predicted 
using the binding algorithm of NetMHC31, as shown by T-cell recognition of 
donor EBV-LCL pulsed with the predicted patient-type, but not donor-type, 
peptide variants. Weak, but patient-specific, recognition was observed for 
peptides derived from APOBEC3B and SSR1. The SSR1 epitope is a 
nonconventional peptide of 14 amino acids. Although recognition was weak, the 
T-cell clone differentially recognized patient-type, but not donor-type, 14-mer 
peptides demonstrating T-cell specificity for this polymorphism. Weak 
recognition of pulsed synthetic peptides may indicate posttranslational 
modification of endogenous epitopes, as previously described for the SMCY 
antigen34. Another explanation may be that the T-cell clone expresses a T-cell 
receptor with a relatively low avidity, which is, however, sufficiently high to 
recognize MiHA that are abundantly expressed at the cell surface of patient 
cells.  
The MiHA described in this study were identified as targets for T cells isolated 
from patients receiving DLI for incomplete donor chimerism or recurrent disease 
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after allo-SCT. Specific tetramer staining of CD8 T cells was shown for the 
majority of the novel MiHA, and peak frequencies coincided with the 
development of clinical responses in the patients. Despite staining of the 
respective T-cell clones (data not shown), no tetramer-positive T cells were 
detected in the samples of patient Z using LB-APOBEC3B-1K and LB-EBI3-1I 
tetramers. Intermediate TCR avidity, as expressed by the intermediate EC50 
value for recognition of APOBEC3B-derived peptides, may cause the lack of 
detection of the LB-APOBEC3B-1K–specific T cells. The absence of tetramer-
positive T cells for LB-EBI3-1I may be explained by a low frequency of 
circulating T cells. Whereas the individual contribution of each MiHA-directed T-
cell response cannot be determined, the induction of strong GvT reactivity and 
the absence of severe GvHD in both patients suggest involvement of one or 
more MiHA with selective or predominant expression in malignant 
hematopoietic cells.  
In conclusion, we present an efficient WGAs-based strategy for broad 
characterization of MiHA. Our WGAs approach is valuable as a high-throughput 
method for detailed analysis of the specificity and diversity of T-cell responses 
in patients with different clinical responses as well as for selective identification 
of clinically relevant MiHA with hematopoietic restricted expression.  
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Figure S1. Whole genome association scanning results data 
WGAs results for 12 T-cell clones showing significant association with SNP-genotypes in 
single genomic regions are given. Individual graphs represent the result of the indicated 
T-cell clone. The p value of array SNPs depicted as dots are shown relative to their 
physical position in the genome, with chromosome numbers plotted on the X-axis. P 
values depicted on the Y-axis indicate the significance of association of each array SNP.  
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Table S1. Primer sequences 
  
Start Stop Remark* Primer sequence†
ARHGDIB 1175 1216 105-710 69 701 BamH1 For                                                            CGCGGATCCGGACAGAGACGTGAAGC
EcoR1 Rev                                                            CCGGAATTCACCACTCCTTCTTAATCGACAG
510 1216 BamH1 For                                         CGCGGATCCACCATGGTGGATAAAGCAACATTTATGG
XhoI Rev                                                            CCGCTCGAGCTCAGCCAGAACACACACAG
GEMIN4 15721 3757 120-3296 854 2420 BamH1 For                                                           CGCGGATCCACCATGCTGACTGTGTTTGCGC
EcoR1 Rev                                                               CCGGAATTCAGTCTAGCTGTTCTAACTTG
2287 3655 BamH1 For                                                        CGCGGATCCACCATGGATAGGAAGGATCTAGCGA
EcoR1 Rev                                                              CCGGAATTCAGTTATGAACATGTTCCTCC
TTK 1166691 3019 124-2694 124 1515 BamH1 For                                                           CGCGGATCCACCATGGAATCCGAGGATTTAAGTG
XhoI Rev                                                               CCGCTCGAGTCAGCTCATGTAATCATCCAAG
1343 2215 BamH1 For                                                           CGCGGATCCACCATGCAGATTCCGGAGTTAGCC
EcoR1 Rev                                                             CCGGAATTCACATATCTTTGATTGCTTCTGG
2132 2963 BamH1 For                                                      CGCGGATCCACCATGCAACCAGATACAACAAGTG
XhoI Rev                                                           CCGCTCGAGCTTGCTATCCACCCACTATTC
ERAP1 1040458 5085 348-3173 140 816 - For                                                                                   GTTTACCCTTTCCCCAGCTC
- Rev                                                                                       CCGAAAGATTGCCAGCATAG
669 1290 - For                                                                                   AGGAAGGGAGCTGGAGAGAG
- Rev                                                                                  GAAAGTCGGGAATAGCAGCA
1268 1973 - For                                                                                       TCTTGCTGCTATTCCCGACT
- Rev                                                                                    TACATTCCTCCCCCTCACTG
1890 2583 - For                                                                              GTGGATGTGAAAACCATGATGA
- Rev                                                                              TCTGTACGCACGGCTGATAG
BCAT2 1190 1616 38-1216 510 972 - For                                                                              ATCGAAGTGGACAAGGACTG
- Rev                                                                              GAGCCATGTCCAGTAGACTC
918 1472 - For                                                                              CTGAATGGTGTTATCCTGCCTG
- Rev                                                                              GCACGACAAGGAGTAATGGG
ERGIC1 1031711 2949 195-1067 191 1439 BamH1 For                                                                              CGCGGATCCACGATGCCCTTTGACTTCA
EcoR1 Rev                                                                              CCGGAATTCGCGAGATTGTCGAAGCCTG
1395 2910 BamH1 For                                                                              CGCGGATCCAGAATGCATATCGATCAGC
EcoR1 Rev                                         CGGGAATTCTAGTTGAACCCAACGAGTG
*Restriction endonuclease cleavage sites were included for cloning of PCR products.
†Primers were selected to completely overlap the transcript, or transcript regions that contained SNPs.
PCR product
Name Accession  NM id Length CDS
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Table S2. Detection of known MiHA by Illumina1M array
 
* Both alleles of this polymorphism encode an immunogenic epitope. 
†  Call rate expresses the percentage of successful SNP measurements by the Illumina 
1M array after analysis of 80 DNA samples obtained from EBV-LCL. 
  
Identifier Function Nucleotide Measured dbSNP
ACC-1 rs1138357 missense G* 0,69 0,75 100
ACC-2 rs3826007 missense G 0,69 0,75 100
HA-1 rs1801284 missense G 0,62 0,67 97
HA-3 rs7162168 missense T 0,37 0,33 98
HA-8 rs2173904 missense G 0,53 0,53 99
HB-1H/Y rs161557 missense C/T* 0,8 0,86 100
HEATR1 rs2275687 missense A 0,32 0,33 100
HwA-10 rs5758511 missense C 0,72 0,74 100
HwA-9 rs1365776 protein splicing G 0,45 0,38 100
LB-ADIR-1F rs2296377 alternative RF T 0,27 0,21 99
LB-LY75-1K rs12692566 missense A 0,17 0,23 100
LB-MR1-1R rs2236410 missense A 0,92 0,82 95
LB-MTHFD1-1Q rs2236225 missense G 0,64 0,54 100
LB-PTK2B-1T rs751019 missense A 0,55 0,49 99
SLC19A1 rs1051266 missense A 0,34 0,19 99
ACC-4 ACC-5 rs2289702 missense









UGT2B17 rs10034124 gene deletion
MiHA
SNP Frequency immunogenic allele
Call rate†
Not included in Illumina 1M array
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Table S3. Identification of associating genomic regions 
 
Clone type 
Associating genomic region* 
# SNP P<10-9 Location Length (kbp) 
H 1 3 12p13.3 38 
H 2 12 6p24.3 99 
H 3 5 11q14 62 
H 4 17 6q13 76 
H 6 0 - - 
H 8 14 5q15 90 
H 9 3 19q13 9 
H 10 1 12p12.3 <1 
H 11 13 10q24.33 46 
H 12 0 - - 
H 13 0 - - 
H 14 0 - - 
Z 1 7 17p13 49 
Z 2 8 19p13.3 31 
Z 3 2 22q13.1 7 
Z 4 3 5q35.1 8 
Z 5 0 - - 
 
*For each T-cell clone, associating genomic regions were defined by the number of 
SNPs with P<10-9  as calculated by Fisher’s exact test. 
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Patients with hematologic malignancies can be successfully treated with donor 
lymphocyte infusion after HLA-matched allogeneic hematopoietic stem cell 
transplantation. The effect of donor lymphocyte infusion is mediated by donor T 
cells recognizing minor histocompatibility antigens. T cells recognizing 
hematopoietic restricted minor histocompatibility antigens may induce selective 
graft-versus-leukemia reactivity, whereas broadly expressed antigens may be 
targeted in graft-versus-host disease. We analyzed in detail CD8 T-cell 
immunity in a patient with relapsed chronic myelogenous leukemia who 
responded to donor lymphocyte infusion with minimal graft-versus-host disease 
of the skin. CD8 T-cell clones specific for 4 HLA-B*40:01 restricted minor 
histocompatibility antigens were isolated which were identified by screening a 
plasmid cDNA library and whole genome association scanning. Detailed T-cell 
reactivity and monitoring experiments were performed to estimate the clinical 
and therapeutic relevance of the novel antigens. Three antigens were 
demonstrated to be expressed on primary leukemic cells of various origins as 
well as on subtypes of non-malignant hematopoietic cells, whereas one antigen 
was selectively recognized on malignant hematopoietic cells with antigen 
presenting cell phenotype. Skin derived fibroblasts were only recognized after 
pre-treatment with IFN-γ by two T-cell clones. Our data show evidence for 
different roles of the HLA-B*40:01 restricted minor histocompatibility antigens in 
the onset and execution of the anti-tumor response. All antigens may have 
contributed to a graft-versus-leukemia effect, and one minor histocompatibility 
antigen (LB-SWAP70-1Q) has specific therapeutic value based on its in vivo 
immuno-dominance and strong presentation on leukemic cells of various 
origins, but absence of expression on cytokine-treated fibroblasts. 
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Patients with hematologic malignancies can be successfully treated with HLA-
matched allogeneic hematopoietic stem cell transplantation (alloSCT).1 To 
reduce the development of graft-versus-host disease (GvHD), donor T cells can 
be depleted from the stem cell graft, and re-administered after alloSCT pre-
emptively in case of persistent mixed chimerism or upon detection of relapsed 
or residual malignant cells.2 The risk and severity of GvHD after this 2-step 
procedure of T-cell depleted alloSCT and donor lymphocyte infusion (DLI) is 
reduced compared to non-T-cell depleted alloSCT. 
The anti-tumor effect of DLI after HLA-matched alloSCT is mediated by donor T 
cells recognizing minor histocompatibility antigens (MiHA) in the context of HLA 
molecules.3–7 MiHA are peptides which are differentially expressed at the cell 
surface of patient and donor cells due to amino acid differences encoded by 
single nucleotide polymorphisms (SNPs). Donor T cells recognizing MiHA with 
restricted expression to hematopoietic cells may selectively induce graft-versus-
leukemia (GvL) reactivity, whereas donor T cells specific for MiHA with broad 
tissue distribution patterns may also mediate GvHD. 
 
Although various HLA class I associated MiHA have been identified in the last 
decades,3–7 the number of MiHA with therapeutic relevance is still limited. We 
and others recently demonstrated that Whole Genome Association scanning 
(WGAs) is an efficient method for high throughput identification of MiHA,8–12 
illustrated by the discovery of 10 novel MiHA as targets for CD8 T cells in 2 
different patients with leukemia who responded to DLI after HLA-matched 
alloSCT.12 Since these MiHA were all presented in HLA-A*02:01 and B*07:02, 
we selected 80 third-party EBV-transformed B cell lines (EBV-LCL) for co-
expression of these HLA molecules, and genotyped all cell lines for more than 
one million SNPs. MiHA were identified by analysis of association between T-
cell recognition of these EBV-LCL and individual SNP genotypes. 
 
In this report, we identified 4 novel HLA-B*40:01 restricted MiHA as targets for 
CD8 T cells in a patient who developed strong GvL reactivity with minimal 
GvHD of the skin after treatment with DLI for relapsed chronic myelogenous 
leukemia (CML) more than one year after HLA-matched alloSCT. One MiHA 
was identified by screening a plasmid cDNA expression library, whereas the 
other 3 MiHA were identified by WGAs. The data illustrate that our method of 





the HLA restriction allele allows identification of MiHA. Detailed T-cell reactivity 
and monitoring experiments were performed to estimate the clinical and 
therapeutic relevance of the HLA-B*40:01 restricted MiHA. The data showed 
that all MiHA may have contributed to a GvL effect, and that one MiHA (LB-
SWAP70-1Q) has specific therapeutic value based on its in vivo immuno-
dominance and strong presentation on leukemic cells of various origins, but 














A 47-year old woman with chronic phase CML was transplanted with 
hematopoietic stem cells from her HLA-identical sister (HLA-A*02:01, A*24:02, 
B*08:01, B*40:01, C*03:04, C*07:01)13. Nine months after alloSCT, BCR/ABL 
transcripts were detected, indicating a cytogenetic relapse. Retrospective 
molecular analysis of stored samples showed the presence of BCR/ABL 
transcripts at three and six months after alloSCT. In preparation for DLI, she 
was treated with 3×106 units of α-IFN daily s.c. Four weeks later the CML had 
progressed to a hematologic relapse, and 107 donor mononuclear cells per kg 
body weight were administered. After DLI she converted to 100% donor 
chimerism. The DLI was complicated by grade I GvHD of the skin and mouth for 
which no systemic immunosuppressive treatment was necessary. Currently, 
more than 12 years after DLI, she is still in good clinical condition without 
GvHD.  
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Materials and methods 
 
Patient and donor samples 
Peripheral blood (PB) and bone marrow (BM) samples and skin biopsies from 
patients with CML, acute myeloid leukemia (AML), acute lymphoblastic 
leukemia (ALL), chronic lymphocytic leukemia (CLL) and multiple myeloma 
(MM), and PB and BM samples from healthy individuals were obtained after 
receiving approval from the LUMC Institutional Review Board and informed 
consent according to the Declaration of Helsinki. Mononuclear cells were 
isolated by Ficoll-Isopaque gradient centrifugation and cryopreserved. 
 
Isolation and culture of T-cell clones 
Peripheral blood mononuclear cells (PBMC) obtained six weeks after DLI were 
stimulated overnight with irradiated BM cells obtained from the patient prior to 
alloSCT, and single IFN-γ producing CD8 T cells were isolated by flowcytometry 
after staining with PE-conjugated antibody against IFN-γ (Miltenyi Biotec GmbH, 
Bergisch Gladbach, Germany). In addition, PBMC were stained with FITC-
labeled anti-HLA-DR and APC-conjugated anti-CD8 antibodies (BD 
Biosciences, Breda, The Netherlands), and in vivo activated HLA-DR+ CD8 T 




EBV-transformed B cells (EBV-LCL) and COS-7 cells were cultured in IMDM 
with 10% FCS. PHA-T blasts were generated by stimulating PBMC with IL-2 
and PHA similar as described for T-cell clones. Primary fibroblasts (FB) and 
keratinocytes (KC) were cultured from skin biopsies in DMEM with low glucose 
(Cambrex) and 10% FCS supplemented with and without IFN-γ (100 IU/mL; 
Immukine; Boehringer Ingelheim, Alkmaar, The Netherlands) for four days. 
Proximal tubular epithelial cells (PTEC) cultured with and without IFN-γ (100 
IU/mL) were kindly provided by Dr C van Kooten (Dept. Nephrology, LUMC, 







Isolation of CD8 T-cell clones for minor histocompatibility antigens 
A detailed analysis of CD8 T-cell immunity was made in a patient who 
developed a strong GvL response with only limited GvHD after treatment with 
DLI for relapsed CML more than one year after alloSCT. In previous 
experiments, the GvL response in this patient was shown to coincide with a 
peak response in numbers of CD8 T cells specific for hematopoietic restricted 
MiHA HA-1 and HA-2 between 4–8 weeks after DLI.13 To investigate whether, in 
addition to HA-1 and HA-2, other MiHA were targeted in this GvL response, 
single CD8 T cells were isolated by flowcytometry from patient PBMC obtained 
six weeks after DLI. T cells were isolated based on specific production of IFN-γ 
after overnight stimulation with irradiated BM cells obtained from the patient 
prior to alloSCT,14 and based on expression of activation marker HLA-DR as 
previously described.12,15 CD8 T-cell clones showing specific lysis and 
recognition of patient, but not donor, EBV-LCL in 4 h 51Cr-release assays and 
IFN-γ ELISA (Figure 1A) were selected and tested against a panel of EBV-LCL 
sharing one or more HLA class I alleles with the patient. The data demonstrated 
that the T-cell clones (ZRZ16, ZRZ25, 12A2 and 3H1) were specific for 4 
unknown MiHA in HLA-B*40:01, as confirmed by retroviral transfer of the HLA 
restriction allele (Figure 1B). 
 
Identification of minor histocompatibility antigens by screening a plasmid 
cDNA expression library 
To identify the unknown MiHA, a plasmid cDNA expression library was 
constructed from patient derived EBV-LCL as previously described.16 COS-7 
cells stably expressing HLA-B*40:01 were transfected with pools of 50 different 
cDNAs, and screened for T-cell recognition in IFN-γ ELISA using different 
mixtures of the MiHA specific CD8 T-cell clones. By screening COS-7 cells, one 
positive cDNA pool was recognized by clone ZRZ16. In a second round of 
screening of single plasmids, a cDNA was isolated encompassing the 1102 – 
2029 bp region of the gene encoding thyroid hormone receptor interactor 
protein 10 (TRIP10). By cloning different cDNA regions of the TRIP10 gene, the 
MiHA was shown to be encoded within the 1574–1810 bp region that contains 
the stop codon of the TRIP10 coding sequence at 1704 bp (See also Figure 
S1). This region was sequenced in patient and donor cDNA, and 3 SNP 
differences were demonstrated in the 3′ untranslated region (UTR) of the gene 
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ZRZ16 ZRZ25 12A2 3H1 allo-A2
at 1761 bp (rs1049229), 1763 bp (rs1049230) and 1775 bp (rs1049232). Long 
19–22 AA peptides comprising protein sequences in 3 different reading frames 
were synthesized, pulsed on donor EBV-LCL, and tested for T-cell recognition 
in IFN-γ ELISA. One of the long peptides (ARF1) comprising AA sequences in a 
reading frame different from the upstream encoded TRIP10 protein was 
recognized. The minimal epitope LB-TRIP10-1EPC was identified as a 9-mer 
peptide comprising 3 AA encoded by SNP differences (GEPQDLCTL), of which 
the E and C most significantly contributed to T-cell recognition, as determined 
by analysis of patient type peptides containing single AA of donor origin (See 
also Figure S1).  
 
Figure 1. Isolation of CD8 T-cell clones specific for HLA-B*40:01 restricted MiHA. 
(A) A number of selected CD8 T-cell clones showed reactivity against patient, but not 
donor, EBV-LCL. Mean percentage of specific lysis in triplicate wells is shown at E:T 
ratios of 10:1 in 4 h 51Cr-release assays (upper) and of IFN-γ (ng/mL) in 50 μL culture 
supernatants of duplicate wells in ELISA (lower). Reactivity against patient and donor 
EBV-LCL by an allo-HLA-A*02:01 reactive T-cell clone is shown as control. (B) Selected 
CD8 T-cell clones were specific for MiHA in HLA-B*40:01, as demonstrated by specific 
recognition of MiHA+ EBV-LCL after retroviral transfer of MP71-HLA-B*40:01-IRES-
NGFR, but not mock MP71 vector, in IFN-γ ELISA. Specific production of IFN-γ (ng/mL) 






Identification of minor histocompatibility antigens by whole genome 
association scanning 
In addition to screening a plasmid cDNA expression library, WGAs was 
performed to identify the unknown MiHA in HLA-B*40:01. We retrovirally 
transduced third party EBV-LCL, which we previously genotyped for more than 
one million SNPs,12 with MP71-HLA-B*40:01-IRES-NGFR. A total number of 60 
SNP-genotyped EBV-B cell lines expressing HLA-B*40:01 endogenously or 
after retroviral transduction were analyzed for recognition by T-cell clones 
ZRZ25, 12A2 and 3H1 in IFN-γ ELISA (Figure 2A). For each T-cell clone, SNP-
genotyped EBV-LCL were separated into MiHA positive and negative groups 
using a threshold of recognition of 5-fold background production of IFN-γ. T-cell 
recognition patterns of EBV-LCL were subsequently analyzed for association 
with all individual SNP genotypes as previously described,12 and the level of 
matching between both patterns was calculated according to Fisher’s exact test 
using Plink statistical analysis package (http://pngu.mgh.harvard.edu/ 
purcell/plink/version1.03). Table 1 shows the strongest associating SNPs 
(P<10−9) for all T-cell clones. Associating missense SNPs in the genes 
encoding SON DNA-binding protein (SON), SWAP switching B-cell complex 70 
kDa subunit (SWAP70) and nucleoporin 133 kDa (NUP133) were measured for 
T-cell clones ZRZ25, 12A2, and 3H1, respectively. 
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Table 1: Associating SNPs encoding candidate MiHA 
 
1P value as calculated using Fisher's exact test indicates the strength of association 
between the indicated SNP genotype and recognition of a panel of ~60 EBV-LCL 





clone # gene SNP id location pat/don p
1 predicted HLA-
binding peptide
rs7279549 intron 1 1.28*10-10
rs13047599 exon 3 CT/TT 1.28*10-10 SETKQR(C)TVL
rs11088256 3' near gene 1.28*10-10
rs7283856 3' near gene 1.28*10-10
12A2 11 SWAP70 rs415895 exon 10 GC/CC 3.04*10-11 MEQLEQ(E)LEL






To identify the minimal MiHA epitopes, amino acid sequences comprising the 
associating missense SNPs were searched for peptides with predicted binding 
to HLA-B*40:01 using the algorithm of NetMHC (http://www.cbs.dtu.dk/ services 
/NetMHC). For all associating missense SNPs, 9-mer peptides with predicted 
binding to HLA-B*40:01 were synthesized, pulsed on donor EBV-LCL, and 
shown to be recognized by the T-cell clones. This validated the identification of 
3 HLA-B*40:01 restricted MiHA encoded by the genes for SON (LB-SON-1R; 
SETKQRTVL), SWAP70 (LB-SWAP70-1Q; MEQLEQLEL) and NUP133 (LB-
NUP133-1R; SEDLILCRL) recognized by T-cell clones ZRZ25, 12A2 and 3H1, 
respectively (Figure 2B). Donor type peptide variants were not recognized, 
except for the donor peptide encoded by the NUP133 gene. We amplified the 
NUP133 genes from patient and donor derived cDNA by PCR, and cloned the 
genes into expression vector pcDNA-3. Cells transfected with the patient 
derived NUP133 gene encoding the R at position 406 were strongly recognized 
by clone 3H1, whereas cells transfected with the donor derived NUP133 gene 
encoding the Q at this position were not recognized (Figure 2C). These data 
demonstrated that differential recognition of patient and donor derived EBV-LCL 
by clone 3H1 is mediated by differences between LB-NUP133-1R and its donor 
variant in intracellular processing and presentation, and not by differential 
recognition by the T-cell receptor (TCR). In conclusion, by screening a plasmid 
cDNA expression library and WGAs, we identified 4 novel MiHA in HLA-
B*40:01. The population frequencies of the HLA-B*40:01 associated MiHA are 
96% (LB-TRIP10-1EPC; rs1049229, rs1049230, rs1049232), 48% (LB-SON-
1R; rs13047599), 69% (LB-SWAP70-1Q; rs415895) and 48% (LB-NUP133-1R; 
rs1065674) calculated based on allele frequencies of 79%, 28%, 45% and 28% 
as reported in the SNP database  (www.ncbi.nlm.nih.gov/snp), respectively. 
 
Figure 2 (facing page). Identification of MiHA by whole genome association 
scanning. (A) A panel of approx. 60 SNP-genotyped EBV-LCL expressing HLA-B*40:01 
endogenously or after retroviral transfer of MP71-HLA-B*40:01-IRES-NGFR with more 
than 20% of marker gene positive cells were tested for recognition by T-cell clones 
ZRZ25, 3H1 and 12A2 in IFN-γ ELISA. EBV-LCL were divided into MiHApos and MiHAneg 
groups based on a threshold of 5-fold the background production of IFN-γ (horizontal 
bars). Mean release of IFN-γ (ng/mL) in 50 μL culture supernatants of duplicate wells is 
shown. (B) Peptides comprising patient (filled symbols) type amino acids with predicted 
binding to HLA-B*40:01 as well as donor type peptide variants (gray symbols) were 
pulsed on donor EBV-LCL and tested for T-cell recognition in IFN-γ ELISA. LB-TRIP10-
1EPC (GEPQDLCTL) contains 3 patient type amino acids and has been identified by 
cDNA library screening. LB-SON-1R (SETKQRTVL), LB-SWAP70-1Q (MEQLEQLEL) 
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and LB-NUP133-1R (SEDLILCRL) contain single patient type amino acids encoded by 
exon SNPs identified by WGAs based on significant association with T-cell recognition. 
Donor type peptides SETKQCTVL and MEQLEELEL encoded by the genes for SON and 
SWAP70, respectively, were not recognized by the T-cell clones, whereas donor type 
peptide SEDLILCQL encoded by the NUP133 gene was similarly recognized as LB-
NUP133-1R. Mean production of IFN-γ (ng/mL) in 50 μL culture supernatants of 
duplicate wells at various peptide concentrations (μg/mL) is shown. (C) NUP133 genes 
were isolated from patient and donor derived cDNA and cloned into expression vector 
pcDNA-3. Hela cells stably expressing HLA-B*40:01 were transiently transfected with 
patient and donor derived NUP133 genes encoding the R and Q at position 406, 
respectively, and incubated with T-cell clone 3H1. Mean production of IFN-γ (ng/mL) in 





T-cell recognition of non-malignant hematopoietic and non-hematopoietic 
cells 
To investigate the cell type specificity in more detail, all MiHA specific CD8 T-
cell clones were tested for reactivity against patient derived EBV-LCL and PHA-
T cells as well as primary B cells, T cells and monocytes isolated from patient 
PBMC pior to alloSCT by flowcytometry based on expression of CD19, CD3 
and CD14, respectively (Figure 3A). The data showed that all MiHA specific 
CD8 T-cell clones recognized specific types of primary hematopoietic cells, 
except for the T-cell clone for LB-TRIP10-1EPC, which showed reactivity 
against EBV-LCL, but failed to recognize all other non-malignant hematopoietic 
cells tested. The T-cell clone for LB-SWAP70-1Q showed clear recognition of 
hematopoietic cells of B-cell origin, whereas no or only weak reactivity was 
observed against T cells and monocytes. 
In addition to hematopoietic cells, we tested T-cell recognition of non-
hematopoietic FB cultured from a skin biopsy from the patient. FB were treated 
with IFN-γ to mimic the pro-inflammatory cytokine milieu of the early post 
transplantation period. In the absence of IFN-γ, FB were only recognized by  
control T-cell clone (4D8) recognizing an unknown MiHA in HLA-B*08:01 
(Figure 3B). After pre-treatment with IFN-γ, reactivity against FB was measured 
for the T-cell clones for LB-SON-1R and LB-NUP133-1R, whereas no or only 
weak recognition of cytokine-treated FB was observed for the T-cell clones for 
LB-TRIP10-1EPC and LB-SWAP70-1Q. We, therefore, concluded that LB-
TRIP10-1EPC and LB-SWAP70-1Q are MiHA with potential therapeutic value 
based on lack of T-cell recognition of cytokine-treated FB. 
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Figure 3. T-cell recognition of non-malignant hematopoietic and non-
hematopoietic cells. CD8 T-cell clones specific for LB-TRIP10-1EPC, LB-SON-1R, LB-
SWAP70-1Q and LB-NUP133-1R were tested for recognition of non-malignant 
hematopoietic and non-hematopoietic cells in IFN-γ ELISA. (A) T-cell clones were tested 
against patient derived EBV-LCL and PHA-T blasts, as well as primary B cells, T cells 
and monocytes isolated from patient PBMC prior to alloSCT. (B) T-cell clones were 
tested against FB cultured from a skin biopsy obtained from the patient after alloSCT. FB 
were cultured with and without IFN-γ (100 IU/mL) for four days. Reactivity of T-cell clone 
4D8 recognizing an unknown MiHA in HLA-B*08:01 is shown as control. Mean 













































































































































T-cell recognition of leukemic cells of different origins 
Since the HLA-B*40:01 restricted MiHA were identified as targets for CD8 T 
cells in a patient with CML, we tested the capacity of the T-cell clones to 
recognize CD34+ CML cells in IFN-γ ELISA. CD34+ CML cells were isolated 
from BM samples from 3 HLA-B*40:01-positive patients, and tested for T-cell 
recognition directly after isolation as well as after in vitro culture with growth 
factors to generate CML cells with professional antigen presenting cell 
phenotype (CML-APC). All T-cell clones recognized freshly isolated CML cells 
as well as in vitro cultured CML-APC, except for the T-cell clone for LB-TRIP10-
1EPC. This T-cell clone showed strong reactivity against CML-APC, whereas 
freshly isolated CML cells were weakly recognized or not recognized at all 
(Figure 4A). A similar difference in recognition was observed between 
monocytes and monocyte-derived dendritic cells (DC) (data not shown). The 
data demonstrated that LB-SON-1R, LB-SWAP70-1Q and LB-NUP133-1R are 
expressed at the surface of CML cells suggesting that these MiHA served as 
direct targets for CD8 T cells in the GvL response after DLI. The data also 
showed that LB-TRIP10-1EPC is selectively expressed on professional APC, 
suggesting that T cells specific for this MiHA were induced at the onset of the 
immune response but did not contribute to direct lysis of leukemic cells in the 
execution phase of the response. In addition to CML cells, we analyzed T-cell 
recognition of ALL and AML cells of different subtypes (M0–M6). As shown in 
Figure 4B and C, the T-cell clone for LB-TRIP10-1EPC selectively recognized 
AML cells of monocytic (M4/M5) origin, whereas it failed to recognize ALL and 
AML cells of other subtypes. The T-cell clones for LB-SON-1R, LB-SWAP70-1Q 
and LB-NUP133-1R recognized HLA-B*40:01 and MiHA positive ALL and AML 
cells irrespective of their subtype origin. All T-cell clones were capable of 
mediating cytolysis of primary leukemic blasts in 51Cr-release assays (See also 
Figure S2). 
 
Figure 4 (facing page). T-cell recognition of leukemic cells of different origins. CD8 
T-cell clones specific for LB-TRIP10-1EPC, LB-SON-1R, LB-SWAP70-1Q and LB-
NUP133-1R were tested for recognition of malignant hematopoietic cells in IFN-γ ELISA. 
(A) T-cell clones were tested against CD34+ CML cells directly after flowcytometric 
isolation from BM cells from 3 HLA-B*40:01 positive patients (gray bars) as well as after 
in vitro culture with growth factors to generate CML-APC (filled bars). (B) T-cell clones 
were tested against ALL cells from PB and BM samples from 5 HLA-B*40:01 positive 
patients directly after isolation by flowcytometry based on expression of CD19. (C) T-cell 
clones were tested against PB and BM samples from 10 HLA-B*40:01 positive patients 
with more than 40% CD33+ AML cells of different subtypes (M0–M6). Two HLA-B*40:01  
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negative AML-M4 and M5 samples were included as negative controls. The MiHA status 
of the samples is shown as +/+, +/− and −/−. Mean production of IFN-γ (ng/mL) in 50 μL 
culture supernatants of duplicate wells is depicted. Unpaired Student’s t-test showed a 
significant difference in T-cell recognition between MiHApos (+/− or +/+) and MiHAneg (−/−) 
CML, ALL and AML samples for LB-SON-1R (p=5.6×10−5), LB-SWAP70-1Q 
(p=1.2×10−4), and LB-NUP133-1R (p=4.0×10−3). A significant difference for LB-TRIP10-
1EPC (p=3.7×10−3) was demonstrated between MiHA positive (+/− and +/+) AML-M4/M5 
and MiHA positive (+/+ and +/−) CML, ALL and AML samples of other subtypes. 
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We also investigated whether the MiHA specific T-cell clones were capable of 
lysing hematopoietic progenitor cells in colony forming cell (CFC) assays. For 
this purpose, a BM sample obtained from the patient from whom the T-cell 
clones were isolated was selected at the time of relapse of the CML after 
alloSCT prior to DLI. The T-cell clones for the HLA-B*40:01 restricted MiHA 
failed to lyse the CML progenitor cells, whereas substantial inhibition in 
numbers of CFU-GM and erythroid colonies was observed for the T-cell clone 
for HA-1 (See also Figure S3). The cytolytic capacity of the T-cell clone for LB-
SWAP70-1Q was also investigated in a BM sample from a patient with 
transformed juvenile CML and BM samples from 2 healthy individuals. The T-
cell clone failed to lyse hematopoietic progenitor cells from healthy individuals, 
whereas substantial inhibition in numbers of CFU-GM was observed when the 
T-cell clone for LB-SWAP70-1Q was pre-incubated with the juvenile CML 
progenitor cells (See also Figure S3). Outgrowth of erythroid colonies was not 
observed, compatible with the malignant transformed nature of the juvenile CML 
progenitor cells. In conclusion, the data showed that LB-SON-1R, LB-SWAP70-
1Q and LB-NUP133-1R are relevant targets in GvL reactivity against CML, AML 
and ALL, whereas LB-TRIP10-1EPC may only be relevant as a direct target for 
AML-M4/M5. Furthermore, the data suggest that the HLA-B*40:01 restricted 
MiHA may not have played a dominant role in sustaining long-term clinical 
remission of the patient with CML from whom the respective T-cell clones were 
isolated based on lack of cytolysis of the malignant hematopoietic progenitor 
cells. Finally, we conclude that LB-SWAP70-1Q is a MiHA with therapeutic 
potential based on strong presentation on leukemic cells of different origins and 
lack of T-cell recognition of cytokine treated FB. 
 
Expression patterns of the genes encoding the HLA-B*40:01 restricted 
MiHA 
The expression patterns of the TRIP10, SON, NUP133 and SWAP70 genes 
were investigated by microarray gene expression analysis using a panel of 
selected (malignant) hematopoietic and (cytokine treated) non-hematopoietic 
cell samples. For each malignancy (CML, AML, ALL, CLL and MM), malignant 
cells were isolated by flowcytometry from 5 different patients. Non-malignant 
hematopoietic cells (PBMC, B cells, T cells, monocytes, immature and mature 
DC, HSC) were isolated by flowcytometry from 3 different healthy individuals. 
Non-hematopoietic FB, KC and PTEC were derived from 3 healthy individuals. 
These cells were cultured with and without IFN-γ to mimic the pro-inflammatory 
cytokine milieu of the early post transplantation period. The data showed broad 
500834-L-bw-v Bergen
Novel HLA-B*40:01 restricted MiHA 
105 
 
expression patterns and significant expression of all genes in cytokine treated 
non-hematopoietic cell types (See also Figure S4). The data, therefore, 
demonstrate that the threshold for T-cell recognition of the HLA-B*40:01 
restricted MiHA, and in particular of LB-SWAP70-1Q, the MiHA with selective 
GvL effect, is not only determined by gene expression, but rather by intracellular 
processing and presentation mechanisms and/or surface expression of 
adhesion and co-stimulatory molecules. 
 
In vivo monitoring for MiHA specific T cells 
We investigated the in vivo immuno-dominance of the HLA-B*40:01 restricted 
MiHA in the patient with CML from whom the T-cell clones were isolated. We 
previously measured peak responses of HA-1 and HA-2 tetramer positive T 
cells in this patient, and 2 PB samples obtained during this peak response at six 
and seven weeks after treatment with DLI were selected for tetramer analysis. 
The data showed dominance for LB-SWAP70-1Q and LB-NUP133-1R in the 
immune response with 0.94% and 0.42% of tetramer positive cells within the 
PBMC population gated for negative expression of CD4, CD14, CD19 and 
CD56 at week 6 after DLI, respectively (See also Figure S5). These frequencies 
exceeded the T-cell frequencies for HA-2 (0.33%) and HA-1 (0.13%) as 
measured at weeks 6 and 7, respectively. In addition to LB-SWAP70-1Q and 
LB-NUP133-1R, a low frequency of T cells specific for LB-SON-1R (0.03%) was 
detected at week 7 after DLI. T cells specific for LB-TRIP10-1EPC could not be 
detected at significant frequencies.  The in vivo immunogenicity of LB-SWAP70-
1Q, the MiHA with selective GvL effect, was also evaluated in another HLA-
B*40:01 and MiHA positive patient transplanted with an HLA-matched MiHA 
negative donor. The frequency of HLA-B*40:01 in our transplanted patient and 
donor population is 12.5%, which is higher than the 2–9% reported for various 
European countries (www.allelefrequencies.net). We screened 1,069 genomic 
DNA samples for the SNP encoding LB-SWAP70-1Q. A total number of 612 
individuals were positive for LB-SWAP70-1Q, indicating a frequency of 57% in 
our patient and donor population. DNA samples from 398 patient-donor pairs 
included 297 (75%) transplantations with sibling donors and 101 (25%) 
transplantations with matched unrelated donors (MUD). Of the 398 patient-
donor pairs, 56 LB-SWAP70-1Q positive patients were transplanted with MiHA 
negative donors, including 37 (12%) sibling and 19 (19%) MUD donors. Since 
HLA-B*40:01 is expressed in 12.5% of the human population, our data indicate 
a chance for mismatching for LB-SWAP70-1Q of 1.5% and 2.3% after sibling 





patients transplanted with MiHA negative donors, 7 patient-donor pairs were 
positive for HLA-B*40:01. From 4 patients, PB and BM samples were available 
for T-cell monitoring. Three of these patients, however, were not treated with 
DLI and no obvious immune responses were ongoing at the available time 
points after alloSCT. One patient with CLL was successfully treated with DLI, 
and PB samples pre-DLI and six and eight weeks post-DLI were available for T-
cell monitoring. These samples were screened for the presence of T cells for 
LB-SWAP70-1Q directly ex vivo as well as after one week of in vitro stimulation 
with peptide, but no tetramer positive T cells could be detected (data not 
shown). In conclusion, the data show that LB-SWAP70-1Q, the MiHA with 
selective GvL effect, was dominant in the immune response in the patient with 
CML from whom the T-cell clones were isolated. Since only one other patient 
could be monitored for T cells specific for LB-SWAP70-1Q, conclusions as to 








Although an increasing number of MiHA in different HLA molecules have been 
identified in the last decades, the number of MiHA with therapeutic relevance is 
still limited.3–7 We previously demonstrated induction of CD8 T cells specific for 
hematopoietic restricted MiHA HA-1 and HA-2 in a patient who developed a 
strong GvL response with limited GvHD of the skin after treatment with DLI for 
relapsed CML more than one year after HLA-matched alloSCT.13 We also 
isolated CD4+ T cells from this patient, and showed recognition of 6 HLA class II 
associated MiHA, of which 5 MiHA have been identified by screening a 
recombinant bacteria cDNA library.15,17 In this report, we demonstrated that in 
addition to HA-1 and HA-2, which are both presented by HLA-A*02:01, CD8 T 
cells were induced against 4 MiHA in HLA-B*40:01 and one MiHA in HLA-
B*08:01, illustrating the diversity of MiHA targeted in this GvL response. The 
HLA-B*40:01 restricted MiHA were identified by screening a plasmid cDNA 
expression library and WGAs, and detailed T-cell reactivity and monitoring 
experiments were performed to estimate the clinical and therapeutic relevance 
of the MiHA. 
 
T cells specific for LB-SON-1R, LB-SWAP70-1Q and LB-NUP133-1R were 
shown to recognize CML, ALL and AML cells, illustrating the relevance of these 
MiHA as direct targets in GvL reactivity. LB-TRIP10-1EPC, however, was 
expressed on AML-M4/M5 of monocytic origin, but not on ALL and AML cells of 
other subtypes. Surface expression of LB-TRIP10-1EPC was also 
demonstrated for professional APC, including in vitro cultured CML-APC and 
monocyte derived DC, but expression could not be measured on freshly 
isolated CML progenitor cells and monocytes, nor on (specific types of) 
peripheral blood cells (B cells, T cells or monocytes). Based on these T-cell 
recognition data, we speculate that T cells specific for LB-TRIP10-1EPC were 
induced by professional leukemic APC at the onset of the immune response, 
but that these T cells did not mediate direct cytolysis of CML cells in the 
execution phase of the anti-tumor response. Although all T-cell clones for the 
HLA-B*40:01 restricted MiHA required similar amounts of peptide to be 
activated, surface expression of endogenous LB-TRIP10-1EPC in HLA-B*40:01 
may be low, and the affinity of the T-cell receptor as expressed on the T-cell 
clone may not be sufficiently high to recognize endogenous LB-TRIP10-1EPC 
in the absence of high expression of costimulatory and/or adhesion molecules. 





reported for AML-M4/M5,18 and may contribute to recognition of these leukemic 
subtypes by T cells specific for LB-TRIP10-1EPC. 
 
Despite clear recognition and lysis of primary leukemic cells in IFN-γ ELISA and 
51Cr-release assays, all T-cell clones for the HLA-B*40:01 restricted MiHA failed 
to lyse the malignant progenitor cells of the patient with CML from whom the T-
cell clones were isolated in CFC assays. Our data, therefore, suggest that the 
HLA-B*40:01 restricted MiHA are relevant targets in GvL reactivity, but that they 
may not have played a dominant role in sustaining long-term clinical remission 
of the patient with CML. 
 
All T cells specific for the novel HLA-B*40:01 restricted MiHA were tested for 
recognition of skin-derived FB. These cells were cultured with and without IFN-γ 
to mimic the pro-inflammatory cytokine milieu of the early post transplantation 
period.19 In the absence of IFN-γ, all T cells failed to recognize FB. After 
treatment with IFN-γ, the only T cells that failed to recognize FB were specific 
for LB-SWAP70-1Q and LB-TRIP10-1EPC. Lack of T-cell reactivity against FB 
and normal hematopoietic progenitor cells cannot merely be explained by gene 
expression and, therefore, the immunological threshold for T-cell recognition of 
the HLA-B*40:01 restricted MiHA rather seems to be determined by intracellular 
antigen processing and presentation mechanisms and/or surface expression of 
adhesion and costimulatory molecules. 
 
In vivo monitoring of the patient with CML from whom the T-cell clones were 
isolated demonstrated that 2 HLA-B*40:01 restricted MiHA (LB-SWAP70-1Q 
and LB-NUP133-1R) were dominant in the immune response, and exceeded 
the T-cell frequencies for the well-known hematopoietic restricted MiHA HA-1 
and HA-2. One of these MiHA (LB-SWAP70-1Q) has been shown to be 
recognized on leukemic cells of various origins, but not on cytokine treated non-
hematopoietic FB, illustrating the therapeutic potential of this MiHA as target for 
GvL reactivity. However, although the T-cell clone for LB-SWAP70-1Q as 
described in this study failed to recognize cytokine treated FB, various non-
hematopoietic cells were shown to express the SWAP70 gene at significant 
levels. It can not, therefore, be completely excluded that in vitro or in vivo 
strategies to induce LB-SWAP70-1Q specific T cells with high avidities may 
have the potential to mediate GvHD due to reactivity towards non-hematopoietic 
tissues. Expression analysis also demonstrated overexpression of the SWAP70 
gene in B cells, and its protein product has been described to exert relevant 
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functions in nuclear and signal transduction events in activated B cells.20–22 The 
SWAP70 protein has been found to be a component of a complex that 
promotes recombination between DNA regions during heavy chain class 
switching,20,21 and it transduces signals from tyrosine kinase receptors to Rac in 
a Ras-independent manner.22 
 
Recently, the first clinical study on adoptive transfer of MiHA specific CD8 T 
cells to patients with acute leukemia who relapsed after alloSCT has been 
reported by Warren et al.23 The clinical results are encouraging since several 
patients achieved complete remissions, although at the price of significant 
GvHD. The MiHA specific CD8 T cells as administered in the clinical study were 
selected for cytolytic activity against patient, but not donor derived EBV-LCL, 
and lack of reactivity to patient derived dermal FB, but only in the absence of 
cytokines. Our data, however, demonstrated that 2 HLA-B*40:01 restricted 
MiHA were presented on patient derived FB after pre-treatment with IFN-γ. We, 
therefore, support a more stringent selection strategy of MiHA as targets for T-
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Supplementary Materials and Methods 
 
Retroviral transduction 
EBV-LCL were transduced with a retroviral vector encoding HLA-B*40:01 
(MP71-HLA-B*40:01-IRES-NGFR) as previously described1. EBV-LCL with 
transduction efficiencies more than 20% based on marker gene expression 
were included in the panel for WGAs. Cells with less than 20% transduction 
efficiencies were enriched for nerve growth factor receptor (NGFR) marker gene 
expression after staining with PE- or APC-labeled anti-NGFR antibodies (BD 
Biosciences) by flowcytometry or magnetic beads (Miltenyi Biotec). For each T-
cell clone, a total number of 60 EBV-LCL expressing HLA-B*40:01 
endogenously or after retroviral transduction were included for WGAs. 
 
Isolation and culture of primary hematopoietic cells 
Patient PBMC obtained prior to alloSCT were stained with FITC-conjugated 
anti-CD14, PE-conjugated anti-CD3 and APC-conjugated anti-CD19 antibodies 
(BD Biosciences), and monocytes, T cells and B cells were isolated by 
flowcytometry based on expression of CD14, CD3 and CD19, respectively. In 
addition, PB and BM samples from patients with CML, AML, ALL, CLL and MM 
were stained with APC-conjugated anti-CD34, anti-CD33 or anti-CD19, and PE-
conjugated anti-CD5 or anti-CD38 antibodies (BD Biosciences). CD34+ CML, 
CD33+ AML, CD19+ ALL, CD19+CD5+ CLL and CD38+ MM cells were 
subsequently isolated by flowcytometry. Isolated CD34+ CML progenitor cells 
were modified into leukemic APC2 and isolated monocytes were cultured to 
immature and mature dendritic cells (DC)3 as previously described. 
 
Enzyme linked immunosorbent assay 
Stimulator cells (3×104 cells/well) were co-incubated with CD8 T-cell clones 
(5×103 cells/well) overnight at 37°C in U-bottom 96-well plates. Peptide pulsing 
was performed by incubating donor EBV-LCL (1×106 cell/mL) for 2 h with 
synthetic peptides in IMDM with 2% FBS. Peptide-pulsed donor EBV-LCL were 
washed twice and subsequently used as stimulator cells. Release of IFN-γ was 
measured in 50 μL culture supernatants by enzyme linked immunosorbent 
assay (ELISA) according to the manufacturer’s instructions (Sanquin, 
Amsterdam, The Netherlands). 
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Chromium release assay 
Target cells were labeled for 1 h at 37°C with 100 μCi (3.7 MBq) Na251CrO4 
(Amersham, Uppsala, Sweden). After washing, target cells (1×103 cells/well) 
were incubated with CD8 T-cell clones at different effector-to-target (E:T) ratios 
for 4 or 10 h. Release of 51Cr was analyzed in 25 μL supernatants. The 
percentage of specific lysis was calculated with the following formula: 
[experimental release (cpm) – spontaneous release (cpm)]/[maximal release 
(cpm) – spontaneous release (cpm)] x 100%. Maximal release was induced by 
1% Triton (Sigma-Aldrich). 
 
Colony forming cell assay 
BM samples were incubated with irradiated (20 Gy) CD8 T-cell clones at E:T 
ratios of 3:1. After overnight pre-incubation, single-cell suspensions were 
cultured at 2×104 target cells/mL in 30 mm culture dishes containing IMDM with 
methylcellulose supplemented with growth factors (GM-CSF, stem cell factor, 
IL-3, erythropoietin and other supplements; MethoCult, Stemcell Technologies 
SARL, Grenoble, France). As controls, single-cell suspensions containing 2×104 
target cells/mL and irradiated T cells at E:T ratios of 3:1 were seeded without 
pre-incubation. After 14 days of culture, numbers of colony forming units (CFU) 
for granulocyte/monocyte (CFU-GM) and erythroid lineages were scored. 
 
Construction and screening of a plasmid cDNA expression library 
A cDNA library was constructed as previously described4. Poly(A)+ mRNA was 
isolated from patient EBV-LCL, and converted to cDNA using an oligo-d(T) 
primer. The cDNA was size-fractionated using column chromatography and 
ligated into pCR3.1 (Invitrogen, Breda, The Netherlands). Ligation products 
were transformed into E. Coli Top10 bacteria, and ampicillin resistant clones 
were divided into pools of approx. 50 different cDNA. Pools of cDNA were 
transfected into COS-7 cells stably expressing HLA-B*40:01. Transfection and 
screening of the cDNA library was performed using different mixtures of MiHA 
specific   T-cell clones. 
 
Whole genome association scanning 
WGAs was performed as previously described5. Briefly, a panel of 60 EBV-B 
cell lines stably expressing HLA-B*40:01 endogenously or after retroviral 
transduction (>20% marker gene expression) was tested for T-cell recognition in 
IFN-γ ELISA. For each T-cell clone, EBV-B cell lines were divided into MiHA 





production of IFN-γ. All EBV-LCL included in the panel were genotyped for 
more than 1.1 million SNPs by Human 1M-duo arrays (Illumina, Inc., San Diego, 
CA, USA). WGAs analysis was performed by combining T-cell recognition and 
SNP genotyping data using Plink software (http://pngu.mgh.harvard.edu/ 
purcell/plink/ version 1.03), and the significance of association between both 
patterns was calculated using Fisher’s exact test. 
 
Genotyping for single nucleotide polymorphisms 
Genomic DNA was isolated by the Gentra Systems PureGene genomic 
isolation kit (Biocompare, San Francisco, CA, USA). SNP rs1049232 in the 
TRIP10 gene was analyzed using forward and reverse primers for amplification 
and two TaqMan MGB probes labeled with VIC and FAM dyes to detect the 
different alleles (Applied Biosystems, Foster City, CA, USA). Genotyping for 
SNP rs1049229 (TRIP10), rs13047599 (SON), rs415895 (SWAP70) and 
rs1065674 (NUP133) was performed using allele-specific primers labeled with 
VIC and FAM dyes according to the manufacturer’s instructions (KBioScience, 
Hoddesdon, UK). 
 
Microarray gene expression analysis 
Malignant cells were isolated from PB and BM samples from patients with CML, 
AML, ALL, CLL and MM by flowcytometry based on expression of CD34, CD33, 
CD19, CD19/CD5 and CD38, respectively. Non-malignant B cells, T cells and 
monocytes were isolated from PBMC based on expression of CD19, CD3 and 
CD14, respectively. Hematopoietic stem cells (HSC) were isolated from G-CSF 
mobilized PB based on expression of CD34. Non-hematopoietic cells included 
skin-derived FB and KC, and PTEC cultured with and without IFN-γ (100 
IU/mL). Total RNA was isolated using small and micro scale RNAqueous 
isolation kits (Ambion, Inc., Austin, TX, USA), and amplified using the TotalPrep 
RNA amplification kit (Ambion). After preparation using the whole-genome gene 
expression direct hybridization assay (Illumina), cRNA samples were dispensed 
onto Human HT-12 v3 Expression BeadChips (Illumina). Hybridization was 
performed in the Illumina hybridization oven for 17 h at 58°C. Microarray gene 
expression data were analyzed using Rosetta Resolver 7.2 software. 
 
In vivo T-cell monitoring 
PB samples were stained with a mixture of FITC-conjugated antibodies against 
CD4, CD14, CD19 and CD56 as well as a mixture of APC- and PE-conjugated 
tetramers for the HLAB*40:01 restricted MiHA or a mixture of an APC-
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conjugated HA-2 tetramer and PE-conjugated HA-1 tetramer. For each 
tetramer, a minimum of 5×105 PBMC were analyzed. Tetramers were 
constructed as previously described6 with minor modifications. 
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Figure S1. Identification of LB-TRIP10-1EPC by screening a plasmid cDNA library. 
Transfection and screening of a cDNA plasmid library generated from mRNA from 
patient derived EBV-LCL in COS-7 cells expressing HLA-B*40:01 (COS-B*40:01) 
revealed isolation of a 1102 – 2029 bp TRIP10 cDNA recognized by T-cell clone ZRZ16. 
(A) Deletion variants of the 1102 – 2029 bp TRIP10 cDNA were constructed and tested 
for T-cell recognition after transfection into COS-B*40:01 cells in IFN-γ ELISA. Indicated 
is the mean release of IFN-γ (ng/mL) in 50 μL culture supernatants of duplicate wells. 
The results show that the MiHA is encoded by a 1574 – 1810 bp region which contains 
the stop codon of the TRIP10 coding sequence at 1704 bp. (B) Peptides comprising 3 
patient type AA encoded by SNP rs1049229, rs1049230, and rs1049232 that are 
predicted to bind to HLA-B*40:01 were synthesized and tested for T-cell recognition in 
IFN-γ ELISA. The mean release of IFN-γ (ng/mL) in 50 μL culture supernatants of 
duplicate wells is indicated. A 9-mer peptide (GEPQDLCTL) encoded in the 3’ 
untranslated region (3’ UTR) in an alternative reading frame (ARF1) of the upstream 
encoded TRIP10 protein was recognized by clone ZRZ16. The 9-mer donor type peptide 
(GGSQDLGTL) was not recognized. Analysis of patient type peptides containing single 


































Figure S2. T-cell mediated lysis of primary leukemic blasts. CD8 T-cell clones 
specific for LB-TRIP10-1EPC, LB-SON-1R, LB-SWAP70-1Q and LB-NUP133-1R were 
investigated for cytolytic activity against primary leukemic blasts in 10 h 51Cr-release 
assays at E:T ratios of 30:1. Mean specific lysis of triplicate wells is shown for an HLA-
B*40:01 positive and A*02:01 negative AML-M5 sample positive for all 4 HLA-B*40:01 




Figure S3 (next page). T-cell mediated lysis of hematopoietic progenitor cells. 
Lysis of hematopoietic progenitor cells was measured in CFC assays. BM cells (2x104 
cells/mL) were seeded as single-cell suspensions in medium with methylcellulose 
supplemented with growth factors after overnight pre-incubation with irradiated T-cell 
clones at E:T ratios of 3:1. (A) The T-cell clones for LB-TRIP10-1EPC, LB-SON-1R, LB-
SWAP70-1Q and LB-NUP133-1R and a T-cell clone for HA-1 were analyzed for specific 
lysis of the malignant hematopoietic progenitor cells from the patient with CML from 
whom the T-cell clones were isolated. For this purpose, a BM sample was selected at 
the time of relapse after alloSCT prior to DLI. (B) The T-cell clone for LB-SWAP70-1Q 
and an HLA-A*02:01 specific allo-reactive T-cell clone were tested for lysis of 
hematopoietic progenitor cells from an HLA-B*40:01 and LBSWAP70-1Q positive patient 
with transformed juvenile CML (upper graph) and 2 HLA-B*40:01 and LBSWAP70-1Q 
positive healthy individuals. Representative data are shown for one healthy individual 
(lower graph). Indicated are the numbers of CFU for granulocytes and monocytes (CFU-
GM) and erythroid cells as scored after 14 days of culture of BM cells after overnight pre-
incubation with the irradiated T-cell clones (black bars) and, as controls, for BM cells and 






















Figure S3. T-cell mediated lysis of hematopoietic progenitor cells  
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Figure S4. Expression patterns of the genes encoding the HLA-B*40:01 restricted 
MiHA. Expression as measured by microarray gene expression analysis is shown for the 
genes encoding TRIP10, NUP133, SON, and SWAP70 in non-malignant hematopoietic 
cells (PBMC, B cells, T cells, monocytes, immature and mature DC and hematopoietic 
stem cells), malignant hematopoietic samples (CML, ALL, AML, CLL and MM), and non-









Figure S5 (next page). In vivo monitoring for MiHA specific T cells. Screening for 
MiHA specific T cells was performed for the patient with CML from whom the T-cell 
clones were isolated. PB samples pre-DLI and 6 and 7 weeks post-DLI were selected for 
in vivo T-cell monitoring. PBMC were stained with a mixture of FITC-conjugated anti-
CD4, CD14, CD19 and CD56 antibodies and a mixture of PE- and APC-conjugated 
tetramers containing LB-SWAP70-1Q, LBNUP133-1R, LB-SON-1R or LB-TRIP10-1EPC, 
or a mixture of PE-conjugated HA-1 and APC-conjugated HA-2 tetramers. Cells were 
gated for negative expression of CD4, CD14, CD19 and CD56, and mean fluorescence 
intensities are shown for PE- and APC-conjugated tetramers. Percentages are shown of 
gated cells that are double positive for PE- and APC-conjugated LB-SWAP70-1Q, LB-
NUP133-1R, and LB-SON-1R tetramers, single positive for PE-conjugated LB-TRIP10-
1EPC and HA-1 tetramers, and single positive for the APC-conjugated HA-2 tetramer.
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Abstract 
Allogeneic stem cell transplantation (alloSCT) followed by donor lymphocyte 
infusion (DLI) can be applied as immunotherapeutic intervention to treat 
malignant diseases. Here, we describe a patient with progressive metastatic 
clear cell renal cell carcinoma (RCC) who was treated with T-cell depleted non-
myeloablative alloSCT and DLI resulting in disease regression accompanied by 
extensive graft-versus-host disease (GvHD). We characterized the specificity of 
this immune response, and detected a dominant T-cell population recognizing a 
novel minor histocompatibility antigen (MiHA) designated LB-FUCA2-1V. T cells 
specific for LB-FUCA2-1V were shown to recognize RCC cell lines, supporting a 
dominant role in the graft-versus-tumor (GvT) reaction. However, coinciding 
with the gradual disappearance of chronic GvHD, the anti-tumor effect declined 
and 3 years after alloSCT the metastases became progressive again. To re-
initiate the GvT reaction, escalating doses of DLI were given, but no immune 
response could be induced and the patient died of progressive disease 8.5 
years after alloSCT. Gene expression studies illustrated that only a minimal 
number of genes shared expression between RCC and professional antigen 
presenting cells but were not expressed by non-malignant healthy tissues, 
indicating that in patients suffering from RCC, GvT reactivity after alloSCT may 





Allogeneic stem cell transplantation (alloSCT) is a highly effective treatment for 
many hematological malignancies1. Following HLA-matched alloSCT, the 
curative graft-versus-tumor (GvT) reactivity is mediated by donor-derived T cells 
recognizing minor histocompatibility antigens (MiHA) expressed by the 
malignant patient cells. MiHA are polymorphic peptides presented by HLA-
molecules and are the result of genomic single nucleotide polymorphisms 
(SNPs) that are disparate between patient and donor. The repertoire of patient 
specific MiHA can act as non-self antigens to infused donor T cells2. If MiHA are 
co-expressed by malignant cells and normal non-hematopoietic tissues, 
alloreactive donor T cells may induce both GvT reactivity and graft-versus-host 
disease (GvHD). Donor T cells recognizing MiHA exclusively expressed by 
normal and malignant hematopoietic cells from the patient can mediate GvT 
reactivity in the absence of GvHD. Since hematopoiesis after alloSCT is of 
donor origin, complete elimination of patient hematopoiesis does not impair 
normal hematopoiesis and immunological function. T-cell depletion of the graft 
reduces the risk of GvHD, but increases relapse rates by abrogating therapeutic 
GvT reactivity. Postponed donor lymphocyte infusion (DLI) can be applied to 
prevent or treat disease recurrence2,3. 
 
Clinical beneficial effects of alloSCT for treatment of non-hematopoietic tumors 
were mainly observed in patients with metastatic renal cell cancer (RCC)4,5 and 
metastatic breast cancer6. In RCC, alloSCT resulted in an overall response rate 
ranging between 20-40%7. In the majority of these cases, however, GvT 
reactivity was associated with development of clinically significant GvHD. The 
concurrence of GvT reactivity and GvHD indicates that tumor controlling donor 
T cells often recognize MiHA that are co-expressed by tumor cells and by 
normal tissue cells. Specific GvT reactivity and concurrent prevention of GvHD 
by replacement of the normal patient counterpart by donor cells, comparable to 
achievement of full donor chimerism in bone marrow and peripheral blood of 
hematological patients after alloSCT, is obviously not possible in patients with 
solid tumors. 
 
For development and expansion of a primary donor-derived immune response 
after DLI, it may be essential that MiHA are presented by recipient-derived 
dendritic cells (DC)8. DC of patient origin can present both endogenously 
derived MiHA, and cross-present antigens that are generated from proteins 
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taken up from surrounding damaged tissue cells. In patients with hematological 
malignancies, the hematopoietic origin of DC may explain relative skewing of 
the T-cell response towards hematopoietic cells, and targeting of hematopoiesis 
restricted MiHA can result in GvT reactivity in the absence of GvHD9,10. Solid 
tumor cells and DC however, originate from different lineages and successful 
targeting of these malignancies may often involve MiHA that are broadly 
expressed not only on DC and malignant cells, but also on the normal 
counterpart of tumor cells. 
 
In this study, we describe a patient with clear cell RCC who showed tumor 
regression and prolonged survival after alloSCT followed by DLI. Extensive 
chronic GvHD coincided with durable disease control but the disease became 
progressive when GvHD resolved. Subsequent administration of escalating 
doses of DLI could not re-induce the GvT reaction. We identified a strong T-cell 
response targeting a novel MiHA (LB-FUCA2-1V) presented by HLA-B*07:02, 
and induction of LB-FUCA2-1V specific T cells coincided with tumor control and 
GvHD. Broad recognition of GvHD target tissues by LB-FUCA2-1V specific T 
cells correlated with a broad expression profile of the FUCA2 gene. Gene 
expression profile studies showed that, in contrast to leukemic cells, only a 
limited number of genes are selectively co-expressed by RCC and DC, and not 
by cells representing normal tissue cells. GvT reactivity may therefore be 





Materials and methods 
 
Sample collection and preservation 
Peripheral blood samples and skin biopsies were collected from patient, donor, 
and third party individuals after approval by the Leiden University Medical 
Center institutional review board according to the Declaration of Helsinki. 
Written informed consent was given by patient and donor, and by 3rd party 
individuals to investigate materials and to publish data and case details. 
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Isopaque 
separation and cryopreserved. Skin biopsies were immediately processed. 
 
Generation and culture of cell lines 
EBV-transformed B-lymphoblastic cell lines (EBV-LCL) were generated in-
house from PBMC from patient, donor and third party individuals. EBV-LCL 
were generated and cultured in Iscove’s modified Dulbecco’s medium (IMDM, 
Lonza, Verviers, Belgium) with 10% FBS (Lonza)11. To obtain fibroblast and 
keratinocyte cell lines, single cell suspensions were generated from skin 
biopsies by mechanical and enzymatic dissociation. Fibroblasts were obtained 
by culturing in Dulbecco’s modified Eagle’s medium (DMEM) with low glucose 
(Lonza) with 10% FBS and keratinocytes by culturing in keratinocyte serum-free 
medium supplemented with 30 μg/ml of bovine pituitary extract and 2 ng/ml of 
epithelial growth factor (Invitrogen, Carlsbad, CA). RCC and melanoma cell 
lines were previously established in Leiden or kindly provided by Prof. A. Knuth 
(University of Zürich, Zürich, Switzerland) (RCC Mz1774 and RCC Mz1851) and 
Prof. P Straten (Danish Cancer Society, Copenhagen, Denmark, MEL SK23) 
and were cultured in DMEM with 8 % FBS. Immature dendritic cells were 
derived from monocytes isolated from PBMC using MACS CD14 MicroBead 
isolation (Miltenyi Biotec GmbH, Bergisch-Gladbach, Germany) and cultured for 
2 days in IMDM with 10% FBS with 100 ng/ml GM-CSF (Novartis, Basel, 
Switzerland) and 500 IU/ml IL-4 (Schering-Plough, Bloomfield, NJ). DC were 
subsequently matured for 2 days by adding 10 ng/ml TNF-α (R&D Systems, 
Abingdon, UK), 10 ng/ml IL-1β (Immunex, Seattle, WA), 10 ng/ml IL-6 
(Cellgenix, Freiburg, Germany), 1 μg/ml PGE2 (Sigma-Aldrich, Zwijndrecht, The 
Netherlands), and 500 IU/ml IFN-γ (BoehringerIngelheim, Ingelheim am Rhein, 
Germany). In selected EBV-LCL and RCC, transductions with retroviral vector 
pLZRS containing HLA-B*07:02 and the truncated NGFR marker gene were 
performed as previously described12. 
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SNP genotyping 
SNPs encoding known MiHA were determined in patient and donor-derived 
genomic DNA extracted with Gentra Puregene Blood Kit (Qiagen, Venlo, The 
Netherlands). For LB-APOBEC3B-1K, LB-ARHGDIB-1R, LB-BCAT2-1R, LB-
ECGF-1R, LB-MR1-1H and LRH-1, 10 ng DNA was amplified with allele specific 
primers using the KASPar SNP genotyping system (KBioscience, Herts, UK). 
For LB-EBI3-1I, LB-ERAP1-1R, LB-GEMIN4-1V, LB-MTHFD1-1Q, LB-PDCD11-
1F, HwA-9 and HwA-10, 10 ng DNA was amplified in the presence of allele 
specific probes using Taqman SNP genotyping assays (Applied Biosystems, 
Foster City, CA). After amplification, fluorescent signals were analyzed on a 
7900HT device running with SDS software (Applied Biosystems). Allele specific 
primers and probes were selected according to the manufacturer’s instructions 
(See also Supplemental Table S1: MiHA disparities between donor and patient). 
 
Cloning and testing of T cells recognizing known MiHA 
Tetramers were constructed by folding peptides in biotinylated HLA-B*07:02 
monomers followed by multimerization using streptavidin conjugated to PE as 
previously described with minor modifications13. MiHA specific T cells were 
visualized using PE-conjugated tetramers and PE-Cy7 labeled anti-CD8 
antibodies (BD Biosciences, Breda, The Netherlands). Tetramer+ T cells were 
single cell per well sorted on a FACS Aria device (BD) in 96-wells U-bottom 
plates (Corning, Amsterdam, The Netherlands) containing T cell medium (TCM, 
IMDM with 5% pooled human serum, 5% FBS and IL-2 (100 IU/ml, Chiron, 
Amsterdam, The Netherlands)), and stimulated with phytohemagglutinin (PHA, 
0.8 μg/ml, Murex Biotec Limited, Dartford, UK) and 5x104 irradiated allogeneic 
PBMC. Growing T-cell clones were restimulated every 10 days in TCM at a 
concentration of 2x105/ml with 1x106/ml irradiated allogeneic PBMC and PHA. 
TCR β-chain analysis was performed using the TCRBV repertoire kit (Beckman 
Coulter, Mijdrecht, The Netherlands). The reactivity of T-cell clones was 
measured after 24h co-incubation with 3-fold stimulator cells and release of 
IFN-γ in culture supernatants was measured by ELISA (Sanquin, Amsterdam, 
Netherlands). In selected experiments, IFN-γ pretreatment (100 U/ml) of 
stimulator cells was performed for 24h at 37oC and prior to co-incubation, these 





Isolation and characterization of T cells recognizing novel MiHA 
Post-DLI PBMC were stimulated with irradiated (30Gy) pre-alloSCT patient 
derived PBMC. The next day, T cells were purified using pan T cell isolation 
(Miltenyi) and stained with HLA-DR-FITC (BD). HLA-DR-expressing T cells 
were single cell sorted and expanded as described above. Recognition of EBV-
LCL was blocked with 10μg/ml specific monoclonal antibodies for 30 min at 
37oC prior to T cell addition. Whole genome association (WGAs) was performed 
as described previously10,14. Briefly, T-cell recognition of a panel of 80 EBV-LCL 
was mapped to a SNP genotype database containing 1.1 million SNPs of each 
cell in the EBV-LCL test panel. The level of matching was calculated using 
Fisher’s exact test using ‘Plink’ software15. For candidate gene FUCA2 
(NM_032020) sequencing, mRNA from patient and donor was isolated from 
EBV-LCL using Trizol (Invitrogen) and transcribed into cDNA by reverse 
transcriptase (Invitrogen) using oligo-dT primers (Roche Diagnostics, Almere, 
The Netherlands). FUCA2 gene transcripts were amplified by PCR using 
forward (5’-GAATATTGGGCCCACACTAGA-3’) and reverse (5’-CATTTGCTT 
TCTCCATGTGC-3’) primers covering the region of interest. PCR products were 
analyzed by DNA sequencing, and patient and donor sequences were aligned 
to detect disparities. For the SNPs that were identified by WGAs and gene 
sequencing, amino acid sequences spanning the SNP were analyzed using the 
online algorithm of NetMHC to search for sequences with predicted binding to 
HLA B*07:0216. Candidate peptides were synthesized, dissolved in DMSO, 
diluted in IMDM and added to donor EBV-LCL (2x104/well) in 96-well U-bottom 
plates for 2h at 37oC. T cells (2x104/well) were added, and after overnight 
incubation supernatants were tested for IFN-γ production by ELISA. 
 
Microarray gene expression analysis 
Lineage specific hematopoietic cells were purified from 3rd party donor PBMC 
by flowcytometric sorting based on expression of CD19, CD3, and CD14. 
Purified malignant hematopoietic cells were obtained by flowcytometric sorting 
from leukemic samples for CD19+ cells from 2 different B-ALL patients and for 
CD33+/CD14- cells from an AML-M4 and an AML-M5 patient. Non-
hematopoietic normal cell lines included skin-derived fibroblasts, keratinocytes 
and proximal tubular epithelial cells cultured with and without IFN-γ (100 IU/ml, 
2 days). Non-hematological malignant cells included renal cell carcinoma (RCC 
90.03 and RCC 92.11) and melanoma (MEL SK23 and MEL 136.2). Total RNA 
was isolated using small and micro scale RNAqueous isolation kits (Ambion, 
500834-L-bw-v Bergen
                                                          Graft-versus-tumor reactions after alloSCT 
131 
Austin, TX, USA), and amplified using the TotalPrep RNA amplification kit 
(Ambion). After preparation using the whole-genome gene expression direct 
hybridization assay (Illumina), complementary RNA samples were dispensed 
onto Human HT-12 v3 Expression BeadChips (Illumina). Hybridization was 
performed for 17h at 58°C and mean fluorescence intensities (MFI) were 
quantified using a BeadArray 500GX device. Microarray gene expression data 







A 51 year old female patient with progressive metastatic clear cell RCC and 
multiple lung metastases was treated with non-myeloablative alloSCT. Prior to 
stem cell transplantation, the patient received a conditioning regimen consisting 
of Fludarabine (6x30 mg/m2), Busulphan (2x3.2 mg/kg), Cyclophosphamide 
(2x750 mg/m2) and horse anti-thymocyte globulin (Lymphoglobulin, 4x10 
mg/kg). T cells were depleted from the peripheral blood stem cell graft derived 
from her HLA-identical brother by incubation with 20 mg of Alemtuzumab ‘in the 
bag’17. Engraftment was obtained and XY-FISH analysis of PBMC showed full 
donor chimerism one month after alloSCT. However, incomplete donor 
chimerism (84%, 80%, 95% and 93%) was detected after 2, 3, 5 and 7 months, 
respectively (Figure 1). GvHD did not occur after alloSCT, and no change in the 
tumor status was observed. Seven months after alloSCT postponed DLI was 
 
Figure 1. Clinical course. DLI doses, donor chimerism and the clinical course following 
DLI are depicted during time after allo-SCT (months, x-axis). The infused dose of T cells 
(filled triangles) and chimerism status (% of donor cells as measured by XY-FISH in 
PBMC, open circles) are shown in the upper part of the graph. Rectangles in the lower 
part of the graph indicate tumor status, GvHD state and GvHD treatment. 
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administered at a single dose of 5x106 T cells/kg, resulting in conversion to full 
donor chimerism, which persisted during the following years. Severe acute skin 
GvHD occurred 30 days after DLI and developed into persistent extensive 
chronic skin GvHD in the following years. Skin GvHD gradually resolved after 
prolonged topical and systemic treatment with corticosteroids (Figure 1). GvHD 
was accompanied with 50% reduction in size of the measurable lung metastasis 
and stable disease (according to RECIST criteria) for 2 years. Nearly 2 years 
after alloSCT a new lesion developed in the remaining kidney. The gradual 
resolution of chronic GvHD was accompanied by diminished GvT reactivity and 
growth of lung metastases 4 years after alloSCT. In an attempt to re-initiate GvT 
reactivity, escalating DLI doses of 2x106, 5x106, 1x107 and 5x107 T cells/kg 
were given at 51, 57, 64 and 92 months after alloSCT, respectively. No GvHD 
developed but also no GvT reactivity could be achieved and the patient died of 
progressive disease 8.5 years after alloSCT. 
 
Detection of T cells specific for known MiHA 
To characterize the specificity of the immune response, we first measured SNP 
encoding known MiHA to detect disparities between patient and donor. Given 
the HLA-type of the patient, 13 MiHA were selected and analyzed by SNP 
genotyping assays (See also Supplemental Table S1). The only MiHA 
expressed in the patient but absent in the donor, and therefore potentially 
allowing a donor-derived T-cell response targeting patient cells, was the 
previously identified MiHA LRH-1, encoded by a single nucleotide deletion in 
the P2RX5 gene causing a frame shift. Using LRH-1 tetramers, T cells specific 
for LRH-1 were detected in peripheral blood at the onset of GvHD at a 
frequency of 0.14% of CD8 T cells (data not shown). Single LRH-1 tetramer 
positive T cells were subsequently isolated using flowcytometry, expanded, and 
tested for recognition of various normal and malignant cells (data included in 
Figure 3A). Patient derived EBV-LCL strongly stimulated LRH-1 specific T cells, 
as measured by the production of IFN-γ. Recognition of patient-derived skin 
fibroblasts was very weak and could only be observed after pretreatment with 
IFN-γ. Dendritic cells (DC) and keratinocytes were not recognized. No 
recognition of LRH-1 positive RCC cell lines, tested either directly or after pre-
incubation with IFN-γ, was observed, indicating that additional T-cell responses 






Isolation of T-cell clones recognizing the novel MiHA LB-FUCA2-1V 
To further identify T-cell responses targeting unknown MiHA in this patient, we 
incubated peripheral blood taken 37 days after the first DLI at the time that 
GvHD was apparent with pre-transplant PBMC and isolated activated T cells. 
Clonal expansion of CD8 T cells expressing HLA-DR initially resulted in the 
generation of 7 MiHA-specific T-cell clones (data not shown). Two T-cell clones 
could sufficiently be expanded to allow further characterization. One T-cell clone 
was demonstrated to be restricted to HLA-B*38:01, as determined by using a 
panel of partly HLA-matched EBV-LCL (data not shown). Another T-cell clone 
was restricted to HLA-B*07:02 (Figure 2A), allowing characterization of the 
MiHA by WGAs using our panel of SNP-genotyped HLA-B*07:02 positive EBV-
LCL10. T cell recognition of this panel separated MiHApos and MiHAneg EBV-LCL, 
and association between the recognition pattern and a detailed SNP genotype 
map of the tested EBV-LCL identified significantly associating SNPs located on 
chromosome 6 in a genomic region spanning three genes (Figure 2B). The 
majority of the associating SNPs was located in non-coding regions except for 
rs3762001 and rs3762002, which both encoded amino acid polymorphisms in 
the FUCA2 protein (Figure 2C). Predicted binding of polymorphic peptides in 
HLA-B*07:02 was only found for rs3762002, which encoded a valine to 
methionine substitution at position 356 of the FUCA2 protein (NP_114409). 
DNA sequencing of rs3762002 demonstrated the presence of the valine 
encoding SNP in the patient, but not in the donor (Figure 2C). Specific 
recognition of patient type peptide (RLRQVGSWL) at nanomolar concentrations 
confirmed that SNP rs3762002 encoded the novel MiHA, which was designated 
LB-FUCA2-1V (Figure 2D). Tetramers were produced, and staining of T cells in 
a PBMC sample collected at the onset of acute GvHD 35 days after the first 
DLI, revealed 1.5% of circulating LB-FUCA2-1V specific T cells (Figure 2E). In 
samples taken shortly thereafter, frequencies of tetramer positive T cells 
strongly decreased, and became undetectable at 6 months after DLI. In line with 
the absence of any clinical effect following administration of escalating doses of 
donor lymphocytes between 4 and 8 years after alloSCT, LB-FUCA2-1V 
specific T cells remained undetectable. In order to detect low numbers of MiHA-
specific T cells, PBMC samples were stimulated with donor-derived monocytes 
pulsed with LB-FUCA2-1V or LRH-1 peptide and cultured for 7 days prior to 
tetramer staining. LB-FUCA2-1V specific T cells were expanded to 2.64% and 
0.64% of CD8 T cells in samples taken 83 and 128 days after the first DLI, 
respectively. LRH-1 specific T cells were present at low frequencies, but could 
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not be expanded by in vitro stimulation. Interestingly, LB-FUCA2-1V specific T 
cells were induced in an aliquot of the 5th DLI, illustrating that a low precursor 
frequency of LB-FUCA2-1V specific T-cells were present in the donor, but still 





















Figure 2. FUCA2 encodes a novel MiHA presented by HLA-B*07:02. (A) HLA-
restricted reactivity of a T-cell clone with unknown specificity was determined by testing 
recognition of patient EBV-LCL pre-incubated with monoclonal antibodies against HLA 
class-I, HLA class-II and HLA-B*07 prior to addition of T cells. In addition, mock 
transduced and pLZRS-NGFR-HLA-B*07:02-transduced third party EBV-LCL were used 
as test cells. Reactivity was measured by Elisa and is depicted as the concentration of 
IFN-γ (ng/ml) in the supernatant after 24 h of co-cultivation. (B) WGAs identified a region 
on chromosome 6 associated with T cell recognition. Each dot represents a SNP relative 
to its position on chromosome 6 and the significance of association is expressed by P- 
value. Double-headed arrows locate the genes ADAT2, PEX3 and FUCA2. (C) The 
FUCA2 gene contains 2 associating non-synonymous SNPs. The amino acid sequence 
containing these SNPs was investigated for potential peptide binding to HLA-B*07:02, 
resulting in 1 candidate peptide sequence spanning rs3762002. (D) Synthetic peptides 
containing the patient specific valine residue (closed circles) and donor specific 
methionine residue (open circles) were loaded on donor EBV-LCL and tested for 
recognition by the T-cell clone. (E) LB-FUCA2-1V tetramers were used to stain a patient 




Tissue distribution of LRH-1 and LB-FUCA2-1V 
The isolated LB-FUCA2-1V specific T cells were tested for recognition of normal 
and malignant cells. In contrast to the isolated LRH-1 specific T cells, LB-
FUCA2-1V specific T cells broadly recognized tested target cells, including 
mature monocyte derived DC’s (monoDC) (Figure 3A). Furthermore, specific 
recognition of MiHApos RCC cell lines was observed, indicating a dominant role 
for LB-FUCA2-1V specific T cells in tumor control. Recognition of fibroblasts 
and keratinocytes was measured after pretreatment with IFN-γ, suggesting a 
role in development of GvHD. Next, we analyzed mRNA expression levels of 
the P2RX5 and FUCA2 genes, encoding the LRH-1 and LB-FUCA2-1V MiHAs, 
respectively. The analysis confirmed B-cell specific expression of the LRH-1 
encoding gene P2RX5, in the absence of significant gene expression in other 
cell types. Substantial expression of the FUCA2 gene was measured in RCC 
and in proximal tubular epithelial cells (PTEC), but also in fibroblasts and to a 
lesser extent in keratinocytes (Figure 3B). In addition, FUCA2 mRNA was 
detectable in the majority of hematopoiesis-derived cells, which is in line with 
broad recognition of these cell types by the LB-FUCA2-1V specific T cells. 
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Figure 3. LRH-1 and LB-FUCA2-1V recognition and gene expression of P2RX5 and 
FUCA2. (A) LB-FUCA2-1V and LRH-1 specific T cells were tested against patient-
derived cells (EBV-LCL and fibroblasts) and a panel of 3rd party cells expressing HLA-
B*07:02 and the LB-FUCA2-1V and/or LRH-1 MiHA. Cell lines RCC 90.03 and RCC 
Mz1774 were retrovirally transduced to express B*07:02. Fibroblasts, keratinocytes and 
RCC cell lines were tested after 24h pre-incubation in the absence (open bars) or 
presence (hatched bars) of 100 IU/ml of IFN-γ. Reactivity was measured by Elisa and is 
depicted as the concentration of IFN-γ (ng/ml) in the supernatant after 24 h of co-
cultivation. (B) Expression patterns of the MiHA encoding genes P2RX5 (LRH-1) and 
FUCA2 (LB-FUCA2-1V) were determined by quantifying mRNA levels using microarray 
analysis. Expression, depicted as mean fluorescence intensity (MFI), is shown in 
hematopoietic cells (PBMC, B cells, T cells, monocytes, immature and mature DC and 
EBV-LCL), non-hematopoietic cells (fibroblasts, keratinocytes and PTEC pretreated with 
and without IFN-γ) and RCC cell lines. Numbers between brackets indicate the number 
of analyzed individual samples.  
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Identification of genes specifically expressed by RCC 
To estimate the likelihood that a GvT reaction targeting RCC can be induced in 
the absence of GvHD after alloSCT and DLI, we compared gene expression 
profiles of RCC cell lines representing the GvT target cells, and skin-derived 
fibroblasts and keratinocytes representing the non-intended GvHD target cells. 
In addition, since the induction of effective immune responses depends on 
proper stimulation by professional antigen presenting cells, we also included 
gene expression profiles of mature monoDC. Genes with a desired expression 
profile were selected based on significant over-expression in both RCC cell 
lines and monoDC as compared to fibroblasts and keratinocytes. By setting the 
cutoff value for over-expression at 10-fold, 17 genes were shown to be over-
expressed in RCC and monoDC (Figure 4 and Supplemental Table S3). To 
compare these data with another non-hematopoietic malignancy, and with 
leukemic cells that can be targeted in the absence of GvHD, we performed 
similar comparisons as described above using melanoma cell lines, and ALL or 
AML samples instead of RCC cell lines. A similar number of genes (28 genes) 
was over-expressed by both melanoma cell lines and monoDC as compared to 
fibroblasts and keratinocytes. In contrast, the number of genes selectively over-
expressed in AML and monoDC (135 genes) and ALL and monoDC (89 genes) 
was significantly higher (Figure 4). In conclusion, microarray gene expression 
analysis demonstrated that the a priori chance for beneficial GvT reactivity 
without GvHD in patients with solid tumors is significantly lower than in patients 
with hematological malignancies.  
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Figure 4. Genes over-expressed in both malignant cells and monoDC as compared 
to healthy tissue cells. Mature monocyte derived DC (monoDC), RCC cell lines, 
melanoma (MEL) cell lines, ALL and AML were investigated for gene 
expression using microarray techniques. For each cell type, 2 different samples 
were analyzed. Indicated are the numbers of genes showing more than 10, 30 
or 100-fold over-expression in both the malignant cells and monoDC as 
compared to fibroblasts and keratinocytes. Fold over-expression was calculated 
from the difference in mean log-transformed values, and only genes with a 
significant difference (p<0.05) in mean log-transformed values as measured by 
a standard Student’s t-test were selected. 
  

















We analyzed T-cell responses elicited after alloSCT and DLI in a patient 
suffering from progressive clear cell RCC. Tumor regression and stable disease 
was induced coinciding with severe GvHD requiring long term immune 
suppression which not only reduced GvHD, but also GvT reactivity. High 
frequencies of T cells recognizing the novel MiHA LB-FUCA2-1V were identified 
that strongly recognized various cell types, including RCC cells and normal 
tissue cells, demonstrating a dominant role for LB-FUCA2-1V specific T cells in 
GvT reactivity and GvHD. Broad recognition of LB-FUCA2-1V corresponded 
with a broad mRNA expression pattern of the encoding FUCA2 gene. Using 
mRNA expression profiles, only a limited number of genes was found to be 
selectively expressed by RCC, but not by normal tissue cells explaining why 
after alloSCT and DLI for treatment of RCC, effective GvT reactivity may 
unavoidably be associated with GvHD. 
 
Based on SNP genotyping for previously characterized MiHAs, we first 
investigated LRH-1 as a potential target for a donor-derived GvT reaction. We 
detected low frequencies LRH-1 specific T cells in patient samples obtained 
after DLI, which showed selective reactivity to patient-derived EBV-LCL, but not 
to other cell types. This was in line with the absence of P2RX5 transcripts 
encoding the LRH-1 MiHA in the non-recognized cell types. Although it has 
been reported that various carcinoma and melanoma cell lines may be 
susceptible to LRH-1 specific lysis18,19, we could not demonstrate recognition of 
MiHApos genotyped RCC cells by the isolated LRH-1 specific T-cell clones. We 
therefore concluded that LRH-1 specific T cells may have been induced in vivo 
by residual patient-derived B cells at the time of the first DLI, but that the LRH-1 
specific T cells were not likely to be mediators of the GvT reactivity or GvHD. 
 
By analyzing in vivo activated CD8 T cells, we identified by WGAs high 
frequencies of HLA-B*07 restricted T cells recognizing a novel MiHA which we 
designated LB-FUCA2-1V. LB-FUCA2-1V specific T cells strongly recognized a 
variety of target cells including RCC, DC and normal skin-derived fibroblasts 
and keratinocytes. The broad recognition pattern, together with high levels of 
circulating LB-FUCA2-1V specific cells, indicated a dominant role for LB-
FUCA2-1V in the GvT reaction, but also in development of severe GvHD. The 
FUCA2 gene is located on chromosome 6 and encodes an enzyme called 
alpha-L-fucosidase that catalyzes hydrolytic cleavage of terminal fucose 
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residues of glycoproteins20. Interestingly, FUCA2 has been implicated as a 
factor associated with several neoplastic diseases including endometrial, oral, 
gastric, and hepatocellular carcinoma21-24. In vitro recognition of fibroblasts and 
keratinocytes by LB-FUCA2-1V specific T cells only occurred after pre-
treatment with IFN-γ, whereas no difference in gene expression levels was 
detected. This illustrates that the immunological threshold for T-cell recognition 
is not exclusively determined by gene expression, but also by other factors 
increasing the avidity of the T-cell : target-cell interaction. After the first DLI, 
residual or repopulating hematopoietic cells and DC of patient origin may have 
initiated the T-cell response resulting in an inflammatory environment. This may 
have up-regulated adhesion molecules like CD54 on fibroblasts rendering them 
susceptible to T-cell induced cell lysis25,26. Subsequent destruction of tissue 
cells amplifies the inflammation potentially resulting in the cascade leading to 
persistent GvHD. Re-induction of GvT reactivity by administration of escalating 
doses of DLI 4-8 years after the initial DLI failed. This may be due to impaired 
antigenic stimulation by tumor cells in the absence of patient derived APC, 
resulting in T cell tolerance. Furthermore, sustained signalling of T cell co-
inhibitory molecules by tumor cells may have induced an exhausted T cell 
phenotype, resulting in a lost or reduced capacity of the tumor-specific T cells to 
expand in vivo27. 
 
In hematological malignancies, alloSCT followed by postponed DLI can result in 
clinical remissions in the absence of GvHD28. We therefore explored whether 
GvT reactivity in solid tumors might be separable from GvHD in a similar way as 
graft-versus-leukemia can be separated from GvHD. In analogy to 
hematopoiesis restricted expression of MiHA that represent potentially specific 
targets on leukemic cells, the separation of GvT reactivity from GvHD requires 
targeting of MiHAs that are overexpressed in RCC as compared to normal 
counterpart tissue cells. Effort has been made to identify such MiHA that are 
selectively expressed on malignant solid tumor cells, but only a few MiHA, 
including C19orf4829 and ZAPHIR18, and a tumor associated antigen encoded 
by human endogenous retrovirus type E (HERV-E)30  have been identified as 
targets for allo-reactive T cells in patients with RCC after treatment with 
alloSCT. Since it has been reported that DC are essential for the development 
of GvT reactivity after alloSCT, we assumed that specific GvT reactivity will 
occur only if the targeted genes are expressed by both DC and the malignant 




likelihood that a specific GvT reaction will occur in patients with solid tumors is 
determined by the number of genes that is expressed by both DC and the 
malignant cell population but not by normal non-hematopoietic tissues from the 
patient. As illustrated in Figure 4, in RCC tumors only 17 genes fulfilled these 
criteria, whereas in AML and ALL, 133 and 92 genes respectively, were highly 
expressed by both DC and the malignant cells, but not in non-hematopoietic 
tissues, and therefore are candidate targets for a specific graft-versus-leukemia 
response. These results indicate that the likelihood of developing a tumor 
specific allo-immune response after alloSCT is low in patients with solid tumors, 
whereas in patients with hematological malignancies a significant number of 
targets may be identified for a leukemia specific allo-immune response. In 
conclusion, our results indicate that development of GvT reactivity without 
GvHD in patients with solid tumors is unlikely to occur, and that clinically 
effective T-cell mediated tumor control after alloSCT and DLI in the treatment of 
RCC may be unavoidably linked to GvHD. 
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Figure S2. Frequency of circulating MiHA-specific T cells after in-vitro peptide 
stimulation. Donor derived monocytes were isolated using CD14 microbeads and 
pulsed overnight with 0.2 μM or 1 μM of LB-FUCA2-1V or LRH-1 peptide or medium 
alone. Aliquots of donor lymphocytes used for DLI and samples of patient PBMC taken 
before and after DLI were co-cultured with peptide-pulsed monocytes in the presence of 
30 IU/mL IL-2. After 7 days, MiHA-specific T cells were analyzed using CD8-FITC and 
LB-FUCA2-1V-PE (left panels) and LRH-1-APC (right panels) tetramers, respectively. In 
samples containing discrete populations of tetramerpos cells, the percentage of 
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Patients with leukemia who receive a T-cell depleted allogeneic stem cell graft 
followed by postponed donor lymphocyte infusion (DLI) can experience graft-
versus-leukemia (GvL) reactivity with a lower risk of graft-versus-host disease 
(GvHD). We investigated magnitude, diversity and specificity of alloreactive 
CD8 T-cells in patients without or with GvHD after DLI. We found both higher 
magnitudes and diversities of minor histocompatibility antigen (MiHA) specific 
CD8 T cells in patients with GvHD. Whereas strength of MiHA recognition on 
hematopoietic cells was similar, non-hematopoietic cells were stronger 
recognized by T-cell clones from patients with GvHD, especially after activation 
by inflammatory cytokines. Investigation of MiHA-encoding genes showed that 
similar types of antigens were recognized, however, relative skewing towards 
targeting of broadly expressed MiHA in patients with GvHD was observed. An 
inflammatory environment can render tissue cells susceptible to T-cell 
recognition, thereby amplifying the alloreactive response resulting in GvHD. 
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The curative effect of allogeneic stem cell transplantation (alloSCT) as 
treatment modality for hematological malignancies is based on the capacity of 
donor T cells to elicit an effective immune response against malignant 
hematopoietic cells from the patient1-3. Alloreactive donor-derived T cells may 
however also target normal non-hematopoietic tissue cells, resulting in 
potentially life-threatening graft-versus-host disease (GvHD)4. T-cell depletion of 
the graft can prevent GvHD but also impairs development of the associated 
graft-versus-leukemia (GvL) effect5,6. Persistent or recurring malignant 
hematopoietic cells after alloSCT will then require elimination by subsequent 
donor lymphocyte infusion (DLI)7-11. The observation that T-cell depletion 
followed by postponed DLI reduces development of GvHD after alloSCT can be 
explained by the timing of the DLI, when pre-alloSCT chemotherapy induced 
tissue damage and infections have largely been resolved, the ‘cytokine storm’ 
has subsided, and immune response provoking patient-derived antigen 
presenting cell (APC) are gradually being replaced by donor APC3,12. Although 
T-cell depletion of the graft followed by DLI reduces incidence and severity of 
GvHD, this complication remains a serious risk for morbidity and mortality13,14. 
 
Alloreactive T cells recognize non-self antigens on patient cells encoded by 
patient-specific genomic polymorphisms15. In fully HLA-matched alloSCT, target 
antigens are minor histocompatibility antigens (MiHA), which are polymorphic 
peptides presented in self-HLA encoded by single nucleotide polymorphisms 
(SNPs)16,17. Genomic disparities between donor and patient therefore determine 
the potential antigen repertoire that can be targeted by donor T cells. The tissue 
distribution of HLA class I restricted MiHA is a relevant factor that determines 
the clinical effect of donor CD8 T cells after alloSCT. Donor T cells recognizing 
MiHA with restricted expression on hematopoietic cells including the malignant 
cells of the patient are expected to induce the selective GvL effect. Donor T 
cells recognizing MiHA with ubiquitous expression on both hematopoietic and 
non-hematopoietic tissues are more likely to mediate both the GvL effect and 
GvHD18. 
  
In the last decade, increasing numbers of MiHA have been characterized mainly 
due to application of whole genome association scanning (WGAs). We 
identified multiple MiHA by WGAs, and demonstrated in several patients that at 





cells after HLA-matched alloSCT and DLI19-21. Whereas severe GvHD 
frequently coincided with development of T-cell responses against ubiquitously 
expressed MiHA, relatively selective GvL reactivity was not always associated 
with T-cell responses recognizing MiHA selectively expressed by hematopoietic 
cells. Apparently, other factors also determine the balance between GvL 
reactivity and GvHD. We hypothesized that in addition to tissue specificity, 
magnitude and diversity of the immune response will influence this balance. 
Moreover, the effects of immune responses are subject to environmental 
factors, such as inflammatory cytokines and chemokines, which are influenced 
by infections, tissue damage and exogenous immune regulatory drugs. 
Inflammatory cytokines may up-regulate surface expression of HLA, 
costimulatory and adhesion molecules and modify antigen processing and 
presentation resulting in differential clinical effects of donor T cells capable of 
recognizing MiHA on various tissues from the patient22. 
 
In this study, we characterized frequency, diversity and specificity of CD8 T-cell 
responses in 11 patients who entered complete remission and/or full donor 
chimerism after DLI. Our data show that both frequencies and diversity of MiHA-
specific CD8 T cells were higher in patients who developed GvHD as compared 
to patients without GvHD. In patients without GvHD, immune responses were 
skewed towards T cells that were unable to recognize patient non-
hematopoietic fibroblasts. We identified 19 MiHA, including 13 novel MiHA and 
6 previously published MiHA and illustrate that tissue distribution of MiHA-
encoding genes is not the main determinant separating GvL reactivity from 
GvHD, but that also inflammatory environmental circumstances can contribute 
to overcoming the threshold for GvHD development. 
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Materials and methods 
 
Blood samples and skin biopsies 
Peripheral blood samples and skin biopsies were collected from patients, 
donors, and third party individuals after approval by the Leiden University 
Medical Center institutional review board according to the Declaration of 
Helsinki. Written informed consent was given by all patients, donors and by third 
party individuals to investigate materials and to publish data and case details. 
 
Isolation and expansion of CD8 T-cell clones 
PBMC samples were thawed, washed and CD4 T cells and monocytes were 
depleted using magnetic CD4 and CD14 microbeads, respectively (Miltenyi 
Biotec, Bergisch Gladbach, Germany). CD8 T-cell enriched samples were 
stained using fluorescein isothyocyanat (FITC) conjugated CD8 (BD 
Biosciences, Breda, The Netherlands) and phycoerythrin (PE) conjugated anti 
HLA-DR (BD). Single cells were sorted using a BD FACS Aria device with BD 
FACSDiva software and collected in 96-well round-bottom TC-plates (Corning, 
Amsterdam, The Netherlands) pre-filled with 100 μl T-cell culture medium 
(TCM) consisting of Iscove’s modified Dulbecco’s medium (Lonza, Verviers, 
Belgium) with 5% pooled human serum (Sanquin, Amsterdam, The 
Netherlands) 5% FBS (Lonza), 120 IU/ml IL-2 (Chiron, Amsterdam, The 
Netherlands), 2 ng/ml IL-7 and 2 ng/ml IL-15 (Myltenyi). T cells were stimulated 
with phytohemagglutinin (0.8 μg/ml, Murex Biotec Limited, Dartford, UK) and 
5x104 irradiated (50Gy) allogeneic PBMC. Growing T-cell clones were 
transferred to 24-well TC-plates and remaining negative wells were restimulated 
under identical conditions. Alternatively, CD8 T-cell clones were expanded after 
bulk-sorting of HLA-DRpos CD8 T cells followed by manual limiting dilution in 
384-well TC-plates prefilled with 30 μl TCM with 0.8 μg/ml PHA and 2.5x104 
irradiated allogeneic PBMC per well. At day 7, T cells were restimulated with 0.8 
μg/ml PHA and 5x104 irradiated allogeneic PBMC in 50 μl TCM. From day 10 
onward, growing T-cell clones were collected in flat-bottom 96-well TC-plates. 
Expansion of selected T-cell clones by restimulation was repeated every 14 
days in TCM at 2x105 T cells per ml with 0.8 μg/ml PHA and 1x106 allogeneic 






Generation and culture of test cells 
EBV-transformed B lymphoblastic cell lines (EBV-LCL) were generated from 
PBMC from patient, donor and third party individuals and cultured in IMDM with 
10% FBS (Lonza)23. Monocyte derived dendritic cells (monoDC) were 
generated from PBMC after CD14 enrichment using microbeads (Miltenyi) by 
culturing for 2 days in IMDM with 10% FBS, 100 ng/ml GM-CSF (Novartis, 
Basel, Switzerland) and 500 IU/ml IL-4 (Schering-Plough, Bloomfield, NJ) and 
maturation for 2 days with 10 ng/ml TNF-α (R&D Systems, Abingdon, UK), 10 
ng/ml IL-1β (Immunex, Seattle, WA), 10 ng/ml IL-6 (Cellgenix, Freiburg, 
Germany), 1 μg/ml PGE2 (Sigma-Aldrich, Zwijndrecht, The Netherlands) and 
500 IU/ml IFN-γ (Boehringer Ingelheim, Ingelheim am Rhein, Germany). CD40L 
B cells were generated from PBMNC after CD19 enrichment using microbeads 
(Miltenyi) and stimulated with irradiated (70 Gy) murine fibroblasts expressing 
CD40L in IMDM with 10% FBS and 100 IU/ml IL-4 (Schering-Plough). 
Expanding CD40L B-cell cultures were restimulated every 2 weeks24. Fibroblast 
cell lines (FB) were obtained by seeding mechanically dissociated skin biopsies 
in low-glucose Dulbecco’s modified Eagle’s medium (DMEM, Lonza) with 10% 
FBS. Confluent FB cultures were trypsinized, diluted and re-seeded. From 
patient 4716 no skin biopsy could be obtained, but instead a bone marrow-
derived stromal cell line was generated. For stimulation experiments, 
confluently grown FB cultures were maintained in culture medium alone 
(steady-state FB), or were stimulated with 200 IU/ml IFN-γ for 4 days (activated 
FB). Prior to testing, FB were harvested by trypsinization and vigorously 
washed 3 times to remove IFN-γ. 
 
Testing of T-cell reactivity 
For initial screening of growing T-cell clones, resuspended culture aliquots were 
taken, washed in IMDM and diluted in 0.2 ml IMDM with 5% HS, 5% FBS and 
10 IU/ml IL-2. Two thousand T cells were dispended in 20 μl in 384-well TC-
plates. EBV-LCL and CD40L B cells (2x104), monoDC (5x103) and FB (7.5 
x103) were added in a volume of 20μl. For HLA blocking experiments, frequency 
analysis and WGAs, cultures of T-cell clones were washed, diluted to 2x103 T-
cells per 20 μl and added to 7.5 x103 EBV-LCL in 20 μl. After overnight 
incubation, IFN-γ production was measured in 10 μl aliquots by ELISA 
according to the manufacturer’s instructions, adapted to 384-well format 
(Sanquin). Recognition was defined as more than 3 times IFN-γ production in 
the absence of stimulator cells. For measuring tissue specificity, stimulator:T-
cell ratios ranging from 9 to 0.1 were obtained by coculturing 7.5 x103, 2.5 x103, 
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8.3 x102 and 2.8 x102 EBV-LCL or FB with 8.3x103 or 2.5x102 T cells. ELISA 
was performed on undiluted, 3-fold and 10-fold diluted supernatants and the 
amount of IFN-γ produced per single T cell was calculated. 
 
Tetramer staining and TCRvβ identification 
HY-antigen specific tetramers were constructed by folding peptides into 
biotinylated HLA monomers and multimerization using streptavidin conjugated 
to PE as previously described25. T-cell receptor-β variable chain usage was 
determined using IO Test (Beckmann Coulter). Data were acquired on a FACS 
Calibur device (BD). 
 
HLA restriction and MiHA frequency analysis 
HLA restriction of MiHA-specific T-cell clones was determined by blocking of 
recognition of patient EBV-LCL that were pre-incubated for 30 minutes with 
antibodies specific for HLA-class I (W6.32), HLA-BC (B1.23.2), Bw4/A*24 
(MUS4H4), Bw6 (KAM3H9), A*02 (BB7.2), B*13 (JOK3H5) or B*35 (IND2D12). 
In addition, EBV-LCL were transduced with potential HLA restriction molecules 
using a retroviral LZRS vector, containing the truncated nerve growth factor 
receptor (ΔNGFR) marker26,27. Retroviral supernatants were generated of HLA-
A*11:01, A*24:02, B*13:02, B*35:01, B*44:02, B*44:03, B*51:01, C*05:01, 
C*14:02 and C*16:01. Non-treated 96-well plates (Greiner) were coated with 
Retronectin CH-296 (Clontech) and blocked with 2% human albumin (Sanquin). 
Viral supernatants were diluted 3 times in IMDM with 10% FBS and aliquots of 
50μl per well were spun at 3000G for 30’. Supernatants were discarded and 
5x104 EBV-LCL were transferred to each well. EBV-LCLs showed a retroviral 




Whole genome association scanning (WGAs) was performed as previously 
described20. Briefly, a panel of 80 EBV-LCL was genotyped for 1.1 million SNPs 
using micro-arrays. T-cell recognition of the panel was measured and 
recognition patterns were compared to the SNP genotype data. The level of 
matching between the patterns of recognition and SNP genotypes was 
calculated by Fisher’s exact test using ‘Plink’ software28. MiHA-encoding genes 
were amplified and Sanger sequenced from both patient- and donor-derived 
EBV-LCL using cDNA that was obtained by reverse transcription of Trizol-





The Netherlands). See also Supplemental experimental procedures for gene 
specific primer sequences. Sequences were searched for donor-to-patient 
disparities using alignment software (Geneious, Auckland, New Zealand). 
Protein sequences spanning SNP-encoded amino acid polymorphisms were 
analyzed by NetMHC (Buus et al., 2003) to identify peptides with predicted HLA 
binding. Candidate peptides were synthesized, dissolved in DMSO, diluted in 
IMDM and incubated with 2x104 donor EBV-LCL cells in 20 μl in 384-well TC-
plates for 2 hours at 37oC. Thereafter, 2x103 T cells were added to each well in 
20 μl, and after overnight incubation, supernatants were tested for IFN-γ 
production by ELISA. 
 
Gene expression profiles 
Total RNA was isolated from EBV-LCL and FB using RNAqueous (Ambion, 
Austin, TX, USA), and amplified using the TotalPrep RNA (Ambion). After 
preparation using the whole-genome gene expression direct hybridization assay 
(Illumina), samples were dispensed onto Human HT-12 v3 Expression 
BeadChips (Illumina) and hybridized for 17 h at 58°C. Mean fluorescence 
intensities (MFI) were quantified using a BeadArray 500GX device. Raw data 










To compare CD8 T-cell responses in GvL reactivity and GvHD after DLI, 11 
patients were selected who were treated for chronic myeloid leukemia in chronic 
phase (CML-CP), acute myeloid leukemia (AML) or high risk myelodysplastic 
syndrome (MDS) between 2000 and 2010 with a T-cell depleted stem cell graft 
from a fully HLA-matched sibling or unrelated donor. Pre-transplant conditioning 
was either myeloablative (cyclophosphamide and total body irradiation) or 
nonmyeloablative (fludarabin, busulphan and in vivo T-cell depletion using 
Alemtuzumab combined with horse ATG in case of an unrelated donor). 
Peripheral blood stem cells were the main stem cell source. After engraftment 
and development of no or limited grade I GvHD, patients with mixed chimerism 
or with residual or relapsed disease were treated with escalating doses of donor 
lymphocytes starting at 6 months with 3*106 CD3+ T cells/kg until a response 
was observed. Patients with unrelated donors received half this dose. With the 
exception of patient 7103, no cytoreductive treatment was administered prior to 
DLI (See also Table S1). Samples after DLI were taken at routine follow-up time 
points or when GvHD was observed. GvL reactivity was defined by conversion 
to full donor chimerism or disappearance of leukemic cells indicating molecular 
remission. Of the 11 patients, 10 patients were evaluable for GvL reactivity and 
6 patients remained free of GvHD (Figure 1A). Five patients developed GvHD 
and received systemic immunosuppression (Figure 1B, see also Table S1). 
Four of 6 patients without GvHD were treated with DLI in the second year after 
alloSCT whereas all 5 patients with GvHD received DLI in the first year after 
alloSCT (p=0.06, Fisher’s exact test). One patient died 74 days after DLI due to 
complications related to grade IV GvHD and could not be evaluated for GvL 





Figure 1. Clinical course of selected patients. Interventions and follow-up are 
depicted per patient on horizontally dotted lines. Regular monitoring post-alloSCT 
included donor chimerism (squares) or BCR-ABL (circles) by PCR and the presence of 
blasts in bone marrow aspirates by morphology. Open symbols indicate full donor 
chimerism or absence of disease. Filled squares indicate disease recurrence as detected 
by bone marrow blasts (black squares), detectable BCR-ABL transcripts (black circles) 
or mixed chimerism (grey squares). 
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 DLI was performed (filled triangles, dose given in 106 CD3+ T cells/kg) and patients 
remained free of GvHD (n=6, A) or were diagnosed with GvHD (n=5, open diamonds, B) 
requiring systemic immunosuppressive treatment (filled diamonds). Arrows indicate 
collected samples. A vertical dotted line is plotted at 1 year post-DLI. Patient 4716 died 






















Selection of alloreactive T cells 
We hypothesized that activated CD8 T cells in post-DLI immune responses 
express HLA-DR. We analyzed frequencies of circulating HLA-DRpos CD8 T 
cells in samples taken before and after DLI by flowcytometry (Figure 2). A 
significant increase in HLA-DRpos CD8 T cells was observed from 10.3% ± 5.3 
% (mean ± SD) in pre-DLI samples to 33.2% ± 19.1% (p=0.002, Wilcoxon 
matched-paired signed rank test) in post-DLI samples, which was irrespective of 
the presence of GvHD. To investigate in which compartment alloreactive T cells 
resided, we separated HLA-DRpos and HLA-DRneg T cells from selected post-DLI 
samples of patients 4461, 5866 and 6181. T-cell clones were generated from 
sorted single cells and were tested for alloreactivity as defined by recognition of 
patient, but not donor EBV-LCL. Of 261 T-cell clones obtained from sorted HLA-
DRpos CD8 T cells, 41 T-cell clones were alloreactive, whereas only one 
alloreactive T-cell clone was identified in 268 T-cell clones from HLA-DRneg 
cells. In contrast, levels of EBV-LCL reactive T-cell clones, as defined by 
recognition of both patient and donor EBV-LCL, were similar between HLA-
DRpos and HLA-DRneg compartments (data not shown). Tetramer staining of 
EBV-LCL reactive T-cell clones from patient 5866 revealed that 56% of EBV-
LCL reactive T-cell clones recognized validated EBV epitopes derived from viral 
proteins BRLF1, BMFL1 EBNA3B or BZLF1 (data not shown). In conclusion, 
our results confirmed that alloreactive T cells during clinical immune responses 
after DLI specifically reside in the HLA-DRpos CD8 T-cell compartment. 
 
Figure 2. HLA-DR expression of CD8 T cells. In samples taken pre- and post-DLI, 
HLA-DRpos CD8 T cells were detected by flowcytometry. Percentages of CD8 T cells that 
expressed HLA-DRpos within the total CD8 T-cell population are depicted. Lines connect 
pre- and post-DLI samples for each patient (patient ID’s are depicted in the graph). 
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Frequencies of the alloreactive T-cell response 
To compare magnitudes of alloreactive responses between patients without and 
with GvHD, we selected 20 samples from patients without GvHD and 12 
samples from patients with GvHD. HLA-DRpos CD8 T cells were single-cell 
sorted and T-cell clones were generated. T-cell clone reactivity was tested 
using patient and donor EBV-LCL. In addition, if sufficient patient pre-alloSCT 
cells were available, monocyte-derived dendritic cells (monoDC) and B cells 
that were expanded using CD40L expressing mouse fibroblasts (CD40L B cells) 
were tested (See also Table S2). Alloreactive T-cell clones were defined by 
selective recognition of patient cells in the absence of recognition of donor cells. 
Per sample, alloreactive T-cell clones are expressed as a percentage of total 
growing T-cell clones (Figure 3A). The median percentage of alloreactive T-cell 
clones in post-DLI samples was significantly lower in patients without GvHD 
(0.6% range 0%-17.1%) as compared to patients with GvHD (30% range 0.5%-
36.6%, p=0.001 Mann-Whitney test). In addition to alloreactive T-cell clones, T-
cell clones were detected that recognized EBV-LCL of both patient and donor. 
These T-cell clones do therefore not target allo-antigens but recognize antigens 
that are expressed by B cells after EBV transformation. In 4 of 6 patients 
without GvHD and 3 of 5 patients with GvHD, more than 50% of the T-cell 
clones were EBV-LCL reactive, illustrating that patients in both groups were 
equally capable to elicit anti-viral immune responses and that the low 
frequencies of alloreactive T cells in patients without GvHD cannot be explained 
by general suppression of the immune system (Figure 3B). To exclude the 
possibility that we missed alloreactive T-cell clones during screening by testing 
solely with hematopoietic cells, we tested all growing T-cell clones from 3 
patients with GvHD against fibroblasts (See also Table S2). To obtain maximal 
recognition, FB were activated for 4 days in the presence of IFN-γ (200 IU/ml) 
prior to testing. No T-cell clones that recognized FB in the absence of 
recognition of EBV-LCL were identified (data not shown). In conclusion, our 
data show that patients with GvHD after DLI have higher frequencies of 
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Figure 3 (facing page). Frequencies of the alloreactive T-cell response. HLA-DRpos 
CD8 T cells were single-cell sorted and expanded from samples taken prior (day 0) and 
after DLI. Patients are stratified by development of GvHD and time points of sample 
collection are indicated on the x-axes per patient. Y-axes depict percentages of tested T-
cell clones that were alloreactive (A) or EBV-LCL reactive (B). 
(A) Alloreactive T-cell clones are defined by recognition of patient, but not donor test 
cells. Percentages of alloreactive T-cell clones in post-DLI samples were compared 
between patients without GvHD and patients with GvHD using Mann Whitney unpaired 
test (insert). 
(B) In the same samples, T-cell clones recognizing EBV-LCL from both patient and 
donor were quantified and depicted as the percentage EBV-LCL reactive T-cell clones. 
No differences in percentages of EBV-LCL reactive T-cell clones were detected between 
patients without GvHD and patients with GvHD by Mann Whitney unpaired test. For 
sorting details and tested stimulator cells, see also Table S2. 
 
 
Diversity of alloreactive T cells 
To identify the diversity of targeted MiHA by 158 isolated T-cell clones, we 
determined HLA restriction, MiHA frequency and TCR clonality. HLA restriction 
was determined in most cases by using broad and allele-specific HLA blocking 
antibodies. In the remaining cases, additional retroviral HLA transduction 
experiments were performed resolving HLA restriction for in total 154 T-cell 
clones (Table 1, see also Table S3). 
 
Table 1. Response diversity
1st allele 2nd allele 1st allele 2nd allele 1st allele 2nd allele
7103 1 1
3356 2 1 5 2 10
4461 2 1 1 4
5835 1 2 3
5866 1 1
5596 2 5 3 (5) 1 1 12 (14)
7995 1 (2) 2 1 (2) 4 (6)
5852 7 (9) 7 (9) 2 3 1 20 (24)
6181 1 (3) 1 3 (4) 5 (8)
4716 3 (6) 1 3 3 2 12 (15)
Numbers respresent MiHA diversity per HLA allele as indicated in the table heading.
In case multiple TCR were found to recognize the same MiHA, the total number of different TCR is given
between brackets.








To detect T-cell clones that targeted identical MiHA, recognition was tested of 
24 EBV-LCL that endogenously expressed HLA-A*02 and B*07. Recognition of 
MiHA restricted to other HLA molecules was tested after retroviral transduction 
of the relevant HLA molecule. Obtained recognition patterns were used to group 
identical T-cell clones which resulted in identification of 19 MiHA targeted in 
patients without GvHD and 53 MiHA in patients with GvHD (Table 1). The 
average number of MiHA targeted in patients without GvHD (3.8 ± 1.7) was 
significantly lower than in patients with GvHD. (10.6 ± 2.9, mean ± SD, p=0.04, 
Mann Whitney test). Of the 72 MiHA targeted by CD8 T cells from 10 patients, 
33 MiHA were recognized by 2 or more T-cell clones. For these T-cell clones, 
we determined whether identical TCRvβ were expressed using an antibody 
panel covering 60% of all different TCRvβ. We found that T-cell clones specific 
for the same MiHA isolated from patients without GvHD expressed 1 TCR-vβ 
whereas T-cell clones for the same MiHA from patients with GvHD expressed 2 
or more TCR-vβ in at least 13 cases (Table 1). The data show that repertoires 
of targeted MiHA as well as diversities of the T-cell responses for each MiHA 
are larger in patients with GvHD than in patients without GvHD. 
 
Tissue specificity of alloreactive T cells 
We next investigated whether MiHA targeted in patients without GvHD were 
expressed on different cell types compared to MiHA targeted in patients with 
GvHD. T-cell specificities for the entire repertoire of targeted MiHA in patients 
without or with GvHD were tested against titrated numbers of hematopoietic 
cells (EBV-LCL, Figure 4A). As non-hematopoietic cells, FB obtained from skin 
biopsies were tested. FB were cultured in the absence of cytokines (steady-
state FB, Figure 4B), or in the presence of IFN-γ (200 IU/ml) for 4 days to mimic 
inflammatory conditions (activated FB, Figure 4C). Under inflammatory 
conditions, higher expression of HLA, molecules involved in antigen processing, 
costimulatory ligands and adhesion molecules leads to a lower threshold for T-
cell recognition4,12. We quantified T-cell recognition by calculating the absolute 
amount of IFN-γ produced per single T cell during overnight stimulation. Despite 
activation, recognition of FB was absent or lower as compared to recognition of 
EBV-LCL by most T-cell clones. Comparison of stimulation including the entire 
range of stimulator-to-T cell ratios was performed by application of mixed 
models (See also: Supplemental experimental procedures: Statistical analyses). 
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This showed comparable IFN-γ production after EBV-LCL recognition between 
T-cell clones from patients without or with GvHD (at ratio 9:1, without GvHD 
87.8 fg IFN-γ/T cell/20h, with GvHD 137.0 fg IFN-γ/T cell/20h, p=0.26, Figure 
4D.). Stimulation by steady-state FB revealed a trend towards higher IFN-γ 
production by T-cell clones from patients with GvHD (at ratio 1:1, without GvHD 
0.7 fg IFN-γ/T cell/20h, with GvHD 1.9, fg IFN-γ/T cell/20h, p=0.10, Figure 4E). 
Activation of FB resulted in significantly stronger stimulation (at ratio 1:1, without 
GvHD 1.3 fg IFN-γ/T cell/20h, with GvHD 4.4 fg IFN-γ/T cell/20h, p=0.03, Figure 
4F). This shows that T-cell clones that broadly recognize MiHA were more 
frequently found in patients with GvHD. In contrast, MiHA-specific T-cell clones 
with selective recognition of hematopoietic EBV-LCL, but not non-hematopoietic 












Figure 4 (next page). Tissue specificity of alloreactive T cells. T-cell clones 
representing all specificities targeted in patients without GvHD (left) and patients with 
GvHD (right) were incubated at 833 and 2500 T cells per well with 0.1, 0.3, 1, 3 and 9-
fold excess of stimulator cells. On the x-axis, T-cell specificities are plotted per patient, 
including the number of isolated T-cell clones with identical specificity (see also Table 
S3). As stimulator cells were used: EBV-LCL (A), FB cultured under steady-state 
conditions (B) and activated FB cultured for 4 days with 200 IU/ml IFN-γ (C). Bars 
represent the dose-response range between lowest and highest ratio of stimulator cells 
as measured by production of IFN-γ in femtogram (fg) per single T cell per 20 h. Mixed 
models were applied to compare dose-response ranges between T-cell clones from 
patients without GvHD (dashed line) and with GvHD (solid line) after stimulation with 
EBV-LCL (D), steady-state FB (E), or activated FB (F). X-axes of E and F are in log 
scale since inclusion of log(ratio) instead of ratio led to a better model fit for FB 
outcomes. P-values refer to differences in outcome between both patient groups at 
stimulator:T cell ratios of 9:1 for EBV-LCL (D) and 1:1 for FB (E and F). See also 
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To molecularly characterize the MiHA that were targeted by the isolated T-cell 
clones, we applied whole genome association scanning (WGAs) to detect 
MiHA-encoding single nucleotide polymorphisms (SNPs). T-cell clones 
restricted to HLA-A*02 or B*07 were tested on an extensive panel of SNP-
genotyped EBV-LCL that endogenously expressed these HLA molecules20. T-
cell clones restricted to other HLA class I molecules were tested against the 
same EBV-LCL panel after retroviral transduction of the relevant HLA molecule. 
From a total of 72 tested T-cell clones, 3 T-cell clones selectively recognized 
male EBV-LCL, indicating recognition of Y-chromosome encoded antigens 
which was confirmed in 1 case by staining with KDM5D-A*02 tetramers (Table 
2). For the remaining 69 T-cell clones, 23 associating SNPs could be found. 
From patients 5569 and 4716, T-cell clones associated with an identical SNP in 
the NDC80 gene. From the 22 unique associations, 13 SNPs were located in 
coding sequences of known genes and 9 SNPs were located in noncoding 
regions. For the latter 9 SNPs, sequencing revealed additional donor-to-patient 
SNP disparities in 6 cases, of which 5 were located in known genes and 1 was 
located in a genomic region that was not near any known gene but that 
encoded an amino acid polymorphism in a 255 bp open reading frame. For 3 
associating SNPs in noncoding gene regions of POLE, RWDD4A and TTK, no 
disparities between patient and donor transcripts were found, hampering further 
characterization of the antigenic peptide . Peptide sequences spanning the 19 
identified amino acid polymorphisms were searched for T-cell epitopes by the 
prediction algorithm NetCTLpan30. T-cell specificity for predicted patient-type 
epitopes but not donor-type controls was tested after loading of titrated 
synthetic peptides on donor EBV-LCL. Predicted epitopes were recognized at 
IC50 levels ranging from 5x10-6 M to 1x10-10 M, whereas donor variants were 
recognized at 2x102 to 1x105 fold higher concentrations, which validated the 
identification of 19 MiHA (Table 2). In conclusion, our strategy identified 19 
MiHA targeted by alloreactive CD8 T-cell clones isolated from 9 patients 
responding to DLI. Of these 19 MiHA, 6 MiHA have previously been 









gene ID SNP function
7103 1 0.56 A*02 rs1801284 1.1*10-12 HMHA1 missense
3356 2 0.41 A*02 rs1634508 4.4*10-14 CCL4 near gene
5 0.69 B*07 rs2071915 7.3*10-12 TMEM8A missense
6 0.25 B*07 rs11541046 1.1*10-9 MOB3A missense in ARF2)
9 0.29 B*07 rs305087 1.1*10-14 C16ORF no gene
10 0.31 B*13 rs1049564 3.8*10-11 PNP missense
4416 13 0,13 A*02 rs12292394 2.4*10-8 NCAPD3 missense
14 0,88 B*07 rs4918752 2.0*10-10 ZDHHC6 ARF2) in 5'UTR
5835 17 0.61 C*14 rs5745001 4.6*10-11 POLE intron
5866 19 0.53 B*35 rs4547833 5.7*10-12 RWDD4A intron
5596 22 0.43 A*02 rs7233405 1.2*10-15 NDC80 intron
27 0.68 B*08 rs2076109 1.0*10-15 APOBEC3B missense
28 0.68 B*08 rs1695 2.0*10-19 GSTP1 missense
29 0.46 B*08 rs1045491 1.4*10-15 GEMIN4 3' UTR
5852 37 0.50 A*02 rs608962 3.6*10−20 TTK intron
38 0.50 A*02 rs12828016 1.1*10−16 WNK1 missense
44 0.67 B*07 rs26654 1.2*10−19 ERAP1 intron
45 0.60 B*07 rs4703 5.5*10−16 ARHGDIB missense in ARF2)
46 0.37 B*07 rs4801775 1.3*10−16 BCAT2 intron
47 0.53 B*07 rs2986014 4.2 *10−15 PDCD11 missense
6181 58 0.51 B*51 rs4801853 2.2*10-14 C19ORF48 missense
4716 61 0.58 A*02 male associated na KDM5D na
62 0.58 A*24 male associated na unknown na
63 0.58 B*40 male associated na unknown na
64 0.43 A*02 rs7233405 1.2*10-15 NDC80 intron
66 0.30 B*40 rs238221 6.2*10-18 ZNFX1 missense
1) determined by Fisher's exact test
2) alternative reading frame











Characteristics of CD8 T-cell responses after DLI 
171 
 
   
coding SNP3) peptide4) IC50 (M)
IC50 (M)    
donor var designated
7103 1 VLH (R) DDLLEA 1*10-10 1*10-5 HA-1
3356 2 rs1130371 CADPSET (S) WV 5*10-10 5*10-7 LB-CCL4-1T
5 RPRSVTI (V) QPLL 1*10-8 5*10-5 LB-TMEM8A-1I
6 C (S) PRPGTWTC 5*10-8 >1*10-4 LB-MOB3A-1C
9 R (W) PCPSVGLSFL 5*10-7 >1*10-4 LB-C16ORF-1R
10 TQAQIFDYS (G) EI 5*10-8 1*10-5 LB-PNP-1S
4416 13 WLQ (R) GVVPVV 1*10-10 1*10-6 LB-NCAPD3-1Q
14 RPRY (H) WILLVKI 1*10-8 1*10-5 LB-ZDHHC6-1Y
5835 17 not found - - - -
5866 19 not found - - - -
5596 22 rs9051 HLEEQIP (A) KV 1*10-9 >1*10-4 LB-NDC80-1P
27 K (E) PQYHAEMCF 5*10-6 >1*10-4 LB-APOBEC3B-2K
28  DL 5*10-7 >1*10-4 LB-GSTP1-1V
29 rs4968104 FPALRFVEV (E) 5*10-9 5*10-5 LB-GEMIN4-2V
5852 37 not found - - - -
38 RTLSPEI (M) ITV 4*10-9 5*10-5 LB-WNK1-1I
44 rs266531 HPR (P) QEQIALLA 2*10-8 >1*10-4 LB-ERAP1-1R
45 LPRACWR (P) EA 4*10-9 >1*10-4 LB-ARHGDIB-1R
46 rs11548193 QPR (T) RALLFVIL 6*10-9 1*10-5 LB-BCAT2-1R
47 GPDSSKTF (L) LCL 3*10-8 >1*10-4 LB-PDCD11-1F
6181 58 TAWPGAPE (G) V 4*10-10 5*10-6 LB-C19ORF48-2E
4716 61 FIDSYICQV5) - - KDM5D
62 unknown - - unknown
63 unknown - - unknown
64 rs9051 HLEEQIP (A) KV 1*10-9 >1*10-4 LB-NDC80-1P
66 NEIEDVWQ (H) LDL 3*10-7 >1*10-4 LB-ZNFX1-1Q
3) if discrepant from associating SNP, detected by Sanger sequencing 
4) donor variant amino acid is depicted between brackets of patient and donor cDNA
   (see also Supplemental experimental procedures.)











Expression of MiHA-encoding genes 
To investigate whether mRNA expression profiles of the identified MiHA-
encoding genes could explain FB recognition patterns as observed in figure 4, 
we quantified MiHA gene expression levels of 6 EBV-LCL and 4 FB by micro-
array techniques. Of the 22 MiHA-encoding genes, probe fluorescences for 
CCL4, PDCD11 and KDM5D did not exceed background, and no probe was 
included for the LB-C16ORF-1R encoding transcript. We grouped MiHA 
according to the level of FB recognition (Figure 5A, right panel). Type 1 MiHA 
were not recognized on steady-state or activated FB. Type 2 MiHA could be 
recognized on FB, but only after activation by IFN-γ. Type 3 MiHA were 
recognized on both steady-state and activated FB. MiHA gene expression 
levels are depicted adjacent to T-cell recognition bars (Figure 5A, left panel). In 
both steady-state and activated FB, absence of recognition of type 1 MiHA 
correlated in 5 of 6 cases with low MiHA-encoding gene expression as 
compared to EBV-LCL. In steady-state FB, absent or low recognition of type 2 
MiHA correlated in 6 of 8 cases with relative low MiHA-gene expression. In 
activated FB however, increased recognition could not be explained by 
increased expression of the MiHA-encoding genes. In type 3 MiHA, gene 
expression levels were comparable between FB and EBV-LCL in 4 of 5 cases. 
For type 2 MiHA, increased recognition after FB activation was not associated 
with increased MiHA gene expression levels. We therefore investigated 
accessory genes involved in peptide generation (PSMB8, PSMB9), intracellular 
translocation (TAP1, TAP2) and presentation (HLA-A, HLA-B and HLA-C). We 
observed strong up-regulation in activated versus steady-state FB (Figure 5B). 
Whereas similar numbers of T-cell clones targeting relative hematopoiesis-
restricted MiHA (type 1) and inducible FB recognition (type 2) were isolated 
from patients without or with GvHD, a relative high contribution of type 3 MiHA 
was isolated from patients with GvHD. The data indicate that gene expression is 
required, but is not always sufficient for recognition of FB. In addition, between 
patients without and with GvHD, no strict distinction in the type of targeted MiHA 
was observed, but only skewing towards recognition of non-hematopoietic MiHA 
in patients with GvHD. 
 
Figure 5: mRNA levels of MiHA-encoding and accessory genes (facing page). Gene 
expression levels in 3rd party cell lines were obtained from 6 EBV-LCL (open bars) and 4 
FB cell lines using micro-array analyses. FB were analyzed in steady-state (grey bars) or 
after activation with 200 IU/ml IFN-γ for 4 days (black bars). (A) Expression levels are 
depicted per gene as mean fluorescence intensity ± sd (MFI, left panel). Stimulation of T 
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cells by patient EBV-LCL and FB (steady-state and activated) was measured by IFN-γ 
Elisa after incubation at stimulator:T-cell ratios of 9:1 (fg/cell/20h, right panel). 
Specificities are stratified by GvHD status of the patient from who the T-cell clones were 
isolated (top: without GvHD, bottom: with GvHD). MiHA specificities with comparable 
recognition patterns are grouped: type 1: no FB recognition, type 2: recognition of 
activated FB only, type 3: recognition of both steady-state and activated FB. (B) 
Expression levels of genes involved in MiHA processing and presentation were analyzed 
and MFI values ± sd are depicted for immunoproteasome subunits PSMB8 and PSMB9, 
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In this study we analyzed alloreactive T-cell responses in 11 patients who 
responded to DLI after T-cell depleted alloSCT, and compared CD8 T-cell 
response characteristics between patients without and with GvHD. In vivo 
activated CD8 T cells were isolated, clonally expanded and analyzed for 
reactivity against hematopoietic and non-hematopoietic cells representing 
targets of GvL reactivity and GvHD, respectively. We measured higher 
frequencies of MiHA-specific T cells in patients with GvHD as compared to 
patients without GvHD. Moreover, alloreactive T-cell responses in patients with 
GvHD were more diverse by both the repertoire of targeted MiHA and the 
variety of T-cell receptors targeting each MiHA. Furthermore, MiHA-specific T-
cell clones from patients with GvHD displayed stronger reactivity against FB 
than T-cell clones from patients without GvHD, whereas the T-cell clones 
responded equally strong to EBV-LCL. We identified 22 SNPs associating with 
MiHA recognition, and validated 19 MiHA, including 6 previously described and 
13 novel MiHA. For MiHA-encoding genes, analysis of mRNA expression and 
MiHA recognition in EBV-LCL and FB showed relatively frequent targeting of 
broadly expressed genes in patients with GvHD. Our data demonstrate that 
both magnitude and diversity of the alloreactive T-cell response in patients with 
GvHD is higher than in patients without GvHD. In patients without GvHD, the 
alloreactive T-cell response was sufficiently strong to mediate GvL reactivity, 
but apparently below the threshold for GvHD development due to skewing 
towards T cells that efficiently target hematopoietic cells but are relatively 
unable to target non-hematopoietic cells.  
 
Following DLI, development of clinically appearing acute GvHD marks 
alloreactivity which enables accurate sampling. In patients with GvL reactivity 
without GvHD the moment of a clinical response is difficult to precisely 
determine. However, testing of multiple post-DLI samples identified alloreactive 
T-cell clones in 5 of 6 patients without GvHD. It is conceivable that in one 
patient the immune response was missed due to either the interval between 
sampling or a very low response magnitude. We show that the alloreactive CD8 
T-cell repertoire resides in the HLA-DRpos T-cell population indicating an active, 
ongoing immune response. Detection of alloreactive T-cell clones was based on 
selective recognition of patient but not donor-derived hematopoietic test cells. 
During GvHD, responding T cells may however also target non-hematopoietic 
MiHA. Testing of FB recognition by all growing T-cell clones from 3 patients with 
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GvHD did not identify additional alloreactive T-cell clones that failed to 
recognize hematopoietic cells. These results indicate that EBV-LCL present a 
repertoire of MiHA specific for both various hematopoietic lineages and non-
hematopoietic cells that are recognized during GvL reactivity and GvHD 
responses. 
 
Our analyses show a significant higher magnitude and diversity of CD8 
alloreactivity in patients with GvHD. This could not be explained by different 
capacities to generate immune responses, since patients in both groups were 
equally able to elicit responses against EBV. Remarkably, all patients with 
GvHD received DLI within the first year after alloSCT as compared to only 2 of 6 
patients without GvHD. It was shown that the probability to survive without 
GvHD was highest if DLI was given beyond 1 year from alloSCT32,33. Early after 
alloSCT, higher levels of residual patient APC may elicit higher response 
magnitudes. APC may also persist longer due to the non-myeloablative pre-
transplant conditioning that was given to 3 of 5 patients with GvHD as 
compared to 1 of 6 patients without GvHD. During immune recovery, patients 
are susceptible to viral infections leading to release of inflammatory cytokines 
thereby increasing alloreactivity after DLI, as was demonstrated by 
development of severe GvHD in two cases of CMV reactivation22. Whereas 
genetic donor-to-patient disparities determine the maximal repertoire of MiHA 
that can be targeted, the presence of residual patient APC and/or inflammatory 
conditions are likely to contribute to the magnitude of the alloreactive response. 
 
In addition to higher response magnitudes, we observed stronger FB 
recognition by T-cell clones from patients with GvHD, especially under 
inflammatory conditions. This was not caused by a lower response capacity of 
the T cells, since strength of EBV-LCL recognition was comparable. MiHA 
recognition of EBV-LCL and steady-state FB indicates broad MiHA expression, 
whereas MiHA that are selectively recognized on EBV-LCL but not on activated 
FB are more likely to be hematopoiesis specific. FB recognition after activation 
with IFN-γ may be caused by a direct increase of MiHA gene expression. It may 
however also be the indirect result of more efficient processing of the antigenic 
peptide, stronger adhesion and costimulation, and higher HLA expression 
levels. Following initiation of hematopoiesis-directed alloreactivity, the chance 
that T cells target non-hematopoietic tissues may depend on the response 





inflammatory environment that increases antigen presentation on non-
hematopoietic tissues resulting in GvHD. 
 
For one third of the isolated MiHA specificities, we could identify associating 
SNPs and genes. Failure to characterize remaining MiHA can be explained by 
high or low MiHA population frequencies, or by absence of the MiHA-encoding 
SNP in the dataset we used. In addition to a range of novel MiHA, we isolated T 
cells recognizing a known MiHA (HA-1), and from two different patients T cells 
were isolated that both recognized the novel LB-NDC80-1P. Furthermore, the 
genes GEMIN4, APOBEC3B and C19ORF48 were found to encode MiHA 
restricted to HLA molecules different from those previously reported20,34. This 
suggests that despite countless missense SNP-disparities between donor and 
patient, the repertoire of immunogenic polymorphic peptides is limited. Further 
analysis of patient samples and MiHA discovery, as we describe here, will give 
rise to a panel of MiHA that are clinically relevant both for GvL reactivity and 
GvHD. 
 
Differential T-cell recognition patterns against steady-state and activated FB 
enabled clustering of 3 types of MiHA. Type 1 MiHA were not recognized on FB, 
type 2 MiHA recognition on FB was absent or low but could be induced or 
increased, respectively. Type 3 MiHA were recognized on FB, irrespective of 
the FB activation state. Absence of FB recognition in type 1 MiHA could in the 
majority of cases be explained by low gene expression levels. Strong 
recognition of type 3 MiHA on FB correlated in the majority of cases with 
comparable levels of gene expression between FB and EBV-LCL. For type 2 
MiHA however, more diverse unpredictable gene expression patterns were 
observed, including very low gene expression levels in FB for NDC80. On FB, 
type 2 MiHA are probably presented at levels that are insufficient for T-cell 
recognition. Inflammatory conditions may lead to recognition by enhancing 
antigen processing and HLA surface expression, and increasing expression of 
costimulatory and adhesion molecules. We identified T cells specific for all 3 
MiHA types irrespective of GvHD development and propose that during initiation 
of the immune response after DLI, professional APC present all 3 MiHA types. 
Subsequent skewing towards more broadly expressed MiHA may occur under 
inflammatory conditions, resulting in GvHD. This implies that GvHD prevention 
after DLI should focus both on specificity of the response, for example by 
depletion of donor T cells that recognize broadly expressed immuno-dominant 
MiHA, and on monitoring and manipulation of in vivo circumstances. 
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In conclusion, our data show that frequencies of alloreactive CD8 T cells are 
higher in patients with GvHD than in patients without GvHD but that there is no 
strict separation in the type of MiHA targeted by T cells from both patient 
groups. However, the alloimmune response in patients with GvHD is skewed 
towards T cells with stronger FB recognition, especially after treatment of FB 
with inflammatory cytokines. Identification of MiHA targeted in these patients 
significantly increased the repertoire of known hematopoiesis-restricted and 
broadly expressed MiHA. Improvement of the outcome of alloSCT in favor of 
GvL reactivity and reduced risk of GvHD may be obtained by infusion of 
selected hematopoiesis-specific T cells and depletion of T cells that target 
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Supplemental experimental procedures 
 
Statistical analyses 
Fisher’s exact test was applied to calculate significance of correlation between 
the time point of DLI after alloSCT and GvHD occurrence (Figure 1), and to 
detect SNP associating with recognition patterns of EBV-LCL panels (Table 2: 
Antigen specificity). Wilcoxon’s matched-pairs signed rank test was applied to 
calculate significance of difference of HLA-DR expression in pre-, and post-DLI 
samples (Figure 2). Mann-Whitney’s test was applied to calculate significance 
of difference in magnitudes of alloreactivity (Figure 3A) and response diversity 
between patients without and with GvHD (Table 1). To analyse experiments 
determining recognition strength and tissue specificity, mixed models were 
applied to calculate differences of recognition of EBV-LCL (Figure 4D), steady-
state FB (Figure 4E) and activated FB (Figure 4F) between patients without or 
with GvHD and its dependence on the stimulator : T-cell ratio, taking into 
account clustering of patients and T-cell clones. Recognition of EBV-LCL was 
evaluated in a separate model, while steady-state FB and activated FB 
recognition were both assessed in a combined model. For all statistical 







































































































































































































































































































































































































































































   





































































































































































































































































































































































































































   







   
   











































































   
   










pat don pat don pat don pat
6268 0 5760 384 3  (157)
56 14976 10  (1534)
105 11520 13  (1462)
7103 0 3072 384 10 (75)
17 6604 10 (192)
24 6374 11 |(192)
52 6604 31 (384)
3356 0 480 96 10  (50)
56 2080 9  (191)
122 864 11  (96)
4461 0 923 96 13  (123)
28 1212 7  (90)
84 960 4  (36)
182 1152 11  (131)
5835 0 1) 384 96 20  (78)
44 1) 2016 6  (129)
72 1) 480 16  (78)
5866 0 864 96 15  (126)
43 3396 8  (272)
99 3168 3  (94)
cloning efficiency (mean ± SD) 10.8 ± 6.4 %
number of growing clones (mean ± SD) 277 ± 432
5596 0 480 384 8  (36)
42 1) 4702 5  (237)
49 1) 9310 2  (206)
7995 62 16282 384 3  (518)
78 16282 6  (936)
5852 45 2000 96 10  (132)
6181 0 384 96 7  (25)
49 1440 14  (202)
84 960 12  (115)
4716 0 480 384 11  (52)
23 16454 2  (287)
cloning efficiency (mean ± SD) 8.7 ± 7.2 %
number of growing clones (mean ± SD) 202 ± 183
1) Indicated are the days after the 2nd DLI.
2)Shaded boxes indicate that cells in column header were tested.
3)FB were tested after 4 days activation in the presence of 200 IU/ml IFN-γ.
























Table S3. Response diversity
7103 1 A*02 0.54 2 22 1
3356 2 A*02 0.42 2 8 10
3 A*02 0.04 1 1
4 A*24 0.38 1 neg*
5 B*07 0.67 2 13.2
6 B*07 0.25 2 neg
7 B*07 0.71 1 20
8 B*07 1.00 5 17
9 B*07 0.29 1 neg
10 B*13 0.29 2 neg
11 B*13 0.04 1 neg
4461 12 A*02 0.75 1 1 4
13 A*02 0.13 2 8
14 B*07 0.88 1 neg
15 B*44 0.29 1 neg
5835 16 B*44 0.98 1 8 3
17 C*14 0.63 2 3
18 C*14 0.04 2 neg
5866 19 B*35 0.54 1 5.3 1
5596 20 A*01 0.67 2 5.1 12
21 A*01 0.67 1 13.2
22 A*02 0.42 1 20
23 A*02 0.63 2 neg
24 A*02 0.04 1 neg
25 A*02 0.29 1 8
26 A*02 0.38 1 neg
27 B*08 0.67 7 7.1 neg
28 B*08 0.67 3 16
29 B*08 0.46 2 21.3 1
30 B*51 0.96 1 3
31 unknown 0.46 1 13.2
*Not staining with TCRvβ-specific antibodies included in the assay.
Patients with GvHD
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Table S3. Response diversity (continued)
7995 32 A*01 0.96 6 2 neg* 4
33 B*35 0.00 2 16
34 B*35 0.67 1 neg
35 C*04 or C*12 0.96 16 14 neg
5852 36 A*02 0.50 4 9 17 20
37 A*02 0.50 1 neg
38 A*02 0.21 1 1
39 A*02 0.04 2 5.1 20
40 A*02 0.13 3 8 neg
41 A*02 0.98 1 neg
42 A*02 0.08 1 neg
43 B*07 0.67 1 1
44 B*07 0.58 1 neg
45 B*07 0.38 3 neg
46 B*07 0.54 1 neg
47 B*07 0.13 3 12 16
48 B*07 0.04 2 1 neg
49 B*07 0.17 1 8
50 B*44 0.71 1 12
51 B*44 0.04 1 neg
52 C*05 0.96 2 23
53 C*05 or C*07 0.04 3 9
54 C*05 or C*07 0.08 1 17
55 unknown not tested 2 neg
6181 56 A*11 0.63 4 12  20 21.3 5
57 B*44 0.88 2 5.1
















59 B*51 0.04 3 1 17 
60 B*51 0.04 3 1
4716 61 A*02 0.58 2 12 13.1 12
62 A*24 0.58 1 neg
63 B*40 0.58 1 9
64 A*02 0.42 3 14 23 neg
65 A*02 0.04 1 neg
66 B*40 0.29 1 neg
67 B*40 0.83 4 14
68 B*44 0.04 1 neg
69 B*44 0.88 2 neg
70 B*44 0.96 1 neg
71 B or C 0.00 1 13,1
72 unknown 0.79 1 neg






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Donor alloreactivity contributes to the curative effect of allogeneic stem cell 
transplantation (alloSCT) and donor lymphocyte infusion (DLI). Characterization 
of minor histocompatibility antigens (MiHA), the molecular structures targeted 
by alloreactive donor T cells in the HLA-matched setting, provides insight into 
the mechanisms of graft-versus-leukemia (GvL) reactivity and graft-versus-host 
disease (GVHD) and may identify MiHA that are effective and safe targets for 
adoptive immunotherapy. 
 
MiHA are polymorphic peptides encoded predominantly by single nucleotide 
polymorphisms (SNP) that encode amino acid substitutions in proteins. After 
proteasomal degradation, polymorphic patient-specific peptides that bind to 
human leukocyte antigens (HLA) are presented to donor T cells which can lead 
to activation, expansion and targeting MiHApos patient cells. Discovery of MiHA 
focuses on isolation and characterization of the antigenic peptide by 
biochemical techniques or on identification of the MiHA-encoding transcript by 
cDNA cloning techniques. Whole genome association scanning (WGAs) 
identifies the MiHA-encoding SNP and is based on separation of MiHAneg from 
MiHApos test cells from which detailed SNP genotype data are available. 
 
MiHA expression on target cells of GvL reactivity and GVHD, can be tested 
directly by T-cell recognition and by quantification of MiHA-encoding gene 
expression levels. Alloreactive donor T cells targeting MiHA that are exclusively 
expressed by malignant cells may induce selective GvL reactivity without 
GvHD. 
 
In chapter 2 we show the biochemical purification and mass spectrometric (MS) 
characterization of LB-ADIR-1F, a MiHA that was targeted by a dominant 
alloreactive T-cell response in a multiple myeloma (MM) patient who obtained 
complete remission after alloSCT and DLI. LB-ADIR-1F specific T cells lysed 
MM cells in vitro but also demonstrated weak recognition of non-hematopoietic 
cells, which may have caused the GvHD that was observed after DLI. We 
identified the antigenic peptide that contained an amino acid polymorphism 
encoded by SNP rs2296377. In a panel of 74 test cells, the presence of this 
SNP correlated in all cases with T-cell recognition. The amino acid 
polymorphism occurred in a reading frame that was initiated by an alternative 
out-of-frame start codon located upstream of the normal start codon. Tetramer 
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analysis showed high levels of circulating LB-ADIR-1F specific T cells at 7 
weeks post-DLI thereby confirming that targeting of this novel MiHA can 
contribute to GvL reactivity but may also cause GvHD. Despite labor-intense 
biochemical purification and MS analyses, application of biochemical 
techniques and MS can lead to identification of antigenic peptides presented by 
HLA. 
 
Whereas biochemical techniques and MS can robustly identify MiHA, we set out 
to increase the speed of MiHA discovery by WGAs. Chapter 3 describes 
implementation and validation of WGAs for MiHA discovery using a panel of 80 
EBV-LCL that was high-resolution SNP-genotyped. From 2 patients who 
responded to DLI, 20 different HLA-A*02 or B*07 restricted MiHA-specific T-cell 
clones were analyzed. For 12 T-cell clones, WGAs detected SNP that were 
present in MiHApos but not in MiHAneg EBV-LCL. To define the MiHA peptides, 
we performed HLA-binding prediction of peptide sequences that spanned the 
SNP-encoded amino acid polymorphism. Specific T-cell recognition of patient-
type peptides but not donor-type peptides validated the discovery of 10 novel 
MiHA. Tetramer analysis of blood samples that were collected after DLI showed 
significant numbers of circulating T cells specific for several of the novel MiHA 
thereby validating that WGAs enables rapid discovery of clinically relevant 
MiHA. 
 
In chapter 4, we applied retroviral transduction of the EBV-LCL used for WGAs 
to discover MiHA that are restricted to other HLA molecules than HLA-A*02 or 
B*07. We analyzed 4 HLA-B*40 restricted T-cell clones that were isolated from 
a patient who was treated with alloSCT and DLI for chronic myelogenous 
leukemia. WGAs identified SNP in SON, SWAP70 and NUP133 as potentially 
MiHA-encoding. For 1 T-cell clone, cDNA library screening was performed 
which identified a SNP with high population frequency in TRIP10. Specific 
recognition of patient-type peptides validated LB-SON-1R, LB-SWAP70-1Q and 
LB-TRIP10-1EPC as 3 novel MiHA. For LB-NUP133-1R, also the donor peptide 
was recognized, in contrast to selective recognition of patient but not donor-
derived NUP133 transcripts. This suggests that LB-NUP133-1R immunogenicity 
does not result from specific recognition of the patient amino acid 
polymorphism. It is more likely that the complete LB-NUP133-1R peptide is not 
presented by donor cells which may be due to differential processing of the 
parental NUP133 protein caused by the amino acid polymorphism. The data 




molecule. In regard to population frequency, recognition of various 
hematological malignant cells and absence of fibroblast recognition, LB-
SWAP70-1Q is a promising target for adoptive immunotherapy to treat patients 
who suffer from hematological malignancies. 
 
Due to better treatment tolerability, T-cell depleted alloSCT and DLI were also 
applied to elicit graft-versus-tumor reactivity in patients with solid tumors. 
Chapter 5 describes a patient with metastasized renal cell carcinoma (RCC) 
who, after alloSCT and DLI, suffered from acute GvHD and severe chronic 
GvHD. This strong response coincided with tumor regression resulting in stable 
disease for 4 years. A MiHA specific T-cell clone was isolated from blood that 
was taken at the onset of GvHD. WGAs identified LB-FUCA2-1V as the target 
of this alloreactive T cell that was detectable at high levels in blood. The FUCA2 
gene was broadly expressed as measured by mRNA analyses. Concordant with 
this, LB-FUCA2-1V specific T cells strongly recognized RCC cell lines and also 
fibroblasts that were activated by IFN-γ. We therefore concluded that this T-cell 
clone was involved in both GvT reactivity and development of GvHD. In patients 
with solid tumors, alloreactivity was more often accompanied with GvHD than in 
patients with leukemia. To estimate the chance that GvT can occur without 
GvHD, we analyzed gene expression profiles of both RCC cell lines as targets 
of GvT reactivity, and skin-derived cells representing targets of GvHD. Given 
the prerequisite that efficient T-cell responses are initiated by professional 
antigen presenting cells (APC), GvT reactivity without GvHD requires targeting 
of genes that are expressed by both professional APC and RCC cells but not by 
epithelial cells. Only a limited number of genes fulfilled these criteria. 
Significantly more genes were found when RCC cells were replaced by 
leukemic cells in the analysis. This indicates that induction of GvT reactivity to 
treat patients with solid tumors may unavoidably lead to development of GvHD. 
 
Patient suffering from hematological malignancies can achieve GvL reactivity 
after alloSCT and DLI without or with development of GvHD. Chapter 6 
describes a comparison of both quantitative and qualitative aspects of 
alloreactive CD8 T-cell responses after DLI between the patient groups. We 
observed a significant increase in the absolute number of circulating HLA-DRpos 
CD8 T cells after DLI, independently of development of GVHD. Activated CD8 T 
cells were clonally expanded and we found both higher magnitudes and 
diversities of the alloreactive T-cell response in patients with GvHD. Whereas 
isolated T-cell clones from patients without or with GvHD were equally capable 
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to respond to hematopoietic cells, recognition of skin-derived fibroblasts (FB), 
representing targets of GvHD, was stronger by T-cell clones isolated from 
patients with GvHD. Inflammatory conditions further increased this difference of 
FB recognition. WGAs was applied to identify the MiHA that were targeted. This 
allowed analysis of expression levels of MiHA-encoding genes. This showed 
that increased recognition of MiHA under inflammatory conditions could not be 
explained by increased expression levels of MiHA-encoding genes. However, 
higher expression of genes involved in MiHA processing and presentation was 
observed confirming the prominent role of the micro-environment on recognition 
of MiHA on non-hematopoietic cells.  
 
In summary, from patients who receive alloSCT and DLI, T-cell clones can be 
isolated that recognize MiHA that can be selectively expressed by 
hematopoietic and leukemic cells resulting in GvL reactivity. However, 
recognition of normal tissue cells can also occur, which is likely to be correlated 
with development of GvHD. By developing methods for high-throughput 
discovery of MiHA, we are now able to perform comprehensive analyses of in 
vivo allo-immune T-cell repertoires to gain insight in the biology of GvL/GvT 







Treatment with alloSCT and DLI can be considered as cellular immunotherapy, 
since donor T, B, and NK cells can be immune effector cells capable of inducing 
curative GvL reactivity. Candidate target antigens for donor T cells mediating 
GvL reactivity after HLA matched alloSCT are polymorphic peptides that are 
presented on the tumor cell by HLA surface molecules, the so-called minor 
histocompatibility antigens (MiHA). 
 
After successful alloSCT, donor stem cells replace patient hematopoiesis. 
Alloreactive T cells in DLI after alloSCT have the potential to attack all cells of 
patient origin, which may include leukemic cells (GvL reactivity), healthy non-
hematopoietic tissues (GvHD) or residual hematopoietic cells of patient origin in 
case of mixed chimerism (graft-versus-patient hematopoiesis). Hematopoietic 
cells that originate from the donor stem cells, however, express antigens that 
are considered as “self” for the donor lymphocytes and will therefore be ignored. 
In contrast to anti-tumor therapies for non-transplanted patients, T-cell therapies 
for hematological malignancies after alloSCT do not require targeting of 
antigens that are specifically expressed on leukemic cells, but may also be 
directed against MiHA that are expressed by all hematopoietic patient cells. As 
such, a large repertoire of hematopoiesis-restricted antigens can be suitable 
targets to treat hematological malignancies after alloSCT. 
 
This thesis describes the role of CD8 T cells in clinical immune responses that 
are induced in patients after alloSCT and DLI. From these patients, large 
repertoires of T-cell clones have been isolated representing in vivo alloimmune 
responses. We focused on patients with malignant hematopoietic diseases, but 
also investigated the response after alloSCT and DLI in a patient who was 
treated for metastatic renal cell carcinoma (RCC). Different strategies have 
been followed to identify the molecular targets of donor-derived alloreactive 
CD8 T cells, which greatly increased our understanding of how genetic 
polymorphisms encode MiHA. 
 
By comparing alloimmune responses between transplanted patients who 
responded to DLI without or with GvHD, a correlation between magnitude and 
diversity of MiHA-specific CD8 T cells and development of GvHD was 
demonstrated. From these patients, we isolated alloreactive T-cell clones and 
investigated T-cell recognition of target cells of GvL reactivity (malignant 
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hematopoietic cells), graft-versus-patient hematopoiesis (healthy hematopoietic 
cells) and cells representing non-hematopoietic tissues that are targeted in 
GvHD. The data show that T cells can be distinguished by hematopoiesis-
restricted recognition or broad reactivity against hematopoietic as well as non-
hematopoietic cells. T cells with hematopoiesis-restricted recognition can 
induce selective GvL-reactivity without GvHD, whereas T cells with broad 
reactivity that includes non-hematopoietic tissues can mediate both GvL-
reactivity and GvHD. As such, T cells with hematopoiesis-restricted recognition 
are of special interest, since these T cells recognize MiHA that may be suitable 
targets for adoptive immunotherapy. 
 
In this chapter, we discuss strategies to isolate alloreactive T cells from post DLI 
samples and different methods that can be used to discover MiHA, including 
‘reversal’ of the MiHA discovery approach. In addition, the tissue distribution of 
MiHA and the effect of environmental factors on T-cell recognition are 
considered. Finally, developments in post-alloSCT cellular immunotherapy to 
induce GvL reactivity without GvHD, including application of alloreactivity to 
treat solid tumors, are discussed. 
 
Selection of alloreactive T cells 
In vivo activated antigen-specific T cells can reach levels in peripheral blood 
that allow detection and isolation. Within the total number of PBMC, however, 
antigen-specific T cells do not exceed percentages of 1-5% of CD8 T cells. 
Clonal analysis of circulating alloreactive T cells therefore requires enrichment 
by in vivo or in vitro induced cell surface proteins or secreted proteins. In 
chapters 3 and 6 of this thesis, in vivo activated T cells were directly isolated by 
surface expression of HLA-DR from post-DLI patient samples. In chapters 2, 4 
and 5, post-DLI samples were stimulated in vitro with patient cells obtained prior 
to alloSCT and activated T cells were isolated by secreted IFN-γ (chapters 2 
and 4) or up-regulated HLA-DR (chapter 5). Direct post-DLI isolation by HLA-
DR surface expression allows quantitative analysis of circulating activated 
MiHA-specific T cells. Compared to isolation of in vivo activated T cells by HLA-
DR, more efficient selection of MiHA-specific T cells may be obtained after in 
vitro stimulation with patient cells, but T-cell reactivity is likely to be skewed 





The biological function of HLA-DR on T cells is largely unknown. TCR ligation 
can lead to HLA class II gene expression and cell surface presentation via 
signaling of CD2 or CD31. However, T cells have also been demonstrated to 
‘snatch’ HLA class II from nearby APC through trogocytosis2,3. Non-
hematopoietic tissues lack HLA class II, but expression can be up-regulated by 
inflammation. HLA class II expression on T cells may be similarly up-regulated 
by IFN-γ produced after antigenic stimulation via autocrine signaling. There may 
also be a role for HLA-DR expression in amplification of virus specific immune 
responses. The intimate contact of T cells with virus-infected tissue cells may 
lead to viral infection of T cells, which subsequently present viral epitopes and 
amplify the virus-specific immune response. Despite the poorly understood 
biological function of HLA-DR surface expression on T cells, this thesis clearly 
shows that in patients with GvHD after DLI, higher frequencies of MiHA-specific 
T cells are found within the HLA-DRpos compartment than in patients who 
remained free of GvHD. 
 
Isolation of alloreactive T cells depends on immune response dynamics at the 
time of sampling. Expression of the in vivo activation marker may vary during 
initiation, expansion, effector, retraction and memory phases of the immune 
response. Moreover, systemic immunosuppression to treat GvHD may alter 
phenotypes and expression levels of activation markers of alloreactive T cells. If 
multiple MiHA are targeted, the dynamics of individual specificities may also 
vary, as demonstrated by early detection of LB-ARGHDIB-1R as compared to 
LB-ERAP1-1R specific T cells in chapter 3 and early detection of HA-2 as 
compared to HA-1 specific T cells in chapter 4. In addition to HA-1 and HA-2, 
which are both expressed by HLA-A*02:01, T cells for HLA-B*40:01 restricted 
MiHA also showed different kinetics in the same patient. These data suggest 
that an order of events may take place in which strong primary responses 
support development of secondary responses. Since T cells are often isolated 
from single samples, it is important to realize that the relative T-cell frequencies 
as detected in the sample of choice may not reflect the actual contribution of the 
T cells during the overall in vivo immune response. 
 
In vitro stimulation of peripheral blood or bone marrow samples using pre-
alloSCT patient cells may synchronize T cells that are in different phases of the 
immune response. This may identify a more comprehensive repertoire of MiHA-
specific T cells with naïve and memory phenotypes. Moreover, in vitro 
stimulation with malignant cells may result in isolation of T cells that recognize 
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MiHA with therapeutic relevance. Using in vivo activation marker HLA-DR, we 
also isolated MiHA specific T-cell clones that produced low levels of IFN-γ in 
response to patient EBV-LCL. These T cells may have been missed in 
experiments in which T cells are isolated by secretion of IFN-γ. We previously 
demonstrated that in addition to IFN-γ secretion, expression of CD137 and 
CD154 can be used to detect alloreactive T cells4. Compared to IFN-γ 
secretion, these markers are expressed for a prolonged time, which facilitates 
more efficient T-cell isolation. The relative in vivo abundance of MiHA specific T 
cells may however be lost following in vitro stimulation. 
 
It has been suggested in various studies that ex vivo analysis of peripheral 
blood may not reliably represent alloimmune responses that take place in situ5,6. 
It is indeed likely that peripheral blood mainly serves to transport immune cells 
throughout the body, while initiation of immune responses occurs in lymphoid 
organs and immune cells exert their effector function in other tissues. In a 
limited number of patients with leukemia, we compared simultaneously taken 
bone marrow and peripheral blood samples, but did not observe significant 
discrepancies in frequencies of MiHA-specific T cells between both 
compartments (data not shown). 
 
MiHA discovery strategies 
Genetic polymorphisms are transcribed into mRNA and are subsequently 
translated into amino acid polymorphisms that can be presented as antigenic 
peptides by HLA class I or II surface molecules. Different approaches have 
been developed to discover MiHA. HA-1 and HA-2, which are the first MiHA that 
have been identified, were discovered by mass-spectrometric analysis of 
peptide pools after elution from immuno-precipitated HLA molecules and HPLC 
fractionation. This method has successfully been applied to discover LB-ADIR-
1F as described in chapter 2. In contrast to HLA class I restricted antigens, HLA 
class II restricted antigens are difficult to identify by mass spectrometry probably 
due to low surface expression of the antigen and the presence of peptide length 
variants that can be bound by HLA class II molecules. HLA class II restricted 
MiHA have, however, successfully been identified by screening cDNA 
expression libraries7,8. By this method, pools of plasmids containing cDNA from 
MiHApos cells are expressed as protein pools by bacteria. Lysed bacteria are 
exogenously loaded on HLA class II of MiHAneg EBV-LCL and tested for 




CD8 T-cell clones, MiHA encoding cDNA can be identified in plasmid pools after 
transfection in COS-7 cells for endogenous presentation by HLA class I. This 
method resulted in discovery of several HLA class I MiHA, including LB-
TRIP10-1EPC as described in chapter 4. In both mass spectrometric analysis of 
HPLC peptide pools and cDNA library screening, T-cell clones need to carry 
high affinity TCR and possess an avidity that is sufficient for recognition of low 
antigen levels in peptide or cDNA pools. Moreover, large numbers of T cells are 
required thereby limiting these approaches to T-cell clones that can be 
expanded to large numbers. 
 
Mass spectrometric analysis of HPLC peptide fractions and cDNA library 
screening as described above also allow identification non-polymorphic 
antigens that are recognized by alloreactive T cells in mismatched HLA-
molecules9 or tumor antigens that result from somatic mutations or 
overexpression10. Still, these approaches are very laborious. For high-
throughput identification of MiHA, the more global approach of whole genome 
association scanning (WGAs) proved to be more successful. WGAs identifies 
the MiHA-encoding SNP by testing T-cell reactivity against a panel of EBV-LCL 
containing both MiHApos and MiHAneg cells. In this thesis, we demonstrated the 
high-throughput capacity of WGAs by discovery of 25 novel HLA class I 
restricted MiHA (10 in chapter 3, 3 in chapter 4 and 12 MiHA in chapter 6). For 
WGAs, a panel of 80 HLA-A*02 and B*07 expressing EBV-LCL was assembled, 
frozen and stored in microtiter plates. Using micro-array techniques, one million 
SNPs were measured for each EBV-LCL. Reactivity of MiHA specific T-cell 
clones against the EBV-LCL panel was tested and MiHA-encoding SNPs have 
been identified by comparing patterns of recognition with patterns of SNP 
distribution. As WGAs has demonstrated to be an efficient method for MiHA 
discovery using the endogenously expressed HLA-A*02 and B*07, we 
expanded the method towards additional HLA class I restriction molecules by 
batch-wise retroviral transduction as described in chapters 4 and 6. 
 
Detection of MiHA-encoding SNP by WGAs depends on segregation of MiHApos 
and MiHAneg test cells. In chapter 3 we observed that despite strong 
segregation, WGAs fails to detect associating SNP in some cases. It is required 
that the MiHA-encoding SNP, or a SNP that is in linkage disequilibrium with the 
MiHA-encoding SNP, is genotyped. Our panel of 80 EBV-LCL was genotyped 
for one million SNP and therefore still lacks many genotypes of the 38 million 
SNPs as estimated to be present in human genomes. Currently, data of the 
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‘1000-Genomes’ project are available which contain the complete SNP 
landscape of the human genome11. EBV-LCL used for the 1000-Genomes 
project are available and can thus be used to assemble new panels for WGAs12. 
 
WGAs may also identify SNP in intron regions that are involved in mRNA 
splicing. If MiHA are encoded by alternative transcripts, it may be difficult to 
identify the MiHA peptide. Various reports demonstrated that MiHA can be 
encoded by alternative transcripts13,14. Alternative transcripts may explain why 
in some cases significant association with SNP in noncoding gene regions has 
been found, but no MiHA peptide could be resolved (chapters 3 and 6). In one 
case, we identified an associating SNP in a genomic region that is unknown to 
contain a functional gene. The associating SNP was located on chromosome 16 
at the border of a 500kbp ‘gene desert’ 26 kbp from the nearest known gene. 
Translation of the associating SNP in different reading frames revealed a 
peptide with strong predicted binding to HLA-B*07:02. We demonstrated 
recognition of this peptide by the T-cell clone and designated the MiHA as LB-
C16ORF-1R. These data demonstrate that T cells can recognize polymorphic 
structures encoded or generated by SNP in alternative transcripts in which 
intron regions are retained or by SNP in transcripts derived from genomic 
regions that are unknown to contain a functional gene. 
 
An important factor that influences the power of WGAs is the frequency of the 
MiHA-encoding SNP in the panel of test cells. The chance to detect SNP by 
WGAs is optimal if MiHA frequencies range between 10-90%. To identify MiHA 
with frequencies outside this range, the panel of test cells should be enlarged, 
thereby enabling discovery of the full repertoire of MiHA as targeted by in vivo 
immune responses in patients after alloSCT (and DLI). For discovery of targets 
with therapeutic value, however, MiHA with low or high frequencies are less 
relevant. 
 
MiHA discovery revealed that SNP can generate immunogenic peptides in 
different ways. First, SNP can be transcribed into mRNA and directly encode 
amino acid changes in peptides that are recognized by T cells. In addition, SNP 
as present in primary gene transcripts can be translated in alternative reading 
frames or encode immunogenic peptides when located in 5’ or 3’ untranslated 
regions. Furthermore, SNP can encode amino acid changes in peptides that 
influence proteasomal cleavage of the parental protein. Finally, SNP can be 




splice variants that encode immunogenic peptides. To facilitate high throughput 
identification of SNP involved in RNA splicing, all transcripts as expressed by 
MiHAneg and MiHApos test cells can be analyzed in RNA sequence data. RNA 
sequencing on EBV-LCL from the 1000-Genomes project has been performed 
by the Geuvadis consortium15. Combining these data with whole genome SNP 
data from the 1000-Genomes project allows analysis of all SNPs present in the 
human genome by WGAs and analysis of the transcripts in MiHAneg and 
MiHApos cells. As such, this combined strategy may provide a powerful tool for 
future discovery of MiHA. 
 
Reversing the MiHA-discovery approach 
Above described ‘forward’ approaches for MiHA discovery rely on established 
T-cell clones that have been isolated from in vivo immune responses. The 
presence of the T-cell clone proves both the antigenic capacity of the MiHA and 
the existence of MiHA-specific T-cells. A disadvantage of the ‘forward’ approach 
however, is that many isolated T-cell clones recognize broadly expressed MiHA 
that thereby lack therapeutic value. As an alternative, MiHA discovery can start 
by first selecting genes with leukemia- or hematopoiesis-restricted expression. 
Next, these genes are assessed for the presence of polymorphic amino acids, 
and peptides spanning these polymorphisms can be tested for HLA-binding, 
leading to a panel of MiHA candidates16. As a validation step for HLA 
presentation, MiHA candidates can be searched in databases of eluted 
peptides, which drastically reduces the number of MiHA candidates17,18. 
Confirmation of MiHA immunogenicity requires detection of high-avidity T cells 
in MiHAneg individuals using HLA-peptide tetramers. Previous experiments 
showed that tetramers can bind to T-cells with weak functional reactivity against 
endogenously processed and presented MiHA. This can be overcome by 
assessing ‘structural avidity’ which measures the dynamics of dissociation of 
the HLA-peptide ligand from the TCR, thereby allowing identification of 
functionally relevant T cells19. Due to these technical advances, this ‘reverse’ 
approach has become increasingly attractive as a tool for MiHA discovery.     
 
MiHA tissue distribution 
The in vivo effect of alloreactive T cells is likely to depend on the tissue 
distribution of each individual MiHA as targeted in the immune response after 
alloSCT and DLI. The tissue distribution of MiHA can be assessed by 
measuring T-cell recognition of cells of various tissues. This analysis requires 
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expression of the relevant HLA-restriction molecule as well as presence of the 
MiHA-encoding SNP by the test cells. Due to different population distributions of 
MiHA-encoding SNP, specific panels of tissue cells need to be collected for 
analysis of each MiHA. As non-hematopoietic cell type, FB can be relatively 
easily collected and cultured from patient derived skin biopsies. As such, MiHA 
specific T-cell clones isolated from a patient can be analyzed for reactivity to 
autologous patient FB. Whereas absence of recognition of skin FB does not 
exclude T-cell reactivity against non-hematopoietic cells of other tissues, it 
allows initial separation of hematopoiesis-restricted MiHA from ubiquitously 
expressed MiHA, as shown in chapters 4, 5 and 6. 
 
In addition to the MiHA expression level on target cells, T-cell recognition may 
also depend on the affinity of the TCR that is expressed by the T-cell clone that 
is available for testing. It can be expected that T-cell clones isolated from in vivo 
clinical immune responses express high-affinity TCR. However, recognition of 
target cells that lack sufficient expression of ligands required for costimulation 
and adhesion may be low or undetectable. As such, results as to whether a 
MiHA is targeted during GvHD may be biased by the T-cell clone used for 
analysis. 
 
An alternative approach to estimate involvement of MiHA in GvL and GvHD is 
quantification of MiHA-encoding gene transcripts. The main advantage of this 
approach is that cells from various tissues can be collected and analyzed 
independently of the presence of specific HLA alleles and MiHA-encoding SNP. 
Expression of single genes can be quantified by real-time PCR, whereas 
transcriptome-wide analysis can be performed using micro-array based 
platforms. In both techniques, expression of MiHA-encoding genes can be 
compared between malignant cells, normal hematopoietic cells and normal 
tissue cells. This approach does however not allow comparison of different 
gene transcripts within one cell type, due to different primer- and probe-binding 
efficiencies per gene. Furthermore, MiHA may be encoded by (rare) splice 
variants that are not detected. Although these problems may be solved by RNA 
sequencing as advanced technique for transcriptome analysis, gene transcripts 
may still vary in efficiency to encode proteins, and antigens may differ in their 
processing and presentation behavior. In chapter 6 of this thesis, we compared 
gene expression of MiHA-encoding genes with T-cell recognition of 
hematopoietic and non-hematopoietic cells. We found that absence of MiHA 




expression. Strong FB recognition correlated with ubiquitous expression of the 
MiHA-encoding genes. Interestingly, we also isolated T cells that failed to 
recognize FB, whereas the MiHA-encoding genes seemed to be ubiquitously 
expressed. Lack of FB recognition may be explained by expression of 
intermediate affinity TCR by the T cell combined with low MiHA expression 
levels and insufficient expression of adhesion and costimulatory molecules. 
Future experiments are required to investigate whether these TCR and/or MiHA 
are valuable to induce GvL reactivity without GvHD after alloSCT. 
 
In this thesis we show that post-DLI immune responses can be induced in the 
presence of low levels of patient hematopoietic cells. These responses are most 
likely induced by residual patient professional APC, which is supported by the 
observation that MiHA have been identified that are exclusively expressed by 
mature DC. T cells for LB-EBI3-1I20 and LB-TRIP10-1EPC21 have been isolated 
from patients suffering from CML, but expression of EBI3 and TRIP10 was 
undetectable in CML cells. In contrast, significant expression of these genes 
was found in mature DC. Similar to this, in chapter 5, LRH-1 specific T cells 
were detected in a patient with RCC after HLA-matched alloSCT and DLI22. The 
P2RX5 gene that encodes LRH-1, shows restricted expression in B cells, which 
is in line with B-cell specific recognition by LRH-1 specific T cells. These cases 
illustrate that patient residual professional APC and B cells elicited in vivo T-cell 
responses that not directly mediated GvL or GvT reactivity or GvHD. These 
responses may however have contributed indirectly to the immune response by 
creating inflammatory conditions that initiated or amplified other T cell 
reactivities. 
 
As described above, T cells with specific reactivity against mature DC have 
successfully been isolated based on recognition of patient, but not donor, EBV-
LCL. To investigate whether T cells exist that exclusively recognize mature DC 
and lack reactivity against patient EBV-LCL, we screened all T-cell clones from 
selected patients against mature monocyte-derived DC and EBV-LCL. In all 
cases, recognition of mature DC was accompanied with reactivity against EBV-
LCL, suggesting that EBV-LCL are equally ‘professional’ in presenting antigens 
as mature DC (chapter 6). Furthermore, since professional APC can cross-
present antigens derived from non-hematopoietic cells, T-cells may be activated 
that target antigens that are not presented by other hematopoietic cells. Since 
our strategy to identify MiHA is predominantly based on recognition of 
hematopoietic cells, we may have missed this type of reactivity. In chapter 6, for 
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a limited number of patients who developed severe GvHD after DLI, all growing 
T-cell clones were tested for recognition of fibroblasts (FB). We never observed 
FB recognition without recognition of hematopoietic test cells. This suggests 
that targeting of MiHA that are exclusively expressed by tissue cells and not by 
hematopoietic cells is rare. 
  
Influence of the micro-environment on T-cell recognition of 
MiHA 
During pathogenic infections, tissue damage and inflammation cause 
maturation of professional APC and presentation pathogen-derived antigens to 
T and B cells. AlloSCT conditioning regimens also induce tissue damage 
followed by cytopenia and infections during the early post-alloSCT period. 
Therefore, to predict the role of MiHA in GvHD, T-cell reactivity to non-
hematopoietic cells should be analyzed under similar conditions. This is 
supported by 2 cases of severe GvHD that occurred after DLI in patients who 
were treated with HLA-DP mismatched alloSCT23. In these patients, CMV 
infections early after alloSCT induced cytokine release by the T-cells involved in 
the anti-viral response. These cytokines subsequently induced HLA-DP 
alloantigen expression on non-hematopoietic cells that enabled targeting by 
alloreactive donor T cells. 
 
The pro-inflammatory cytokine IFN-γ is known to up-regulate molecules 
involved in antigen processing (PSMB8 and PSMB9) and peptide transport into 
the endoplasmic reticulum (TAP1 and TAP2). Furthermore, IFN-γ increases 
surface expression of HLA and adhesion and costimulatory molecules24. As a 
result, higher MiHA presentation and increased T-cell avidity are expected to 
lower the threshold for T-cell activation resulting in targeting of MiHA that are 
not recognized under steady-state. This is demonstrated in chapter 6, where we 
characterized various MiHA encoded by genes with ubiquitous expression 
profiles. A substantial number of these MiHA however, were only recognized 
after FB activation by IFN-γ. Addition of TNF-α and IL-4 in some cases resulted 
in recognition that was not observed in the presence of IFN-γ alone, suggesting 
that synergistic effects may further lower the threshold for T-cell recognition 
(data not shown). In chapter 5, we isolated T cells specific for LB-FUCA-1V 
from a patient with RCC who suffered from extensive chronic GvHD after HLA 
matched alloSCT and DLI. Similar as described above, LB-FUCA-1V specific T 




It is evident that T-cell recognition is dependent on multiple factors. Whereas 
our in vitro data may explain some in vivo observations, both T cell and 
stimulator cell variables complicate the translation of single laboratory 
parameters to clinical effects. 
 
Cellular therapies to treat recurring disease after alloSCT 
Clinical observations indicate that delayed infusion of donor lymphocytes after 
T-cell depleted alloSCT can induce GvL reactivity in the absence of GvHD. This 
can be explained by the presence of limited numbers of residual patient APC at 
the time of DLI and a less inflammatory micro-environment. However, in the 
majority of patients as described in this thesis, GvL reactivity after DLI was 
accompanied with GvHD. As described above, the occurrence of viral infections 
early after alloSCT can trigger development of GvHD23. This illustrates that 
environmental factors can strongly influence the balance between GvL reactivity 
and GvHD. Further investigation should focus on how to manipulate this 
balance. 
 
In addition to the micro-environment, the specificity of responding T cells is 
likely to play a role in GvHD development. Various strategies have been 
developed to separate potentially harmful from beneficial T-cells. One strategy 
that has been proposed to prevent GvHD is selective transfer of memory T 
cells. As compared to unseparated DLI, the TCR repertoire of the memory T-
cell compartment is limited, which limits the repertoire of alloantigens that can 
be recognized. However, in vivo activation of memory T cells may be obtained 
at lower antigen presentation levels, which may increase the risk of targeting of 
non-hematopoietic tissues. It seems therefore unlikely that by selecting a subset 
of T cells more selective GvL reactivity can be obtained25. 
 
Another strategy that can be followed to enhance immune reconstitution without 
GvHD is selective infusion of CD4 T cells from the donor. The rationale for this 
therapy is that HLA class II is predominantly expressed on normal and 
malignant hematopoietic cells, but not on non-hematopoietic tissues. 
Administration of CD4 T-cell DLI may therefore prevent GvHD while preserving 
GvL26,27. Preclinical models demonstrated that purified CD4 cells are indeed 
capable to control tumor growth28. Human studies also confirm that CD8 
depleted DLI after HLA-matched alloSCT can induce GvL reactivity in the 
absence of severe GvHD27,29. In our laboratory, we isolated various MiHA-
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specific CD4 T-cell clones from patients responding to alloSCT and DLI. In vitro 
studies demonstrated that these CD4 T-cell clones are capable of recognizing 
leukemic cells, whereas they often fail to react with FB even after HLA class II 
up-regulation by inflammatory cytokines. These data illustrate that alloreactive 
CD4 T cells may induce GvL reactivity after alloSCT without GvHD8. However, 
we also demonstrated that CD4 DLI in patients treated with HLA-DP 
mismatched alloSCT can lead to severe GvHD. A substantial number of CD4 T-
cell clones for mismatched HLA-DP molecules from these patients were shown 
to recognize HLA class II positive FB in vitro, illustrating that although the risk 
may be lower for CD4 DLI than for unmanipulated DLI, GvHD can still develop if 
T-cell reactivity exceeds a critical threshold. 
 
In addition to phenotypic characteristics, donor T cells for infusion can be 
selected by functionality. Alloreactive T cells can be selected for reactivity 
against leukemic cells or other patient-derived hematopoietic cells or, 
alternatively, T cells can be removed based on reactivity to non-hematopoietic 
cells. In our department, a clinical study is ongoing in which patients are treated 
with alloreactive T cells that respond to leukemic cells using activation markers 
for selection. Although this strategy may augment GvL reactivity, T cells are not 
selected for lack of reactivity against non-hematopoietic cells and development 
of GvHD can therefore not be excluded. In another clinical study, patients are 
treated with alloreactive T cells that have been selected in vitro for lack of 
reactivity against patient FB30. Although this strategy may reduce the risk for 
GvHD, T-cell reactivity against other non-hematopoietic cell types was not 
tested, which may explain the frequent occurrence of pulmonary toxicity. 
Moreover, in this clinical study, T-cell reactivity against cytokine pre-treated FB 
was not tested, and it has been clearly demonstrated in this thesis that MiHA 
encoded by broadly expressed genes are often recognized on FB only after pre-
treatment with IFN-γ. 
 
Separation of GvL reactivity from GvHD by abovementioned strategies skews 
the repertoire of donor T cells to desired anti-tumor immunity without defining 
the exact molecular nature of the antigens that are targeted. Therefore, T cells 
can be infused that recognize well-defined hematopoiesis or leukemia specific 
MiHA. Various strategies can be followed for in vitro production of such donor T 
cells for adoptive transfer. Donor T cells for hematopoiesis-restricted MiHA can 
be isolated from the DLI by HLA-peptide multimers. However, frequencies of 




remains therefore difficult to isolate sufficient numbers of high-avidity T cells 
capable of recognizing leukemic cells for adoptive transfer31. 
 
Another strategy is gene transfer of TCR recognizing hematopoiesis-restricted 
MiHA. These TCR can be isolated from established T-cell clones that have 
been selected for selective and strong reactivity against leukemic cells. In our 
department, a clinical study has been started in which patients are treated with 
donor T cells that have been genetically engineered with the TCR for HA-1, 
which is a well-defined hematopoiesis restricted MiHA32. The HA-1 TCR is 
transferred to EBV- and CMV-specific T cells, which strongly limits the TCR-
repertoire that is expressed by the infused donor cells. This reduces the risk for 
unknown reactivity by pairing of one of the introduced TCR chains with an 
endogenous TCR chain. Furthermore, EBV and/or CMV reactivation after 
alloSCT may lead to expansion of the genetically modified donor T cells via 
triggering of the endogenous TCR, thereby providing sustained anti-tumor 
immunity. Due to the population distribution of both the HLA-restriction allele 
and MiHA-encoding SNP, a panel of MiHA to treat all patients by TCR-gene 
transfer is required. HA-1, for example, is presented by HLA-A*02:01 which is 
expressed by 50% of Dutch individuals. HA-1 targeted therapy requires the 
combination of an HA-1 positive patient (~60%) and an HA-1 negative donor 
(~40%). In unrelated alloSCT, 60% x 40%= 24% of patient-donor pairs meet 
this criterion resulting in eligibility of only 12% of all transplanted patients. In 
related alloSCT, the chance to find a MiHAneg sibling donor for a MiHApos patient 
is even lower. To cover the majority of individuals in the Caucasian population, 
it has been suggested that T-cell therapy should focus on targeting MiHA in the 
5 most common HLA-A alleles A*01, 02, 03, 11 and 2433. 
 
In this thesis, we identified two MiHA (LB-SWAP70-1Q, LB-ARGHDIB-1R34), 
which may have therapeutic value to augment GvL reactivity after alloSCT 
without GvHD. Both MiHA are encoded by hematopoiesis-restricted genes and 
their specific T cells failed to recognize FB. In addition, we discovered three 
MiHA with potential therapeutic value (LB-TTK-1D, LB-CCL4-1T and LB-
C16ORF-1R). T cells specific for these MiHA showed hematopoiesis-restricted 
recognition, but expression profiles for the MiHA-encoding genes still need to be 
established. 
 
We demonstrated that large numbers of T-cell clones could be isolated from in 
vivo immune responses by HLA-DR expression. By screening for reactivity 
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against test cells derived from different tissue types, T-cell clones have been 
identified that either recognized hematopoietic MiHA or MiHA that are 
ubiquitously expressed. For selective identification of therapeutic MiHA, other 
strategies may be more efficient in which T cells are activated in vitro by 
stimulation with patient-derived normal or malignant hematopoietic cells. 
Moreover, during first screening of growing T-cell clones, lack of reactivity 
against patient FB can be tested, thereby increasing the chance to discover 
MiHA with therapeutic value. 
 
AlloSCT as treatment modality for solid tumors 
AlloSCT and DLI for treatment of hematological malignancies demonstrated the 
potential of donor T-cells to mediate immune reactions resulting in long-term 
clinical remissions. This initiated several clinical trials that applied alloSCT as 
treatment of patients with solid, non-hematopoietic tumors. Graft-versus-tumor 
(GvT) reactions were observed in various patients, although at the cost of 
GvHD in most cases. This was also observed in a patient with RCC as 
described in chapter 5, who showed tumor regression and long-term stable 
disease at the cost of severe acute and extensive chronic GvHD. Evidence was 
obtained that induction of strong alloimmunity in this patient depended on the 
presence of residual APC or other hematopoietic cells of patient origin as 
detected by mixed chimerism at the time of the first DLI, whereas escalating 
doses of DLI in the presence of full donor chimerism failed to elicit an 
alloimmune response. 
 
Since GvT-reactivity and GvHD are strongly associated in patients with solid 
tumors and the presence of residual patient APC seems to be crucial for 
efficient induction of alloimmunity, we investigated in chapter 5 the number of 
genes with shared expression between professional APC and RCC by micro-
array gene expression analysis. This analysis showed that the number of genes 
with shared expression between APC and RCC are significantly lower than 
between APC and leukemic cells, illustrating that the chance that T cells are 
induced with reactivity to RCC is low. Moreover, the majority of genes that are 
shared between APC and RCC are also expressed in FB, demonstrating that T 
cells with reactivity to RCC are likely to recognize healthy non-hematopoietic 
tissues. 
These data are in line with clinical observations that GvL reactivity can be 




selective GvT reactivity in the absence of GvHD is difficult to achieve in patients 
with non-hematopoietic malignancies. 
 
The advantage of MiHA directed TCR-gene therapy is that donor T cells acquire 
their specificity by genetic modification and therefore do not depend on in vivo 
activation by professional patient APC. Broad application of TCR gene therapy 
to target non-hematopoietic MiHA on solid tumors after alloSCT requires 
identification of multiple tumor-specific MiHA with balanced population 
frequencies in common HLA molecules. The chance that sufficient numbers of 
such MiHA can be identified, however, is low. It may therefore be more 
attractive to treat RCC using TCR or chimeric antigen receptors (CAR) that 
target non-polymorphic tumor antigens. In CAR therapy, the antigen-binding site 
of an antibody that recognizes a cell surface antigen is introduced into T cells by 
gene transfer. Clinical studies have showed that patients suffering from 
chemotherapy-refractory chronic lymphocytic leukemia or relapsed B-ALL can 
effectively be treated with autologous T cells transduced with a CAR for a non-
polymorphic CD19 cell surface antigen35. Additionally, patients suffering from 
solid tumors have successfully been treated with autologous T cells that were 
transduced with a TCR for a non-polymorphic intracellular NY-ESO-1 antigen36. 
If non-polymorphic antigens with selective expression on RCC can be targeted, 
these therapies may be preferable above alloSCT.  
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Patiënten met hematologische maligniteiten kunnen effectief behandeld worden 
met allogene stamceltransplantatie (alloSCT). De intensieve voorbehandeling 
die erop gericht is maligne cellen te vernietigen brengt ook ernstige schade toe 
aan de normale bloedvorming waardoor het nodig is om gezonde 
hematopoëtische stamcellen van een donor te transplanteren. Deze groeien 
vervolgens uit in de patiënt en nemen de vorming van alle typen bloedcellen 
over. In het stamceltransplantaat bevinden zich naast de stamcellen echter ook 
rijpe cellen van het immuunsysteem van de donor, zoals T-lymfocyten (T-
cellen). Een ernstige bijwerking van allogene stamceltransplantatie is de graft-
versus-host (GvH)-ziekte, waarbij normale weefsels worden aangevallen door 
onder andere T-cellen van de donor. De ontwikkeling van GvH-ziekte gaat 
meestal ook gepaard met een krachtige graft-versus-leukemie (GvL)-reactie 
van donor T-cellen tegen achtergebleven maligne cellen, en zorgt voor 
langdurige onderdrukking van de maligniteit. Verwijdering van T-cellen uit het 
stamceltransplantaat kan de GvH-ziekte voorkomen, maar het vermindert ook 
de gewenste GvL-reactie. Het is gebleken dat een uitgestelde donor lymfocyten 
infusie (DLI) enkele maanden na de alloSCT de gewenste GvL-reactie kan 
veroorzaken zonder dat daarbij altijd ernstige GvH-ziekte optreedt. We nemen 
aan dat dit komt omdat door alle voorbehandelingen op het moment van de 
transplantatie de omstandigheden in de patiënt, zoals weefselschade en 
infecties, zodanig veranderd zijn dat donor T-cellen gemakkelijk geactiveerd 
worden. Bij de uitgestelde DLI kan de situatie in de patiënt in zekere mate weer 
genormaliseerd zijn waardoor wel een GvL-reactie ontstaat maar de kans op 
GvH-ziekte sterk afneemt. 
 
Transplantatie antigenen 
Het is bekend dat bij transplantatie van organen de weefseltypering van donor 
en ontvanger zo veel mogelijk gelijk moet zijn om het risico op afstoting zo klein 
mogelijk te maken. Het kiezen van een donor die volledig identieke ‘humane 
leukocyten antigenen’ (HLA) heeft kan echter niet voorkomen dat 
afstotingsreacties optreden. De oorzaak hiervan zijn ‘minor histocompatibiliteits 
antigenen’ (minors). Dit zijn fragmenten van eiwitten, ofwel peptiden, die 
verschillend kunnen zijn tussen individuen ten gevolge van genetische 




aan HLA-moleculen en worden gepresenteerd aan het immuunsysteem 
gedragen zij zich als antigenen en kan een afweerreactie van T-cellen op gang 
komen. Er zijn 2 typen HLA-moleculen te onderscheiden: HLA klasse I dat op 
alle kernhoudende cellen tot expressie komt en kan worden herkend door CD8 
T-cellen, en HLA klasse II dat vooral op hematopoëtische cellen tot expressie 
komt en kan worden herkend door CD4 T-cellen. Bij alloSCT als behandeling 
van leukemie kunnen T-cellen van de donor die minors herkennen die op 
patiënt leukemiecellen tot expressie komen een GvL-reactie geven. Als er 




Ons immunologisch onderzoek in het kader van alloSCT en DLI richt zich op de 
identificatie en karakterisering van minors. Omdat gebleken is dat T-cellen die 
minors op leukemiecellen herkennen GvL-reactiviteit en dus genezing kunnen 
geven, wordt cellulaire immunotherapie ontwikkeld met T-cellen die minors 
herkennen. Het is hiervoor van belang om de mechanismen te begrijpen die ten 
grondslag liggen aan het verschil tussen GvL-reactiviteit en GvH-ziekte. Het is 
waarschijnlijk zo dat niet alleen de expressie van de minor zelf, maar ook de 
omstandigheden waaronder dit plaatsvindt bepalen of zich GvH-ziekte zal 
ontwikkelen. Minors ontstaan door SNPs en gedragen zich als antigenen omdat 
ze in het ene individu wel, en in het andere individu niet voorkomen. Daarnaast 
komt een minor tot expressie in een specifiek HLA molecuul. Zowel SNPs als 
HLA moleculen hebben een verdeling in de bevolking en binnen een donor-
patiënt paar kan een immuunreactie alleen plaatsvinden als de donor minorneg 
en de patiënt minorpos is. Om cellulaire immunotherapie beschikbaar te maken 
voor de meeste patiënten is het daarom noodzakelijk om een aantal minors in 
verschillende HLA moleculen ter beschikking te hebben. 
 
In hoofdstuk 2 beschrijven we de ontdekking van een minor die herkend werd 
door een groot aantal CD8 T-celklonen, verkregen uit een patiënte die 
succesvol werd behandeld voor ziekte van Kahler met alloSCT en DLI. Van een 
groot aantal gekweekte cellen die herkend werden door deze T-celklonen 
hebben we de HLA-gebonden peptiden geïsoleerd. Op basis van biochemische 
eigenschappen werden de peptiden gescheiden. De verkregen peptide-fracties 
werden getest op hun vermogen om testcellen van de donor, die eerst niet 
herkend werden door de T-celkloon, gevoelig te maken voor herkenning. Door 




peptide oplossen, dat afkomstig bleek te zijn van het ATP-dependent interferon 
responsive (ADIR) gen. Een SNP in dit gen, aanwezig bij de patiënt en afwezig 
bij de donor, zorgde voor een aminozuurverandering in het peptide waardoor 
donor T-cellen het antigeen herkenden. Recombinant eiwit technieken maken 
het mogelijk om peptide-HLA complexen te produceren. Polymeren van deze 
complexen (tetrameren) kunnen gekoppeld worden aan een fluorescerende stof 
en worden gebruikt als kleurstof om minor-specifieke T-cellen aan te tonen. Met 
behulp van tetrameren zagen we ruim 2% LB-ADIR-1F specifieke T-cellen in 
het bloed van de patiënte op het moment dat aantoonbaar de ziektemarker voor 
Kahler (paraproteïne) daalde. LB-ADIR-1F specifieke T-cellen vertoonden 
sterke herkenning van verschillende typen leukemiecellen en ook van cellijnen 
afkomstig van solide tumoren. Niet-hematopoëtische cellen die positief waren 
voor de LB-ADIR-1F coderende SNP werden zwak herkend, en ook het niveau 
van genexpressie was laag. Dit betekent dat LB-ADIR-1F specifieke T-cellen in 
beperkte mate specifiek zijn voor hematopoëtische cellen, maar onder bepaalde 
omstandigheden ook GvH-ziekte kunnen veroorzaken.  
 
Het karakteriseren van minors volgens de techniek zoals hierboven beschreven 
geeft een helder inzicht in het verband tussen de SNP en het ontstaan van de 
minor. Het is echter zeer bewerkelijk en daardoor niet geschikt voor het 
stelselmatig oplossen van grote aantallen minors. In hoofdstuk 3 laten we zien 
dat whole genome association scanning (WGAs) dit wel mogelijk maakt, door 
gebruik te maken van een panel van testcellen waarvan 1 miljoen SNPs zijn 
gemeten. Na het testen van de herkenning van het gehele panel door een T-
celkloon die een onbekende minor herkent, kan dit herkenningspatroon 
vergeleken worden met de patronen van alle SNPs. Een overeenkomend 
patroon geeft aan dat deze SNP betrokken is bij het ontstaan van de minor. We 
hebben WGAs toegepast op 17 minor specifieke CD8 T-celklonen die 
geïsoleerd waren uit bloedmonsters afgenomen na DLI bij 2 patiënten. Met ons 
panel van testcellen, dat uit 80 cellijnen bestond, vonden we in 12 gevallen 
sterke associatie met een SNP. Na de bevestiging dat de associërende SNPs in 
de patiënt aanwezig, en in de donor afwezig waren, hebben we met behulp van 
online algoritmes die de bindingssterkte van peptiden in HLA moleculen 
voorspellen, voor 10 T-celklonen kandidaat peptiden gevonden. Alle voorspelde 
peptiden werden in meer of mindere mate herkend, wat de juistheid van de 
WGAs resultaten bevestigde. We vonden minors die direct het gevolg waren 
van een aminozuurverandering door de associërende SNP. Daarnaast vonden 




was aan de associërende SNP, de minor veroorzaakte. Voor verschillende van 
de nieuw gekarakteriseerde minors konden we in bloedmonsters van patiënten 
minor specifieke T-cellen aantonen met tetrameren. Dit laat zien dat WGAs een 
zeer geschikte methode is om snel minors te karakteriseren. 
 
In hoofdstuk 4 beschrijven we 4 verschillende minor specifieke CD8 T-
celklonen die geïsoleerd werden uit een patiënt met chronisch myeloïde 
leukemie die na alloSCT goed reageerde op DLI. Deze T-celklonen herkenden 
minors die gepresenteerd werden door HLA-B*40:01. Eén van de minors is 
gevonden door gebruik te maken van een ‘library cDNA’ techniek, en 3 minors 
door het toepassen van WGAs. Om dit te kunnen doen hebben we eerst de 
testcellen van het WGAs panel genetisch gemodificeerd zodat deze het 
betreffende HLA-B*40:01 molecuul tot expressie brachten. Van de 4 T-
celklonen hebben we bepaald of ze verschillende soorten leukemiecellen 
konden herkennen. Bij één T-celkloon zagen we uitsluitend herkenning van 
meer uitgerijpte leukemiecellen, terwijl de andere 3 T-celkonen alle typen 
leukemiecellen konden herkennen. Om de herkenning van niet-
hematopoëtische cellen te testen, werd van de patiënt een huidbiopt 
afgenomen. Hieruit werden zogenaamde fibroblasten gekweekt die we konden 
gebruiken om de herkenning door de T-celklonen te testen, als model voor het 
optreden van GvH-ziekte. Hieruit bleek dat geen van de T-celklonen de 
fibroblasten kon herkennen. Echter, na voorbehandeling van de fibroblasten 
met interferon-gamma, een stof die geproduceerd wordt bij immuunreacties, 
vertoonde 1 kloon zeer sterke herkenning, 1 kloon matige herkenning, en 2 
klonen zeer zwakke herkenning. Dit laat zien dat tijdens immuunreacties na 
DLI, reactiviteit tegen een variëteit aan minors kan ontstaan. De meeste T-
celklonen konden de leukemiecellen goed herkennen, maar sommigen 
herkenden minors die door niet-hematopoëtische cellen tot expressie gebracht 
worden onder condities die voorkomen bij ontstekingsreacties. 
 
 
Door het verminderen van de intensiteit van de voorbehandeling bij alloSCT, 
werden op beperkte schaal patiënten met solide tumoren ook allogeen 
getransplanteerd, met als doel het opwekken van een ‘graft-versus-tumor’(GvT) 
reactie. Het leek er echter op dat bij deze patiënten de GvT-reactiviteit zelden 
optrad zonder GvH-ziekte. In hoofdstuk 5 beschrijven we een patiënt die leed 
aan uitgezaaid niercelcarcinoom en werd behandeld met alloSCT en DLI, en bij 




behandeling hiervoor ontwikkelde zich de uitgebreide chronische vorm van 
GvH-ziekte. Tijdens deze GvH-ziekte werd een afname in de grootte van de 
uitzaaiingen in de longen vastgesteld, en de tumorgroei stabiliseerde. Toen de 
chronische GvH-ziekte na ruim 3 jaar verdwenen was, verdween echter ook de 
GvT-reactie en de patiënt overleed 8 jaar na de alloSCT door progressie van de 
ziekte. Uit een bloedmonster dat was afgenomen bij het ontstaan van de acute 
GvH-ziekte, isoleerden we geactiveerde CD8 T-cellen. Van een T-celkloon 
vonden we met behulp van WGAs een sterke associatie met het FUCA2 gen. 
Een SNP in dit gen bij de patiënt veroorzaakte een aminozuurverandering, en 
dit bleek herkend te worden door de T-celkloon. De minor LB-FUCA2-1V werd 
herkend in niercelcarcinoom cellijnen, maar ook in fibroblasten, zij het na 
voorbehandeling van de fibroblasten met interferon-gamma. Dit was in 
overeenstemming met het patroon van genexpressie van FUCA2. Om 
vervolgens in algemene zin het verband tussen GvT-reactiviteit en GvH-ziekte 
te bestuderen, hebben we gekeken naar de expressie van 40.000 genen, 
verkregen met micro-array technieken. Het opwekken van een efficiënte 
immuunreactie is afhankelijk van presentatie van antigenen door professionele 
antigeen presenterende cellen (APC). Vervolgens kunnen deze antigenen ook 
herkend worden op andere cellen, zoals tumorcellen (GvT-reactie) en normale 
weefselcellen (GvH-ziekte). We hebben daarom eerst alle genen geselecteerd 
die tot expressie kwamen in zowel APCs als in niercelcarcinoomcellen. Binnen 
deze set aan genen hebben we bekeken hoeveel genen niet tot expressie 
kwamen in fibroblasten en keratinocyten, waarbij we aannamen dat presentatie 
van minors door deze huidcellen GvH-ziekte tot gevolg kan hebben. Dit leverde 
slechts een beperkt aantal genen op, zeker als we dit aantal vergeleken met het 
aantal genen dat we vonden als we dezelfde selectie maakten uit genen met 
een gedeelde expressie in APCs en leukemiecellen. Hieruit concluderen we dat 
na alloSCT en DLI de kans klein is om bij niet-hematopoëtische tumoren een 
GvT-reactie op te wekken zonder daarbij ook GvH-ziekte te veroorzaken. 
 
GvL-reactiviteit die wordt waargenomen na uitgestelde DLI gaat soms niet en 
soms wel gepaard met GvH-ziekte. Omdat we aannemen dat dit allebei 
immunologische reacties zijn die veroorzaakt worden door donor T-cellen, 
hebben we in hoofdstuk 6 gezocht naar verschillen in de donor T-cel reactie bij 
6 patiënten zonder en 5 patiënten met GvH-ziekte na DLI. We hebben eerst de 
mate van activatie van CD8 T-cellen in het bloed gemeten aan de hand van de 
marker HLA-DR, die bij geactiveerde T-cellen op het oppervlak komt. We zagen 




dagen na de DLI. Er was echter geen verband tussen deze stijging en het 
optreden van GvH-ziekte. Om te verrijken voor alloreactieve T-cellen in de 
bloedmonsters, hebben we HLA-DRpos CD8 T-cellen gesorteerd en vervolgens 
gekloneerd. Uit alle groeiende T-celklonen hebben we alloreactieve T-celklonen 
geselecteerd die cellen van de patiënt wel, en die van de donor niet herkenden. 
Deze alloreactieve T-celklonen waren bij patiënten met GvH-ziekte in sterk 
verhoogde mate aanwezig. Vervolgens hebben we de herkenning van 
hematopoëtische cellen getest, als model voor GvL-reactiviteit. We vonden 
geen verschil tussen de T-celklonen die geïsoleerd waren uit het bloed van 
patiënten zonder en met GvH-ziekte, wat overeenkomt met de waarneming dat 
in de patiënten uit beide groepen GvL-reactiviteit opgetreden was. Om de 
herkenning van niet-hematopoëtische fibroblasten te testen, als model voor het 
optreden van GvH-ziekte, werd van alle patiënten een huidbiopt afgenomen. 
Enkele T-celklonen uit patiënten zonder GvH-ziekte herkenden de fibroblasten 
zwak, terwijl we sterkere fibroblasten herkenning zagen door T-celklonen uit 
patiënten met GvH-ziekte. Voorbehandelen van de fibroblasten met interferon-
gamma, versterkte de reactiviteit tegen de fibroblasten vooral door de T-
celklonen van patiënten met GvH-ziekte. Deze studie toont aan dat ook in 
patiënten zonder GvH-ziekte alloreactieve T-cellen aantoonbaar zijn op het 
moment van de klinische GvL-reactie. Het aantal circulerende alloreactieve T-
cellen is echter sterk toegenomen bij patiënten met GvH-ziekte waardoor 
mogelijk een sterkere algemene activatie van het immuunsysteem plaatsvindt. 
Hierdoor, en door de aanwezigheid van T-celklonen die ook niet-
hematopoëtische cellen kunnen herkennen, kan GvH-ziekte ontstaan. 
 
In dit proefschrift laten we detailleerde studies zien van klinische 
immuunresponsen die optreden na alloSCT en DLI. We pasten methoden toe 
om de moleculaire structuur van de antigenen op te helderen. De technieken 
om dit op grote schaal te doen hebben we ontwikkeld en geoptimaliseerd 
waardoor we een representatief beeld krijgen van T-cel gemedieerde in vivo 
immuunresponsen. De verschillen die we aangetoond hebben tussen GvL-
reactiviteit en GvH-ziekte kunnen uiteindelijk leiden tot het ontwikkelen van 
therapieën waarbij GvH-ziekte voorkomen kan worden. Hiervoor is het van 
groot belang dat we minors ontdekken die uitsluitend door leukemiecellen en 
andere bloedcellen gepresenteerd worden. T-celklonen die deze hematopoiese 
specifieke minors herkennen kun ingezet worden om zeer gerichte 














Op deze bladzijde van het proefschrift wil ik graag benadrukken dat aan dit 
werk door velen is bijgedragen. Er staat één naam op de voorkant, en daar ben 
ik natuurlijk heel trots op. Tegelijkertijd voel ik diepe dankbaarheid voor alle 
mensen die direct en indirect betrokken waren bij ontstaan, uitvoering en 
afronding van dit proefschrift. 
 
Alles begint met het praktische werk. Daarvoor heb je de gesmeerde machine: 
‘Laboratorium voor Experimentele Hematologie’. Enthousiasme en inzet gaan 
hier hand in hand met betrokkenheid en een geweldige sfeer. Wat voel ik me 
rijk dat ik hier bij hoor! Ik dank ook patiënten en donoren van wie we materiaal 
mogen verzamelen. Dat is de bron van al ons onderzoek. De inspanning die het 
laboratorium levert om de monstercollectie op peil te houden is enorm en 
daarom vraag ik een hartelijk applaus voor alle ‘achterwachters’. 
 
Door de afzonderlijke hoofdstukken heen schijnen al de namen van dierbare 
collega’s die ik speciaal wil noemen en bedanken voor de fijne samenwerking: 
Michel, Edith, Ellie en Willy. Lang vóór de eerste publicatie werd ik enthousiast 
gemaakt door Henriëtte toen ze mij voor het eerst een Ficoll-scheiding en een 
voorlopercelkweek liet zien. Hierbij wil ik ook graag onze emeritus hoogleraar 
Roel bedanken. Voor alle vrolijkheid, hulp én koffie op het stafcentrum dank ik 
Gerrie, Karien, Jacobien en Marion. 
 
T-cellen zijn de rode draad van dit boek. Ze drijven soms tot wanhoop, maar als 
we goed ons best doen en nauwkeurig kijken, laten ze ons iets zien van hun 
geheimen. Dat is erg prikkelend, en tegelijkertijd onmogelijk om alleen te doen. 
Het laten groeien en ‘uitlezen’ van de T-cellen vereist vaardigheid en een 
infrastructuur. Simone, ik dank je voor je bevlogenheid, enorme inzet en het 
delen van je vaardigheid. Nelleke, ik dank jou voor je organisatietalent, 
optimisme en ondersteuning zodat we ons werk optimaal kunnen doen. Dat wij 
als trio met het resultaat hiervan in de senaatskamer staan vind ik geweldig! 
 
Om gezond en fijn te kunnen werken heb je een goede basis en een veilig 
leven nodig. Mijn moeder en mijn vader ben ik dankbaar voor het mooie leven 
thuis op het platteland en de lessen die ik daar leerde. Het was de springplank 
naar het heden waarin we nu leven. Koos, bij jou voel ik me veilig, waar we ook 
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